Stokes
Jennifer
Fungal and Rickettsial Diseases
Fungal Diseases
Systemic fungal infections are rarely documented in cats. Approximately 7 per 10,000
of the total population of animals presenting to veterinary teaching hospitals in
North America are diagnosed with a systemic mycosis.
10
In most cases, dogs are the more susceptible species; the exception is cryptococcosis,
which is 5 to 6 times more likely to be diagnosed in cats.
42
Cryptococcosis, histoplasmosis, coccidioidomycosis, blastomycosis, and sporotrichosis
will be discussed separately, and recommendations for treatment will be described
at the end of the section.
Cryptococcosis
Of the organisms causing systemic mycosis in cats, Cryptococcus is most commonly diagnosed.
In the largest retrospective study evaluating deep mycotic infections in 571 cats,
46.1% of the infections were due to Cryptococcus.
10
The organism is round to ovoid in shape, thin walled with diameter of 2.5 to 8 µm
(Figure 33-1
).17, 20 In tissues, it is surrounded by a heteropolysaccharide capsule that varies
in thickness depending on the strain and environment. The capsule provides resistance
to desiccation and virulence.
20
Cryptococcus multiplies asexually with narrow-based budding. The infectious particle,
the basidiospore, is adapted to be dispersed by air and has properties that allow
it to adhere to and penetrate respiratory epithelium and cause infection.
20
FIGURE 33-1
Cytologic diagnosis of Cryptococcus showing encapsulated yeast forms in a Diff Quik-stained
smear.
(Courtesy Richard Malik. [Figure 61-2, B in Greene CE, editor: Infectious diseases
of the dog and cat, ed 3, St Louis, 2006, Elsevier.])
Typically, cryptococcosis in people and domestic animals is caused by one of two species:
Cryptococcus neoformans (var. neoformans or var. grubii) or C. gattii.
20
Globally, C. neoformans var. grubii is the most common isolate associated with disease
in people and animals. C. neoformans causes almost all cases in the United States
and Europe.20, 31 Within the United States, the highest incidence of cryptococcosis
in cats is reported in California, Florida, Virginia, and Iowa.
10
C. gattii most commonly causes disease in tropical and subtropical areas, including
Australia, Papua New Guinea, Southeast Asia, and Central Africa; it has also been
documented to cause infection in the temperate climate of the Pacific northwest, including
Vancouver, Canada.
37
C. albidus was confirmed to cause one case of systemic disease in a cat in Japan but
has not been recognized as a significant pathogen in cats.
31
Cryptococcus can be isolated from a variety of substances, depending on the geographic
location of the organism as well as the species.
42
C. neoformans is consistently found in pigeon feces and soil enriched by avian feces
and less often in milk, fermenting fruit juices, air, dust, wasp nests, grass, and
insects.20, 42
C. gattii is found in hollows of Eucalyptus and fig trees in Australia and some fir
trees in western Canada.20, 42 Risk factors for C. gattii infection in pets in Vancouver
include proximity to logging sites or other areas of commercial soil disruption and
owners hiking or visiting a botanical garden.
14
It is viable in feces for up to 2 years in moist environments.
20
Ultraviolet light and dry conditions can decrease viability.
The exact mode of transmission is unknown, but most likely occurs by inhalation of
yeast cells or basidospores.13, 20 Once inhaled, Cryptococcus lodges in the nasal
passages and causes mycotic rhinitis; lower respiratory infection is uncommon because
most organisms are larger than the alveolar diameter of 2 µm.
17
Some strains are particularly virulent and will destroy adjacent facial bones and
spread locally.
20
Rarely, cryptococcosis occurs secondary to a penetrating skin wound, causing localized
infection.
37
Clinical signs depend upon location of infection. Infection usually involves the nasal
cavity, skin, subcutis, central nervous system (CNS), and regional lymph nodes. Dissemination
has been documented (Figure 33-2
). As mycotic rhinitis of the rostral nasal cavity occurs most often, sneezing, wheezing,
and unilateral or bilateral nasal discharge are common presenting complaints. Respiratory
signs have been reported in 26% to 83% of cats with cryptococcosis.12, 39 In another
study, 63% of 263 cats had nasal discharge, and 12.5% had cough or dyspnea.
10
Thickening and inflammation of nasal mucosa or nasal granulomas may be visible. Osteomyelitis
may occur, leading to facial deformity, including broadening of the nose or swelling
of adjacent tissue (Figure 33-3
). If the nasopharynx is affected, clinical signs may be absent until the infection
spreads through cribriform plate and causes meningitis.
38
Alternatively, cats may present dyspneic or with stertorous breathing because of obstruction
by fungal granulomas. Lymph node involvement was present in 39% of 263 cats.
10
Mycotic pneumonia and hilar lymphadenomegaly because of Cryptococcus is rare in cats.
FIGURE 33-2
Disseminated Cryptococcus infection.
(Courtesy Richard Malik.)
FIGURE 33-3
Cryptococcal osteomyelitis may lead to facial deformity.
(Courtesy Richard Malik.)
Cutaneous nodules were documented in 41% of 263 cats with cryptococcosis (FIGURE 33-4,
FIGURE 33-5
).
10
Oral lesions occasionally occur in cats with Cryptococcus infection and may appear
as diffuse ulceration of the oral mucosa of the tongue, gingiva, or palate, or as
proliferative lesions.
43
Central nervous system involvement also occurs, either because of erosion of nasal
infection through the cribriform plate or possibly by hematogenous spread. Neurologic
signs occur in 8% to 26% of cats with cryptococcosis and may manifest as blindness,
pupil changes, ataxia, depression, and temperament changes.10, 12, 41
FIGURE 33-4
Cutaneous Cryptococcus nodule on the nasal planum.
(Courtesy Jessica Baron.)
FIGURE 33-5
Cutaneous Cryptococcus nodule on the inside of the pinna.
(Courtesy Paige May.)
Cryptococcosis has been diagnosed in cats less than 1 month of age and in those greater
than 15 years of age. The mean age at diagnosis is about 6 years, with 58% of cats
being between 2 to 7 years of age.10, 17 Some, but not all studies, have shown breed
predisposition, with Abyssinian, Siamese, Birman, and Ragdoll cats being overrepresented
compared with domestic shorthairs.10, 17, 42 Indoor as well as outdoor cats are susceptible
to infection. A gender predisposition for cryptococcosis in male cats is inconsistently
reported. Cryptococcosis occurs most commonly in immunocompromised people, but most
studies of the infection in cats do not show an association with retrovirus infection
or other causes of immunosuppression.
20
A definitive diagnosis of cryptococcosis requires culturing the organism from infected
tissue (Box 33-1
). Both C. neoformans and C. gattii can be cultured from the nasal cavity of asymptomatic
patients. Culture of most systemic fungal infections is laborious and poses a zoonotic
hazard to laboratory staff. Culture of Cryptococcus on Abouraud dextrose agar may
take up to 6 weeks to be evident.
17
In most cases, a presumptive diagnosis is made by cytologic evaluation. The organism
may be detected from nasal swab samples, nasal washing, and nasal tissue biopsy imprint
or from aspiration of other infected tissues. Rhinoscopy or advanced imaging may aid
in diagnosis. If ocular involvement is present without evidence of disease elsewhere,
vitreous or subretinal fluid may be aspirated for cytologic evaluation. Quik-Dip (Mercedes
Medical, Sarasota, Fla.), Wright Giemsa, or new methylene blue stains enhance visualization
of the thickly encapsulated, broad-based budding yeast cells. If cryptococcosis cannot
be confirmed cytologically or histopathologically, then serology can be performed.
The antigen latex agglutination test is highly specific and sensitive in detecting
Cryptococcus capsular antigen in dogs. It can be performed on serum, cerebral spinal
fluid, or vitreous fluid. The specificity and sensitivity has not been described in
cats, but infected cats can have extremely high titers (>1 : 65,536).
37
Serial serologic testing can be used to assess response to treatment, and a favorable
prognosis often accompanies a decrease in titer.
BOX 33-1
Methods for Diagnosis of Cryptococcosis in Cats
1
Fungal culture
2
Cytology
a
Nasal swab or wash
b
Biopsy or aspiration samples
c
Vitreous or subretinal fluid
3
Serology: antigen latex agglutination
a
Serum
b
Cerebrospinal fluid
c
Vitreous fluid
Overall, the prognosis for cats with cryptococcosis is good, if the disease is not
severe, there is no CNS involvement, and treatment is of appropriate duration. Animals
presenting with or progressing to CNS disease are 4 times more likely to die than
those without CNS signs.
12
In one retrospective study of 59 cats from Sydney, Australia with cryptococcosis,
76% were successfully treated.
41
Determining the ideal duration for treatment can be difficult. It is typically recommended
to treat for at least 1 month past clinical resolution, and sometimes therapy is needed
for 9 months or longer. If fungal granulomas are present in the nasal cavity or nasopharynx,
debulking the abnormal tissue may aid in treatment. Itraconazole is the drug most
commonly used for treatment of feline cryptococcosis, but other azoles as well as
amphotericin B have been used successfully.
37
There is no evidence that cryptococcosis is either contagious or zoonotic, but pets
may act as sentinels for people.
Histoplasmosis
The second most common cause of systemic mycosis in cats is due to Histoplasma; 16.7%
of 571 cats diagnosed with systemic fungal disease had histoplasmosis in one study.
10
Histoplasma has a global distribution. Pathogenic species include H. capsulatum, H.
duboisii, and H. farcinminosum. H. capsulatum causes infection in the continental
United States, and H. duboisii is the causative agent in Africa. The organism thrives
in warm (22° C to 29° C) and moist environments, particularly in temperate and subtropical
areas.
22
H. capsulatum is most commonly isolated from moist, nitrogen-rich soil containing
bird or bat feces.20, 32 In the environment, the organism exists as a mycelial form
and within a host as a yeast.
H. capsulatum is most commonly diagnosed in North and South America, India, and southeastern
Asia, although it has been documented in every continent with the exception of Antarctica.
22
H. capsulatum is endemic in the U.S. Midwest, South and areas along the Ohio, Mississippi,
and Missouri rivers. It is sporadically reported elsewhere, including California,
Ontario, Canada, and Australia.
7
Although reported in 31 states within the United States, the highest incidence is
in Oklahoma, Texas, Virginia, and Louisianna.10, 22
The life cycle of H. capsulatum is similar to other dimorphic fungi. The mycelial
stage living in soil is resistant to environmental damage. It sporulates at temperatures
around 22° C, and the spores are known as microconidia or macroconidia.
22
Lower respiratory infection most likely occurs because of inhalation of infective
microconidia. Some cases of histoplasmosis are isolated to the gastrointestinal (GI)
system, but an oral route of infection has not been confirmed.
22
At body temperature (37o C), the inhaled organism transforms into the yeast phase
within the lungs, is phagocytized, and replicates intracellularly. Infection may be
limited to the lower respiratory system and regional lymph nodes, or yeast-laden macrophages
may disseminate the organism via lymphatics or hematogenously. In most patients, cell-mediated
immunity is effective in controlling the infection; however, if a large number of
organisms are inhaled or if immune compromise exists, severe disease may occur.
22
In patients with an effective immune system, dormant infections may be reactivated
because of immunocompromise.
Unlike other systemic fungal infections, histoplasmosis occurs equally in dogs and
cats.
32
Histoplasmosis has been diagnosed in cats less than 8 weeks of age to more than 15
years, and it occurs most commonly in cats less than 4 years of age.10, 32 The mean
age at time of diagnosis is 3.9 years.
7
Both outdoor and exclusively indoor cats are at risk of infection.10, 30 No consistent
gender bias is reported. Breed predilection is not consistently described, but Persian
cats were predisposed in one report.
10
Although one retrospective study found that concurrent infection with feline leukemia
virus (FeLV) was present in 15% of 96 cats with histoplasmosis, in most reports co-infection
with feline retroviruses is uncommon.10, 29, 30, 32
Although infection with H. capsulatum may be asymptomatic and self-limiting, dissemination
is common in cats and may occur in up to 95% of cases, despite a lack of systemic
clinical signs.
10
The organs most commonly affected include the lungs (Figure 33-6
), GI tract, lymph nodes, spleen, liver, bone marrow, eyes, and adrenal glands. The
incubation period is approximately 12 to 16 days in people and dogs and is likely
the same for cats.10, 22 Clinical signs are often present for 2 to 3 months prior
to presentation.
29
In 96 cats with histoplasmosis, the most common clinical signs, which occurred in
67% of infected cats, were nonspecific and included lethargy, weakness, and fever.
10
Respiratory signs were present in 39% of the cats and ocular in 24%. When pulmonary
involvement is present, clinical signs may include abnormal lung sounds, tachypnea,
or dyspnea. Ocular abnormalities included blepharitis, conjunctivitis, anterior uveitis,
chorioretinitis, optic neuritis, and retinal detachment.10, 22 Lymphadenopathy and
hepatosplenomegaly can occur with dissemination. If present, bone marrow involvement
may lead to cytopathies.
32
Uncommon sites for infection include skin, bone, CNS, and oral cavity.33, 53 Specific
GI signs occur less commonly in cats than in dogs. Oral infection may manifest as
ulcerated tissue or proliferative lesions on the gingiva or palate.
33
FIGURE 33-6
Histoplasmosis pneumonia in a cat.
(Courtesy Eric Snook.)
Routine laboratory tests are often abnormal in cats with histoplasmosis, but findings
are not pathognomonic for infection. Anemia, thrombocytopenia, leukopenia, or pancytopenia
may be present. The most common hematologic abnormality is normocytic, normochromic,
nonregenerative anemia, which may be due to chronic inflammation, bone marrow involvement,
and GI blood loss. Neutrophilic leukocytosis with monocytosis can also be diagnosed,
or the leukogram may be normal. The organism can be seen in phagocytic cells on blood
smears, and in a study of 56 cases, it was evident in 20% of the cats with histoplasmosis.
10
Other abnormalities reported include thrombocytopenia and severe pancytopenia.
22
Biochemical abnormalities have included hypoalbuminemia, hyperglobulinemia, elevated
liver enzyme activity, hyperbilirubinemia, and hypercalcemia.
32
In one report, radiographic abnormalities were present in over 87% of cats with histoplasmosis,
and the most common finding was a diffuse or nodular interstitial pattern in the lungs.
10
Hilar lymphadenomegaly was rare. Abdominal fluid, hepatomegaly, or splenomegaly may
be present.
Definitive diagnosis of histoplasmosis requires identification of the organism cytologically
or histologically. Histoplasma is usually present in clusters within cells of the
mononuclear phagocyte system in the infected organs. When stained with Wright or Giemsa,
H. capsulatum appears as a small (2 to 4 µm) round body with a basophilic center and
lighter halo caused by shrinkage of the yeast during the staining process.
22
Diff-Quik can also be used to stain cytologic preparations. In cats, the organism
is most commonly found by fine-needle aspirate cytology of infected organs, including
lung, lymph node, dermal lesions, spleen, liver, or bone marrow. Organisms may be
seen on evaluation of fluid collected by endotracheal wash, bronchoalveolar lavage,
thoracocentesis, or cerebrospinal tap. Histopathologic abnormalities include granulomatous
inflammation, but H. capsulatum may be difficult to see with routine staining. If
fungal disease is suspected then special stains, such as periodic acid–Schiff (PAS),
Gomoris methenamine silver, or Gidley fungal stain, should be requested. Immunostaining
has been used to diagnose histoplasmosis in skin biopsy samples.
22
Diagnosis of histoplasmosis by culture of the organism is rarely performed because
of the zoonotic risk for laboratory personnel; it can also take up to 4 weeks for
results to be available. Serologic testing is unreliable and false negatives are common
in animals with clinical disease, and false-positive results may occur in previously
infected patients with residual antibodies.
22
MiraVista Diagnostics (Indianapolis, Ind., www.miravistalabs.com) has developed a
test that can detect H. capsulatum antigens in urine, serum, or cerebrospinal fluid
(CSF); this has been used to diagnose histoplasmosis in people. Sensitivity is increased
if both urine and serum is tested. The test can be used to monitor response to treatment;
titers decrease with effective therapy and increase with disease relapse. In people,
cross reactivity occurs with blastomycosis, coccidioidomycosis, and penicilliosis.
At the author's institution, the urine antigen test has been used for monitoring purposes
in dogs confirmed to have histoplasmosis, based on cytologic diagnosis. The test is
likely applicable in cats, but more research needs to be performed to determine sensitivity
and specificity.
Although histoplasmosis may be self-limiting when isolated to the lungs, treatment
is recommended to avoid dissemination. As with most systemic fungal diseases diagnosed
in cats, itraconazole is the medication of choice. Prognosis varies depending on the
extent of disease. Of 56 cats in which the outcome was known in one study, 68% died
or were euthanized.
10
Prevention consists of avoiding exposure to soils likely to harbor H. capsulatum,
including those contaminated by bird or bat feces. Histoplasmosis is not zoonotic.
Coccidioidomycosis
Coccidioidomycosis was diagnosed in 9.2% of cats with systemic fungal disease in one
study.
10
Coccidioides is a dimorphic fungus that grows in soil as a mycelium. Mycelia germinate
to form thick-walled, barrel-shaped, rectangular, multinucleate arthroconidia that
are 2 to 4 µm wide and 3 to 10 µm in length.
24
Mycelium can persist in soil indefinitely and arthroconidia are environmentally resistant.
When soil containing Coccidioides is disturbed, arthroconidia are released and dispersed.
24
They can germinate and produce new hyphae or serve as a source of infection.
Coccidioides is found in a specific ecologic location, known as the Lower Sonoran
life zone.
24
This area includes the southwestern United States, Mexico, and Central and South America.
21
It is also known as valley fever. These regions have sandy, alkaline soil, and high
temperatures, with the summer mean greater than 26.6° C and the winter mean 4° C to
12° C.
24
In addition, elevation and annual rainfall are low. During prolonged periods of dry,
hot weather, Coccidioides survives below the soil as deep as 20 cm.
24
After rainfall, the organism replicates near the soil surface and releases large numbers
of infective arthroconidia that disseminate.
24
Infection is most common when the soil is dry and is disturbed, such as by dust storms,
earthquakes, or crop harvesting, or following the rainy season.
21
C. immitis is the species found in California in the San Joaquin Valley, while C.
posadasii is found in all other endemic areas.
24
Disease is most common in California, Arizona, and southwestern Texas and less commonly
diagnosed in New Mexico, Nevada, and Utah. Infections outside of endemic areas are
sporadic. In such cases, the individual may have traveled to an endemic area and then
had activation of dormant organisms years later.
24
In people, most infections are asymptomatic, with only 40% of people developing clinical
signs.
24
This may be true in other species.
Coccidioidomycosis occurs primarily following inhalation of infective arthrospores,
and less than 10 organisms can cause infection.
21
Uncommonly, infection will occur following inoculation of the organism into the skin.
There is one case report of a veterinary assistant developing coccidioidomycosis after
being bitten by an infected cat.
16
Rarely, there have been suspect cases of dogs becoming infected after contacting fomites
contaminated with arthrospheres.
21
Once inhaled and spread to the alveoli, arthroconidia convert to spherules because
of the higher temperature and increased carbon dioxide level.21, 24 Once the spherule
matures, it eventually ruptures, releasing up to 300 endospores.
24
After inhalation, it takes approximately 3 days for the endospores to form, but clinical
signs usually do not occur for 2 weeks.
21
It is thought that endospores are able to disseminate through blood and lymphatics
to distant sites, and cats with disseminated disease may have no infection in the
respiratory system.
49
When skin inoculation occurs, infection may be limited to the dermis or subcutis.
As is typical of fungal disease, cell-mediated immunity is much more effective in
resolving infection with Coccidioides than is humoral immunity. Antibody formation
typically occurs but is more useful as a diagnostic aid than in fighting the infection.
Although people who recover from coccidioidomycosis are considered immune to reinfection,
recurrence in dogs and cats is common. It is not known if this is due to premature
discontinuation of treatment or to a lack of long-term immunity to Coccidioides.
21
Clinical disease varies from subclinical to fatal; it is not known why some infected
animals have self-limiting disease and others die despite treatment. Evaluation of
necropsy reports from 1995 to 2005 from the Arizona Veterinary Diagnostic Laboratory
found that in fatal coccidioidomycosis cases, 25% of the animals involved were cats.
It is unclear if this finding is due to more severe disease in cats or if coccidioidomycosis
is underdiagnosed antemortem in cats. Infection is most commonly reported in middle-aged
cats, with no breed predisposition. There is also no correlation between coccidioidomycosis
and feline retrovirus infection.
21
Specific clinical manifestations depend on the site of infection and are extremely
varied, making early diagnosis a challenge. Coccidioides appears to be able to infect
most tissues. Fever is commonly present at diagnosis, as well as nonspecific signs,
including lethargy, anorexia, and weight loss. Respiratory signs are uncommonly recognized,
and lung and bone involvement occurs less frequently in cats than in dogs. Ocular
lesions, including chorioretinitis and anterior uveitis, occur with similar frequency
among cats and dogs.
24
In cats, approximately 50% of cases are disseminated.
21
Subclinical infection may occur in up to 70% of dogs; it is unknown if this is true
in cats.
21
Coughing is uncommon, but 25% of cats may present dyspneic. The CNS can be infected,
and granulomatous mass lesions in the brain are more common than fungal meningitis.
Ocular signs may include anterior uveitis, subretinal granulomas, retinal detachment,
and blindness. There is also a report of cats that presented for periocular swellings
with systemic signs, including weight loss, unkempt hair coat, and lethargy. Clinical
ophthalmologic abnormalities were bilateral in each cat and included hyperemia, conjunctival
masses, fluid-filled periorbital swellings, granulomatous chorioretinitis, nonhematogenous
retinal detachments, and anterior uveitis.
51
Cats were diagnosed with coccidioidomycosis using a combination of clinical findings,
serology, and, in two cases, visualization of Coccidioides spherules by either aspiration
cytology or biopsy. Active anterior uveitis and periocular swelling resolved with
treatment. Chorioretinal granulomas, although persistent, significantly decreased
in size.
51
Infection is often limited to the lungs and perihilar lymph nodes, although dissemination
of the organism through the blood and lymphatics can occur.
21
When dissemination occurs, the skin is the most frequent site of infection. In 15
cats with coccidioidomycosis that underwent post-mortem evaluation, all had multiorgan
involvement.
21
Nonhealing cutaneous lesions, including abscesses, dermatitis, chronic draining tracts,
and ulcerations are the most common clinical manifestations.
21
Cutaneous and subcutaneous lesions were reported in 56% of cats in one series of 48
cases.
49
In infected cats, laboratory abnormalities have included nonregenerative anemia, neutrophilic
leukocytosis with left shift, monocytosis, eosinophilia, hypoalbuminemia, and hyperglobulinemia.
Sensitivity and specificity of serology in cats is unknown. In the report of 48 cats
with coccidioidomycosis, of the 39 cats undergoing testing, all were seropositive
at some point during their illness.
Cytologic confirmation may be made by evaluation of aspirates of affected lymph nodes,
skin lesions, or lungs. The organism can be seen on unstained slides and appears as
a large (10 to 80 µm) round, double-walled structure containing endospores.
24
Multiple biopsy samples may need to be collected and evaluated in order to see the
organism histologically. Although spherules can be detected with routine hematoxylin
and eosin stain (H&E), they are easier to see when PAS or Grocott-Gomoris methenamine
silver stain is used. Commercial laboratories that practice biosafety precautions
can isolate Coccidioides on culture. The mycelia that grow on culture media are highly
infectious. Serologic testing using tube precipitin and complement fixation techniques
were useful in 48 cats with coccidioidomycosis.
24
Itraconazole is typically used for treatment of feline coccidioidomycosis. Of 53 cats
diagnosed with coccidioidomycosis, 67% survived with treatment.
10
Blastomycosis
Blastomyces dermatitidis is the saprophytic dimorphic fungus that causes blastomycosis.
It exists in a mycelial form and reproduces sexually, producing infective spores.
At body temperature, the spores transform into yeast and replicate asexually. Budding
yeasts are 5 to 20 µm in diameter and have a thick, refractile, double-contoured cell
wall.
36
Dogs and people are the species infected most commonly, but blastomycosis has been
reported in other animals, including bats, horses, sea lions, wolves, ferrets, and
nondomestic cats.19, 36 It is rarely reported in domestic cats.
The most likely reservoir for Blastomyces is soil. Because normal soil organisms destroy
most Blastomyces organisms, specific environmental conditions are needed for Blastomyces
to survive. Blastomyces thrives in a sandy, acidic soil near water. It has also been
isolated from decaying wood and vegetation, animal excrement, a beaver dam, and animal
waste.19, 36 Even in endemic areas, blastomycosis occurs in geographically restricted
foci. Living near water is a risk factor for blastomycosis in dogs. In people, disturbing
soil is associated with infection, and precipitation may facilitate the release of
infective spores. Most people and dogs are likely exposed to Blastomyces on their
own property, because there has been documentation of repeated cases occurring at
the same location despite occupation by multiple families.
3
The source of infection in cats is unclear. Many reported cases of feline blastomycosis
have occurred in strictly indoor cats. One study analyzed 60 environmental samples
obtained from four homes in which blastomycosis was diagnosed in cats, and all were
negative for B. dermatitidis.3, 19
During a 10-year period, eight cases of blastomycosis were diagnosed in cats at the
veterinary teaching hospital (VTH) in Illinois, while during a span of 11 years, 5
cats were diagnosed with blastomycosis at the VTH in Tennessee.3, 19 The prevalence
of canine blastomycosis in Tennessee between 1979 and 1989 was 1.2%, compared with
less than 0.1% in cats.
4
Of 571 cats diagnosed with systemic mycosis, 41 (7.1%) were infected with B. dermatitidis.
10
B dermatitidis mainly causes disease in the United States and Canada, but is endemic
in Africa and India and has been documented in Europe and South America.
6
Within North America, endemic areas include the Mississippi, Missouri, and Ohio river
valleys; the mid-Atlantic states; and the Canadian provinces of Manitoba, Ontario,
and Quebec.
36
Blastomycosis has also been diagnosed in New York, Wyoming, South Dakota, Colorado,
and Saskatchewan.6, 27, 36 In a retrospective review of 41 cats diagnosed with blastomycosis,
most cases occurred in Oklahoma, Tennessee, and Wisconsin.
10
Risk factors and the epidemiology of blastomycosis are unknown in cats because of
its rarity.
Infection occurs most commonly by inhalation of infective spores, which establish
infection within the lungs. Direct inoculation of the organism through skin puncture
may occur. Blastomycosis is thought to disseminate through lymphatics and hematogenously.
There is great variation in host response to infection, because dogs are 10 times
more likely to develop blastomycosis than people; blastomycosis is rarer in cats.
No seasonality has been reported in infected cats.
There are so few cases described in the literature that it is not possible to determine
predisposing factors. Many reports provide conflicting data. Most cases described
in the literature were diagnosed at necropsy.
19
Males may be slightly predisposed; one study reported that 69% of 36 infected cats
were male.
3
Breeds described as being predisposed include Siamese, Abyssinian, and the Havana
Brown, but this is not supported in all reports.10, 19 Affected cats have ranged in
age from 6 months to 18 years.
4
The typical age of infected cats varies among publications: In three studies, 75%
were less than 4 years of age, 42% were less than 4 years, and 87% of cats were greater
than 7 years.
19
Duration of clinical signs prior to diagnosis has ranged from 3 days to 7 months.10,
19 A history of immunosuppression is rarely present; 10% of 41 cats with blastomycosis
were FeLV positive, none were FIV positive, and one was positive for feline infectious
peritonitis (FIP).
10
Based on thoracic radiographs and necropsy data, infection in cats occurs most commonly
in the lung, even though respiratory signs may be absent (Figure 33-7
).
19
B. dermatitidis has been documented in lymph node, kidney, eye, CNS, skin, GI tract,
pleura, peritoneum, heart, liver spleen, trachea, and adrenal glands.19, 36 Infection
is frequently disseminated. Clinical signs vary depending on the site of infection.
The most commonly reported clinical signs in cats with blastomycosis vary among publications,
but dyspnea, lethargy, weight loss, and fever are frequently present.
19
Other reported respiratory signs have included cough, tachypnea, sneezing, and increased
bronchovesicular signs.
19
Central nervous system, ocular, and dermatologic involvement may manifest clinically
as well. Ocular changes described include retinal granulomas and detachment, chemosis,
corneal edema, and uveititis.6, 7, 19 Skin lesions may be draining tracts or nonulcerated
dermal masses and range from a few millimeters to a few centimeters in diameter.
19
FIGURE 33-7
Pulmonary blastomycosis in a cat.
(Courtesy Jennifer Stokes.)
Diagnosis of blastomycosis can be difficult in cats, particularly because there are
no pathognomonic clinical manifestations. Hematologic and biochemical changes are
neither specific nor consistent among infected cats but may include anemia, leukopenia
or leukocytosis, monocytosis, hyperglobulinemia, hypoalbuminemia, and hypercalcemia.
19
Radiographic changes may include poorly defined soft tissue opacities with nodules
or masses or alveolar lung consolidation and pleural effusion.10, 19
Definitive diagnosis is made by cytologic or histologic identification of B. dermatitidis.
Pyogranulomatous inflammation is commonly seen associated with large numbers of broad-based
budding yeasts. Diagnosis has occurred by cytologic exam of fine-needle aspirate samples
of infected skin, draining tracts, lymph nodes, and lung. Bronchoalveolar lavage can
also be performed to diagnose pulmonary blastomycosis.
19
In dogs, the sensitivity and specificity of the agar-gel immunodiffusion test (AGID)
was reported as 91% and 96%, respectively. The usefulness of AGID testing for blastomycosis
in cats is unknown. Of three cats with blastomycosis tested using AGID, one was positive.
10
MiraVista Diagnostics offers an antigen test for B. dermatitidis that has been validated
in dogs and has the greatest sensitivity when urine is tested.
50
It is unknown if this test is sensitive or specific in cats.
Currently, treatment with itraconazole is recommended.
6
The prognosis is guarded to poor. Of four cats treated for blastomycosis, three died
within 12 days of diagnosis.
3
Sporotrichosis
Sporotrichosis is a mycotic disease of humans and many animal species caused by the
dimorphic fungus Sporothrix schenckii, which is endemic worldwide. Zoonotic transmission
of S. schenckii between cats and people has been documented and is considered an emerging
zoonosis.11, 45, 48, 54, 55
S. schenckii survives in the environment, typically in decaying vegetation, and people
and animals are infected by wound contamination or penetrating foreign bodies. The
organism becomes pathogenic because of its dimorphic abilities. After entering the
skin through a puncture, bite, or scratch, the fungus converts to a yeast phase. The
organism has also been isolated from the nails and oral cavity of cats and presumably
can be inoculated into bites, scratches, or puncture wounds.47, 48 Three clinical
syndromes of sporotrichosis are known in cats:
1
Localized cutaneous
2
Lymphocutaneous
3
Multifocal disseminated
The localized and lymphocutaneous forms are the most common. Cutaneous lesions are
most commonly found on the face, nasal planum (Figure 33-8
), tail base, and legs and may be solitary or multiple. Lesions appear after an incubation
period of about 1 month and first appear as draining puncture wounds mimicking bacterial
fight-wound abscesses or cellulitis. Treatment with antibiotics does not result in
resolution. The lesions may then become ulcerated and form large, crusted areas. The
localized form may progress to the lymphocutaneous form, especially if not treated.
In the lymphocutaneous form, cutaneous nodules may progress to draining ulcers of
the skin, subcutis, and lymph nodes. The disseminated form is primarily found in the
liver and lungs, but involvement of other organs has been documented.
FIGURE 33-8
Sporotrichosis nodule on the nasal planum of a cat.
(Courtesy Vic Menrath.)
Outbreaks of sporotrichosis are thought to be rare. In a large series of 347 cats
with naturally acquired sporotrichosis in an epidemic in Rio de Janeiro, the median
age was 2 years, and cats of male gender predominated.
46
Most cats were infected through fight wounds, and multiple skin lesions were common.
Most lesions were on the head. The skin lesions were varied and included small crusted
lesions, subcutaneous nodules that progressed to draining lesions and ulcers, extensive
exudative ulcers, and extensive zones of necrosis that exposed muscle and bone. More
than 25% of cats had lymphangitis and regional lymphadenitis. The most common extracutaneous
signs were respiratory signs, such as sneezing and dyspnea. Subclinical infections
were also documented.
It does not appear that infection with FeLV or feline immunodeficiency virus (FIV)
is a predisposing factor for sporotrichosis in cats.46, 54 Concurrent infection with
FIV does not affect clinical outcome.
46
Diagnosis of sporotrichosis in cats is most often by cytologic examination of exudates
and aspirates from abscesses or nodules or impression smears from skin lesions. Smears
stained with a Romanowsky-type stain typically contain large numbers of yeastlike
organisms that are often cigar shaped but may appear as round budding shapes. Histopathology
is not a reliable method of diagnosis; in two published case series, the organism
was not present in more than 1 of 3 affected cats.9, 46 Failure to find the organism
in biopsy specimens may be due to sampling early in infection or individual variation
in immune response. Definitive diagnosis is by fungal culture of exudate from deep
within a draining tract and/or macerated tissue samples.
The drug of choice for sporotrichosis in cats is oral itraconazole. Ketoconazole and
sodium iodide have also been reported as effective treatments, but the rate of adverse
effects is high.46, 54 Successful treatment of localized disease with a combination
of oral itraconazole and intralesional amphotericin B has been described.
25
Secondary bacterial infections should be treated according to culture and sensitivity
results for 4 to 8 weeks. Antifungal treatment should be continued for 1 month past
resolution of clinical signs to prevent recurrence. Treatment may be required for
months to over 1 year; therefore client compliance may be an obstacle to achieving
cure even though the prognosis is good. People handling cats suspected or confirmed
with sporotrichosis should wear gloves as well as wash their hands and arms with a
disinfectant scrub.
Antifungal Therapy
The best therapy for management of systemic fungal disease in cats is ultimately dependent
on the individual patient. Preexisting medical conditions, site of fungal infection,
and cost of therapy are factors to consider when choosing treatment (Table 33-1
).
TABLE 33-1
Drugs for Treatment of Systemic Fungal Infections in Cats
Drug
Dose
Comments
Amphotericin B
Original formulation:0.5 mg/kg, IV, 3 times/weekLipid mixture (Abelcet):1 mg/kg, IV
for 2 hours, 3 times/week
Cumulative dose in cats should not exceed 4 to 6 mg/kg for the original formulation,
and 12 mg/kg for the lipid mixture
Flucytosine (Ancobon)
50 mg/kg, PO, q8h
Used in combination with amphotericin B
Itraconazole (Sporanox)
10 mg/kg, PO, q24h
Administer capsules with food; administer liquid on empty stomach
Fluconazole (Diflucan)
30-50 mg/cat PO q12h75 mg/cat PO q12-24h
Note: Duration of treatment is difficult to determine but should be at least 1 month
past clinical resolution.
Amphotericin B is fungicidal and causes cell death by binding to ergosterol in the
fungal cell membrane and disrupting membrane stability. It has a broad spectrum of
efficacy against many fungal species and was initially the treatment of choice for
systemic mycosis in people and animals. It has been proven to eliminate fungal meningitis.
37
Its potential for nephrotoxicity limits the total dose that may safely be administered
to a patient, and its use in patients with compromised renal function is not recommended.
Newer formulations are safer but more expensive. The three types of newer formulations
of amphotericin B include a lipid mixture (Abelcet), a colloidal suspension (Amphotec),
and a liposome-encapsulated form (AmBisome). The lipid complex is the least expensive
and has been used the most in veterinary medicine.
26
It is 8 to 10 times less nephrotoxic than the original amphotericin B, when administered
to healthy dogs.
26
The new formulations are taken up rapidly by the reticuloendothelial system, leading
to the high drug levels in infected organs, including the liver, spleen, and lungs.
26
A higher cumulative dose of the new formulations may be administered without increasing
risk of drug uptake by the kidneys and nephrotoxicity. The lipid-complexed amphotericin
B has been used successfully in veterinary patients for treatment of cryptococcal
meningitis, histoplasmosis, coccidioidomycosis, blastomycosis, and other systemic
mycoses.
Indications for use of lipid complexed amphotericin B include cryptococcosis with
CNS involvement, in mycotic infections that are severe or progressive and in cats
that cannot tolerate oral administration of antifungal agents. An appropriate dose
of Abelcet in cats is 1 mg/kg intravenously spanning 2 hours. Therapy is administered
3 times weekly for an accumulative dose of 12 mg/kg.
26
If the original formulation of amphotericin B is used, a dose of 0.5 mg/kg IV 3 times
weekly has been recommended.
37
Monitoring for changes in renal function, such as creatinine, blood urea nitrogen
(BUN), and glucosuria, is indicated. Amphotericin B may also be effective as a fungicide
by causing immunomodulation and activating macrophage uptake and killing of fungal
organisms.
26
Amphotericin B combined with flucytosine may provide the greatest efficacy when treating
cats with disseminated disease and/or CNS involvement. This combination is considered
by some as the treatment of choice for feline cryptococcosis.
37
Flucytosine is rarely used as sole therapy, but is combined with other antifungals
to increase efficacy. It is synergistic when combined with amphotericin B and penetrates
the blood–brain barrier. It has been associated with drug reactions in dogs, and its
use may be limited to the first 10 to 14 days of treatment.
37
Azole antifungals inhibit ergosterol biosynthesis, interfering with fungal membrane
function.
26
One benefit of azole drugs is that they allow for treatment of patients without hospitalization.
Itraconazole is considered the drug of choice for treatment of most cases of systemic
mycoses that are not immediately life threatening in cats.26, 37 It does not easily
cross the blood–brain, blood–eye, or blood–prostate barriers. Although it does not
penetrate these organs well, it has been used successfully to treat fungal meningitis
in cats. Such success may be due to a decrease in the blood–brain barrier associated
with inflammation. It is more effective than ketoconazole and has fewer side effects.
Side effects can include GI upset, hepatic disease with elevations in alanine aminotransferase
activity, and rarely, cutaneous lesions resulting from vasculitis. The capsule formulation
of itraconazole should be administered with food to increase absorption, while the
liquid formulation should be given after a fast. It should not be administered with
antacids. Itraconazole is typically dosed at 10 mg/kg PO q24h for treatment of cryptococcosis,
histoplasmosis, coccidioidomycosis, and blastomycosis.6, 22, 37
Fluconazole is effective in treatment of systemic mycoses, particularly when there
is involvement of the CNS, eye, or urinary system. It may be the most effective antifungal
for treatment of feline cryptococcosis.
37
It has also been used in cats that cannot tolerate itraconazole or in which itraconazole
is ineffective. Published doses include 30 to 50 mg/cat PO q12h and 75 mg/cat PO q12-24h.
37
Ketoconazole is not considered a drug of choice for management of feline fungal disease
but has been used successfully in treatment of C. gattii. It has a higher rate of
side effects and is less efficacious than itraconazole.
Newer azoles are on the market and are being used in veterinary medicine. Voriconazole
is a derivative of fluconazole but has greater potency and a broader spectrum of activity.
It is highly bioavailable when administered orally and also comes in an IV formulation.
26
Posaconazole is an itraconazole analog. It has been used successfully in animal models
for the treatment of systemic histoplasmosis and coccidioidomycosis, as well as cryptococcal
meningitis.
26
There is little published data describing use of these newer azoles in cats.
In summary, itraconazole can be considered the first choice for treatment of systemic
fungal disease in cats. Cats with severe, progressive, or immediately life-threatening
disease may need amphotericin B therapy. When cats are suspected to have CNS involvement,
flucytosine combined with amphotericin B may be the best treatment. Patients should
be monitored regularly for drug toxicity and side effects. The ideal duration of treatment
is unknown, but treatment for at least 1 month past clinical resolution is recommended;
if the patient's owner can afford to treat for an additional month or two, that is
recommended in order to decrease risk of recurrence. A decrease in antibody titers
is often associated with effective treatment but does not always indicate cure. In
the future, with newer diagnostic tests available, including the fungal antigen tests
offered by MiraVista Diagnostics, we may be able to serially monitor antigen levels
in infected cats and determine an appropriate time to discontinue antifungal therapy.
Rickettsial Diseases
Rickettsia are obligate intracellular gram-negative bacteria that are transmitted
by an arthropod vector, typically a tick. Their pathogenicity in people and dogs is
well understood; in cats little is known currently. Ehrlichia organisms primarily
infect leukocytes, while Anaplasma species typically infect erythrocytes, endothelial
cells, platelets, as well as leukocytes. Reclassification of several rickettsial organisms
within the families Rickettsiaceae and Anaplasmataceae (order Rickettsiales) occurred
in 2001.
40
The genera Ehrlichia was moved from the family Rickettsiaceae to the family Anaplasmataceae,
while the genera Rickettsia remains in the family Rickettsiaceae.
40
Within the genera Ehrlichia, E. phagocytophila, E. equi, and E. platys were moved
to the genus Anaplasma, while E. risticii and E. sennetsu now belong to the genus
Neorickettsia.
40
Specific information about ehrlichiosis, anaplasmosis, and Rickettsia felis will be
described subsequently. Cats appear less susceptible than dogs to common vectorborne
diseases, including ehrlichiosis and anaplasmosis. There are several reports of ill
cats presenting with clinical signs that are similar to the ones caused by rickettsial
disease in dogs. Presumptive diagnosis of clinical rickettsial disease in cats has
been based on appropriate clinical signs combined with the presence of morulae (intracellular
clusters of organisms), positive serology, positive polymerase chain reaction (PCR)
analysis, and/or response to treatment with doxycycline.
Confirmation of rickettsial organisms as the causative agent of disease in cats is
difficult. Rickettsia are difficult to culture, and morulae are infrequently present.
35
In addition, the presence of morulae that are E. canis-like, for example, does not
confirm infection with the specific Ehrlichia species because the morulae may belong
to another species or genera. Serology has been used to diagnose rickettsial infections,
but there are limitations. Serologic techniques among diagnostic laboratories are
not standardized. Because there may be yet undiscovered rickettsial species targeting
cats, serology results may be negative despite clinical disease. There is serologic
cross reactivity among some rickettsial organisms, making diagnosis of infection with
a specific species difficult.
The use of molecular techniques including real-time PCR may increase detection of
rickettsial pathogens in cats. PCR is sensitive and specific, particularly in the
early phase of disease prior to antibody formation. It can be used to detect rickettsial
DNA in blood, body fluids, bone marrow, and tissue samples. However, positive PCR
results do not confirm an infection in the absence of clinical disease. Although PCR
is highly sensitive, false-negative results can occur. If a rickettsial organism is
harbored within a tissue, then PCR of blood samples would likely be negative. In addition,
in infections with intermittent or brief bacteremia, negative results from testing
of blood cannot rule out infection.
At this point, it is recommended that both PCR and serology be used to diagnose suspect
rickettsial infections in cats. In addition, measurement of convalescent titers and
serial examination of blood or tissue samples by PCR are likely to increase diagnostic
efficiency. It is also important to recognize that one arthropod host may transmit
multiple pathogens, leading to co-infection. This may explain the variation in clinical
signs and response to therapy of cats suspected of having rickettsial disease. It
is recommended that samples be screened for multiple organisms simultaneously in areas
in which vectors for rickettsial disease are endemic.
Although the most effective therapy for treatment of feline rickettsial diseases is
unknown, the American College of Veterinary Internal Medicine recommends that suspect
ehrlichial cases be managed with doxycycline at a dose of 10 mg/kg/day for 28 days.
35
Treatment of other rickettsial infections with doxycycline is also appropriate.
Ehrlichiosis
Vectors for E. canis include the ticks Rhipicephalus sanguineus and Dermacentor variabilis,
and clinical ehrlichiosis in dogs has been well recognized and understood for decades.
40
Although the first evidence of naturally transmitted ehrlichiosis occurring in cats
was described in 1986, our understanding of the disease in cats and which Ehrlichia
species are infective to cats is incomplete.
35
Evidence for feline ehrlichiosis includes cytologic identification of E. canis-like
morulae on blood smears, positive E. canis serology, and PCR evidence of ehrlichial
organism DNA in blood.
35
Feline ehrlichiosis has been recognized globally, because blood from five cats in
North America and France was positive for DNA most consistent with E. canis.
35
In addition, Ehrlichia-like morulae have been detected in peripheral leukocytes of
cats in the United States, Kenya, France, Brazil, Sweden, and Thailand.5, 35 Serology
has been used as a diagnostic tool for evaluation of feline ehrlichiosis; however,
a limitation is that seropositivity does not equate with active infection. There is
a lack of standardization in available methodologies, and variable serologic cross
reactivity occurs among species of Ehrlichia, Neorickettsia, and Anaplasma.
35
Some cats with presumed ehrlichiosis test negative for E. canis antibodies but positive
for N. risticii. Antibodies for N. risticii and Ehrlichia have been detected cats
from Maryland, Virginia, California, and Colorado.
The pathogenesis of feline ehrlichiosis is thought to be similar to that of ehrlichiosis
in dogs.
35
Clinical disease has been described in 55 cats with probable E. canis-morulae in mononuclear
cells, E. canis-like DNA in blood, or seropositivity for E. canis +/− N. risticii.
35
Affected cats ranged from 1 to 14 years of age with no gender predisposition; most
cats were domestic shorthairs5, 35 Some cats had a history of tick infestation. Clinical
signs included fever, anorexia, lethargy, weight loss, pallor, splenomegaly, lymphadenopathy,
and anemia.
35
Clinicopathologic abnormalities included anemia (both regenerative and nonregenerative),
hyperglobulinemia, hypoalbuminemia, and positive antinuclear antibody titers. Both
leukocytosis and leukopenia were documented.
35
Some cats had radiographic evidence of interstitial lung disease.
35
Concurrent infection with Mycoplasma haemofelis, M. haemominutum, Cryptococcus neoformans,
feline immunodeficiency virus, or feline leukemia virus were documented.
35
Cats with suspect ehrlichiosis have been treated with doxycycline, tetracycline, or
imidocarb.
35
In three cats, clinical resolution occurred with doxycycline therapy: 5 mg/kg PO q12h
for 21 days. Five cats seropositive for N. risticii initially had clinical relapse
after doxycycline therapy, but clinical resolution occurred after treatment with a
higher dose: 10 mg/kg PO q12h for 21 days. Imidocarb dosed at 5 mg/kg IM administered
as two injections 14 days apart was successful in treating two cats in Kenya.
The modes of transmission of feline ehrlichiosis are unknown, although vector transmission
and spread through blood transfusion have been documented. Prevention may be managed
by minimizing a cat's exposure to vectors, administering monthly flea and tick preventatives,
as well as by screening potential blood donors for rickettsial species.
Although people, dogs, and cats may develop ehrlichiosis, there is no evidence that
the disease can be transmitted directly from cats to other species.
Anaplasmosis
Anaplasma phagocytophilum is the causative agent of anaplasmosis in dogs and people,
and there is evidence that cats can develop the disease after experimental inoculation
as well as natural transmission. Ixodes tick species are vectors for transmission
of A. phagocytophilum to dogs and are likely vectors for cats.2, 34 At this point,
it is not known if other modes of transmission, such as the ingestion of or contact
with A. phagocytophilum–infected rodents, occurs in cats.
34
In initial research studies, cats inoculated with A. phagocytophilum were found to
have morulae in eosinophils but were asymptomatic.
34
In a subsequent study, when cats with and without FIV infection were inoculated, they
developed clinical disease.
34
Other evidence for the susceptibility of cats to anaplasmosis includes the detection
of A. phagocytophilum DNA in the blood of naturally infected cats in Sweden, Denmark,
Ireland, and the United States. Additionally A. phagocytophilum–like morulae have
been detected in neutrophils of infected cats in, Brazil, Kenya, and Italy.
34
A. phagocytophilum morulae have been confirmed in the neutrophils of Swedish cats.
34
Prevalence of A. phagocytophilum antibodies in 416 cats from six states in the United
States was 4.3%, but blood samples were PCR negative for DNA from Anaplasma and Ehrlichia
species.
2
In Florida, 553 cats were tested for A. phagocytophilum by PCR and all were negative.
2
At this time, it is not known if the prevalence of anaplasmosis is rare in cats or
underdiagnosed because of limitations of current diagnostic tests.
The pathogenesis of feline anaplasmosis is likely similar to that in other species.
The clinical manifestations of anaplasmosis in six cats diagnosed with infection,
based on PCR documentation of A. phagocytophilum DNA with or without serologic evidence
have been described.
34
Cats were 9 to 14 months of age, and both castrated males and spayed females were
infected.
34
Cases occurred in Massachusetts, Connecticut, and Sweden.
34
Clinical abnormalities were most often mild and included fever, lethargy, anorexia,
tachypnea, and the presence of Ixodes tick.
34
Clinicopathologic abnormalities included thrombocytopenia, neutrophilia with left
shift, lymphopenia, and mild hyperglycemia. All cats were FIV and FeLV negative. Morulae
were detected in only one cat; 24% of its neutrophils were affected. Of the three
cats in which A. phagocytophilum serology was performed at presentation, two were
seronegative and the third had a titer of greater than 1 : 640. Subsequently, the
seronegative cats seroconverted, illustrating that negative serology at the time of
initial clinical illness does not rule out anaplasmosis in cats. Titers for A. phagocytophilum
increased, decreased, or fluctuated over time, so use of serology to confirm resolution
of infection is not recommended. With treatment, five of the six cats became PCR negative
within 15 to 139 days after diagnosis.
34
All cats were seronegative for E. canis.
34
Clinical disease in these 6 cats was milder than anaplasmosis in dogs; data from one
study of cats experimentally co-infected with FIV and A. phagocytophilum suggests
that immunocompromised cats may have more severe clinical disease.
15
Although initial microbial therapy varied among the six affected cats, all were ultimately
treated with tetracycline or doxycycline for 20 to 28 days. The dose of doxycycline
administered was 5 to 10 mg/kg PO q12h and 22 mg/kg PO q8h for tetracycline. All cats
had clinical improvement within 48 hours after administration of tetracycline or doxycycline.
Rickettsia felis
The cat flea, Ctenocephalides felis is a reservoir and vector for R. felis, which
is widely disseminated within tissues of the cat flea.1, 44 Naturally infected C.
felis fleas have been found worldwide, although prevalence of infection based on detection
of R. felis DNA using PCR varies.8, 28, 44, 52 In Italy, prevalence of R. felis in
320 cat fleas from 117 animals was 11.9%, while the prevalence was 9% in Germany.8,
18 In one study in the United States, the prevalence of R. felis DNA in 226 cat fleas
from 103 animals was 9%, while in another study 67% of cat fleas collected from cats
from Alabama, Maryland, and Texas were positive for R. felis.1, 28
R. felis–infected fleas have also been found in California, Florida, Georgia, Louisiana,
New York, North Carolina, Oklahoma, and Tennessee. Rickettsia felis DNA has been found
in two research cats exposed to fleas infected with R. felis.
28
Most cats exposed to R. felis–infected fleas do not develop antibodies. This data
suggest that R. felis may not cause clinical disease in cats, bacteremia may be brief
or intermittent, or the organism is harbored in tissues so that blood samples tested
by PCR are negative.
Cats may be potential reservoirs for Rickettsia felis and a source of infection in
people. The pathogenicity of Rickettsia felis in cats is poorly understood. Cats experimentally
infected remained asymptomatic but seroconverted between 2 to 4 months.
23
References
1
Bayliss
DB
Morris
AK
Horta
MC
Prevalence of Rickettsia species antibodies and Rickettsia species DNA in the blood
of cats with and without fever
J Feline Med Surg
11
2009
266
18786845
2
Billeter
SA
Spencer
JA
Griffin
B
Prevalence of Anaplasma phagocytophilum in domestic felines in the United States
Vet Parasitol
147
2007
194
17493756
3
Blondin
N
Baumgardner
DJ
Moore
GE
Blastomycosis in indoor cats: suburban Chicago, Illinois, USA
Mycopathologia
163
2007
59
17262169
4
Breider
MA
Walker
TL
Legendre
AM
Blastomycosis in cats: five cases (1979-1986)
J Am Vet Med Assoc
193
1988
570
3170335
5
Breitschwerdt
EB
Abrams-Ogg
AC
Lappin
MR
Molecular evidence supporting Ehrlichia canis-like infection in cats
J Vet Intern Med
16
2002
642
12465759
6
Bromel
C
Sykes
JE
Epidemiology, diagnosis, and treatment of blastomycosis in dogs and cats
Clin Tech Small Anim Pract
20
2005
233
16317913
7
Bromel
C
Sykes
JE
Histoplasmosis in dogs and cats
Clin Tech Small Anim Pract
20
2005
227
16317912
8
Capelli
G
Montarsi
F
Porcellato
E
Occurrence of Rickettsia felis in dog and cat fleas (Ctenocephalides felis) from Italy
Parasit Vectors
2
Suppl 1
2009
S8
9
Crothers
SL
White
SD
Ihrke
PJ
Sporotrichosis: a retrospective evaluation of 23 cases seen in northern California
(1987-2007)
Vet Dermatol
20
2009
249
19659536
10
Davies
C
Troy
GC
Deep mycotic infections in cats
J Am Anim Hosp Assoc
32
1996
380
8875352
11
de Lima Barros
MB
Schubach
TM
Galhardo
MC
Sporotrichosis: an emergent zoonosis in Rio de Janeiro
Mem Inst Oswaldo Cruz
96
2001
777
11562701
12
Duncan
C
Stephen
C
Campbell
J
Clinical characteristics and predictors of mortality for Cryptococcus gattii infection
in dogs and cats of southwestern British Columbia
Can Vet J
47
2006
993
17078248
13
Duncan
C
Stephen
C
Lester
S
Follow-up study of dogs and cats with asymptomatic Cryptococcus gattii infection or
nasal colonization
Med Mycol
43
2005
663
16396253
14
Duncan
CG
Stephen
C
Campbell
J
Evaluation of risk factors for Cryptococcus gattii infection in dogs and cats
J Am Vet Med Assoc
228
2006
377
16448359
15
Foley
JE
Leutenegger
CM
Dumler
JS
Evidence for modulated immune response to Anaplasma phagocytophila sensu lato in cats
with FIV-induced immunosuppression
Comp Immunol Microbiol Infect Dis
26
2003
103
12493491
16
Gaidici
A
Saubolle
MA
Transmission of coccidioidomycosis to a human via a cat bite
J Clin Microbiol
47
2009
505
19052181
17
Gerds-Grogan
S
Dayrell-Hart
B
Feline cryptococcosis: a retrospective evaluation
J Am Anim Hosp Assoc
33
1997
118
9111720
18
Gilles
J
Just
FT
Silaghi
C
Rickettsia felis in fleas, Germany
Emerg Infect Dis
14
2008
1294
18680660
19
Gilor
C
Graves
TK
Barger
AM
Clinical aspects of natural infection with Blastomyces dermatitidis in cats: 8 cases
(1991-2005)
J Am Vet Med Assoc
229
2006
96
16817721
20
Gionfriddo
JR
Feline systemic fungal infections
Vet Clin North Am Small Anim Pract
30
2000
1029
11033873
21
Graupmann-Kuzma
A
Valentine
BA
Shubitz
LF
Coccidioidomycosis in dogs and cats: a review
J Am Anim Hosp Assoc
44
2008
226
18762558
22
Greene
C
Histoplasmosis
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Elsevier
St Louis
577
23
Greene
CG
Breitschwerdt
EB
Cat-flea typhuslike illness (Rickettsia felis infection
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Elsevier
St Louis
242
24
Greene
RT
Coccioidomycosis and paracoccidioidomycosis
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Elsevier
St Louis
598
25
Gremião
IDF
Schubach
TMP
Pereira
SA
Intralesional amphotericin B in a cat with refractory localised sporotrichosis
J Feline Med Surg
11
2009
720
19553150
26
Grooters
AM
Taboada
J
Update on antifungal therapy
Vet Clin North Am Small Anim Pract
33
2003
749
12910741
27
Harasen
GL
Randall
JW
Canine blastomycosis in southern Saskatchewan
Can Vet J
27
1986
375
17422705
28
Hawley
JR
Shaw
SE
Lappin
MR
Prevalence of Rickettsia felis DNA in the blood of cats and their fleas in the United
States
J Feline Med Surg
9
2007
258
17276123
29
Hodges
RD
Legendre
AM
Adams
LG
Itraconazole for the treatment of histoplasmosis in cats
J Vet Intern Med
8
1994
409
7884727
30
Johnson
LR
Fry
MM
Anez
KL
Histoplasmosis infection in two cats from California
J Am Anim Hosp Assoc
40
2004
165
15007055
31
Kano
R
Kitagawat
M
Oota
S
First case of feline systemic Cryptococcus albidus infection
Med Mycol
46
2008
75
17885946
32
Kerl
ME
Update on canine and feline fungal diseases
Vet Clin North Am Small Anim Pract
33
2003
721
12910740
33
Lamm
CG
Rizzi
TE
Campbell
GA
Pathology in practice. Histoplasma capsulatum infections
J Am Vet Med Assoc
235
2009
155
19601733
34
Lappin
MR
Bjoersdorff
A
Breitschwerdt
EB
Feline granulocytotropic anaplasmosis
Greene
CG
Infectious diseases of the dog and cat
ed 3
2006
Elsevier
St Louis
227
35
Lappin
MR
Breitschwerdt
EB
Feline mononuclear ehrlichiosis
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Elsevier
St Louis
224
36
Legendre
AM
Blastomycosis
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Elsevier
St Louis
569
37
Malik
R
Krockenberger
M
O’Brien
CR
Cryptococcosis
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Elsevier
St Louis
584
38
Malik
R
Martin
P
Wigney
DI
Nasopharyngeal cryptococcosis
Aust Vet J
75
1997
483
9258419
39
Malik
R
Wigney
DI
Muir
DB
Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation
of treatment using orally administered fluconazole
J Med Vet Mycol
30
1992
133
40
Neer
MT
Harrus
S
Canine monocytotropic ehrlichiosis and neoricketsisos (E. canis, E. chaffeensis, E.
ruminatium, N. sennetsu, and N. risticii infections)
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Elsevier
St Louis
203
41
O’Brien
CR
Krockenberger
MB
Martin
P
Long-term outcome of therapy for 59 cats and 11 dogs with cryptococcosis
Aust Vet J
84
2006
384
17092323
42
O’Brien
CR
Krockenberger
MB
Wigney
DI
Retrospective study of feline and canine cryptococcosis in Australia from 1981 to
2001: 195 cases
Med Mycol
42
2004
449
15552647
43
Odom
T
Anderson
JG
Proliferative gingival lesion in a cat with disseminated cryptococcosis
J Vet Dent
17
2000
177
11968919
44
Reif
KE
Macaluso
KR
Ecology of Rickettsia felis: a review
J Med Entomol
46
2009
723
19645274
45
Reis
RS
Almeida-Paes
R
Muniz Mde
M
Molecular characterisation of Sporothrix schenckii isolates from humans and cats involved
in the sporotrichosis epidemic in Rio de Janeiro, Brazil
Mem Inst Oswaldo Cruz
104
2009
769
19820840
46
Schubach
T
Schubach
A
Okamoto
T
Evaluation of an epidemic of sporotrichosis in cats: 347 cases (1998-2001)
J Am Vet Med Assoc
224
2004
1623
15154732
47
Schubach
TM
de Oliveira Schubach
A
dos Reis
RS
Sporothrix schenckii isolated from domestic cats with and without sporotrichosis in
Rio de Janeiro, Brazil
Mycopathologia
153
2002
83
12000130
48
Schubach
TM
Valle
AC
Gutierrez-Galhardo
MC
Isolation of Sporothrix schenckii from the nails of domestic cats (Felis catus)
Med Mycol
39
2001
147
11270404
49
Shubitz
LF
Dial
SM
Coccidioidomycosis: a diagnostic challenge
Clin Tech Small Anim Pract
20
2005
220
16317911
50
Spector
D
Legendre
AM
Wheat
J
Antigen and antibody testing for the diagnosis of blastomycosis in dogs
J Vet Intern Med
22
2008
839
18482276
51
Tofflemire
K
Betbeze
C
Three cases of feline ocular coccidioidomycosis: presentation, clinical features,
diagnosis, and treatment
Vet Ophthalmol
13
2010
166
20500716
52
Tsai
KH
Lu
HY
Huang
JH
Rickettsia felis in cat fleas in Taiwan
Vector Borne Zoonotic Dis
9
2009
561
19125661
53
Vinayak
A
Kerwin
SC
Pool
RR
Treatment of thoracolumbar spinal cord compression associated with Histoplasma capsulatum
infection in a cat
J Am Vet Med Assoc
230
2007
1018
17397341
54
Welsh
R
Sporotrichosis
J Am Vet Med Assoc
223
2003
1123
14584741
55
Yegneswaran
PP
Sripathi
H
Bairy
I
Zoonotic sporotrichosis of lymphocutaneous type in a man acquired from a domesticated
feline source: report of a first case in southern Karnataka, India
Int J Dermatol
48
2009
1198
20064175
Kennedy
Melissa
Little
Susan E.
Viral Diseases
Viral infections of cats are common, especially in the young. Many of the viral agents
affecting cats can cause serious, even lethal disease. Several cause lifelong infections
and affected cats are important sources in multicat settings. Most of the agents are
very contagious, spreading easily from cat to cat. Additionally, some such as feline
parvovirus and calicivirus, are quite hardy and may persist in the environment for
weeks or months. Identification of the infecting agent is critical in these multicat
settings in order to aid control and prevention. Vaccines to protect against several
of these agents have been developed, some of which are considered core vaccine components.
Like viral diseases in other species, very few antiviral chemotherapeutics are available
for treatment. However, the repertoire of efficacious drugs is increasing as more
research is performed. This chapter describes the most common viral agents of concern
in cats.
Feline Herpesvirus-1
Feline herpesvirus-1 (FHV-1) is the agent of viral rhinotracheitis and is a common
respiratory pathogen of cats. An Alphaherpesvirinae subfamily member of the Herpesviridae
family, the virus is a double-stranded DNA virus with an icosahedral protein capsid
and a lipid envelope containing several viral glycoproteins. As a DNA virus, the mutation
rate of herpesviruses is relatively low; thus antigenic variation among FHV-1 strains
is not a major concern. The lipid membrane encasing the virion is derived from the
infected cell, and contributes to the virus’ ability to survive desiccation, making
it an efficient respiratory pathogen. However, it also contributes to the virus’ lability
in the environment; it survives up to 18 hours in a damp environment (less in dry
conditions) after shedding onto inanimate objects and is unstable as an aerosol.
87
In addition, it is easily inactivated by any detergent or soap.
Transmission and Pathogenesis
Most cats become infected with feline herpesvirus as kittens. Direct contact with
an infected cat is the most efficient mode of transmission, but spread by aerosolized
droplets over short distances or by indirect contact with contaminated objects is
also important. Unlike herpesviruses of other animal species, feline herpesvirus primarily
targets epithelia of the upper respiratory tract and conjunctiva and only rarely spreads
beyond these tissues to cause systemic disease. Virus replication in these cells results
in cell death (cytolysis) and loss. This may manifest as ulceration, necrosis, and
inflammation in the oronasal and pharyngeal tissue. In the conjunctiva, epithelial
necrosis may also occur, with serosanguinous to purulent discharge, which may be profuse.
In severe cases, erosion to the bone may occur in the nasal cavity from rhinitis,
and the resultant distortion of bone and cartilage may lead to chronic rhinosinusitis
(cats known as “snufflers”).
In a manner similar to all herpesviruses, FHV-1 enters a latent state in innervating
sensory nerves after acute infection. In cats, this most commonly occurs in the trigeminal
ganglion, and is estimated to occur in about 80% of infections.
88
From this latent state, the virus can be reactivated, especially during stressful
episodes, leading to replication in the epithelia, virus shedding, and in a minority
of cats, disease. Termed recrudescence, it can be stimulated by any stressor, including
trauma, concurrent disease, parturition, boarding, or changes in social hierarchy.
Recrudescent episodes are often asymptomatic, and may be an important mechanism of
maintaining the virus in a population. As new, immunologically naïve kittens are introduced,
whether by birth (e.g., breeding cattery) or intake (e.g., shelter setting), asymptomatic
shedders may expose them to the virus.
Clinical Signs
The typical presentation of FHV infection is that of upper respiratory tract disease
(see also Chapter 30): sneezing, nasal and/or ocular discharge, fever, depression,
and decreased appetite following an incubation period of 2 to 6 days.
13
Conjunctivitis is not uncommon, and can progress to severe hyperemia and chemosis,
with mucopurulent ocular discharge (see also Chapter 29). Infection may lead to corneal
ulceration because of the viral damage of the corneal epithelium. In fact, FHV-1 is
believed to be the most common cause of feline ocular disease, and corneal ulceration
in a cat should be assumed to be a consequence of FHV-1 infection until proven otherwise.
110
This may manifest as a typical dendritic ulcer or may progress to involve the stroma,
leading to a desmetocele.
110
Occasionally, cats may manifest with stromal keratitis; this uncommon manifestation
is a consequence of the immune response to herpesvirus antigen rather than direct
destruction by the virus itself. The corneal stroma becomes infiltrated with mononuclear
white blood cells, primarily lymphocytes, which may lead to blindness.
110
Less common manifestations of FHV-1 are ulcerative dermatitis and stomatitis. Ulcerative
dermatitis may be multifocal, often involving the face or planum nasale, but may involve
other areas of the skin (Figure 33-9
). Affected cats may not have concurrent or historical evidence of respiratory infection.
161
Because lesions may involve eosinophils in addition to neutrophils, and intranuclear
viral inclusions may not always be found, misdiagnosis as eosinophilic granuloma complex
is a concern.
161
Cases of stomatitis are also relatively uncommon and may involve the soft palate and
tongue.109, 161 An association with chronic gingivostomatitis has not been found.
238
FIGURE 33-9
Herpesvirus may cause an ulcerative dermatitis that may be multifocal, often involving
the face or planum nasale.
Diagnosis
Diagnostic testing for FHV-1 infection primarily involves virus detection, because
most cats are seropositive from either natural exposure or vaccination. Prevalence
rates for seropositive status may be as high as 97%.
180
In addition, studies have shown that the magnitude of the FHV-1-specific antibody
levels does not necessarily correlate with presence of either acute or chronic FHV-1
infection.
180
Diagnosis of the classic presentation of upper respiratory tract disease in kittenhood
is relatively straightforward. Methods for viral detection include virus isolation,
viral antigen detection, and detection of viral genetic material. With ocular involvement,
conjunctival and/or corneal swabs, scrapings, or brushings are collected for testing.
In addition, pharyngeal and/or nasal swabs should be collected from cats with upper
respiratory tract disease.
299
Virus isolation is the gold standard because it identifies actively replicating virus,
but may have a turn-around time of several days to a week. Samples should be shipped
chilled and preferably overnight to the testing laboratory. Virus isolation may be
falsely negative with chronic herpesviral-induced disease. This is due to the presence
of locally produced neutralizing antibodies on the mucosal surface, preventing viral
replication in cell culture. In addition, virus may be isolated from clinically normal
cats.
277
Viral antigen detection using immunofluorescence is fast and inexpensive; however,
sensitivity is relatively low, especially in chronic infections. This testing is done
on corneal, conjunctival, or oropharyngeal scrapings, and samples must be collected
prior to fluorescein administration to avoid test interference.
Genetic detection using polymerase chain reaction (PCR) has become the most commonly
used assay for virus detection. This assay, done on similar samples as those described
above, amplifies viral genetic material through repeated rounds of DNA synthesis.
The amplified viral material is generally identified using a probe (e.g., TaqMan real-time
PCR). This technology has very high sensitivity and specificity, and does not require
viable virus, unlike virus isolation. The exquisite sensitivity of PCR is a double-edged
sword, however, because it may detect subclinical, recrudescent, and even latent infections;
thus positive results must be interpreted carefully.110, 284, 291 Studies have shown
that, using PCR, FHV-1 may be detected in many clinically normal cats,178, 276, 291
as well as in normal corneas.
277
In addition, it appears possible that PCR assays may detect vaccine virus as well
as field strains.
178
Therefore an increase in test sensitivity does not necessarily equate with diagnostic
sensitivity. Genetic detection by PCR may also be used to identify virus in skin lesions
of ulcerative dermatitis resulting from FHV-1.
161
In addition, histopathology may identify viral inclusions, and immunohistochemistry
can be used for viral detection in biopsy samples.109, 161
Treatment
Advancements have been made in the treatment of FHV infection in cats, and in fact,
this is one agent for which specific antiviral medications are available. Although
none are approved for veterinary use in the United States, some success has been achieved
with their use. It is critical to remember, however, that human antiviral medications
should not be used unless safety and efficacy have been proven in cats because some
have proven to be highly toxic, even fatal to cats. Topical antivirals used in cases
of FHV-1 ocular disease include trifluridine, vidaribine, and idoxuridine. These drugs
are virostatic, and must be given often; thus owner compliance may be a challenge.
Typically, recommendations are to apply these as many times as possible throughout
the day, usually every 4 to 6 hours being the maximum. Recently, topical instillation
of a 0.5% cidofovir solution every 12 hours led to clinical improvement and decreased
viral shedding in experimental FHV-1 infection.
80
Its usefulness in natural infection is being evaluated. The advantage to this medication
is its less frequent administration.
Systemic nucleoside analogs developed for human herpesvirus infections have shown
some efficacy against feline herpesvirus, at least in vitro. Toxic side effects have
been reported with some, such as acyclovir, but others, such as ganciclovir, may prove
to be useful clinically. Famciclovir has been shown to be effective for FHV-1–associated
ocular disease, rhinosinusitis, and dermatitis in at least one study.
184
Clinical trials are required to optimize the dose and schedule.
Interferon (IFN; both human IFN-alpha and recombinant feline IFN-omega) has been used
with some success, and has been shown to be efficacious in vitro.
267
To date, recombinant feline interferon omega (rFeIFN) is not available in North America.
Effectiveness of rFeIFN in vivo for dermatitis associated with FHV-1 has been shown
in at least one case report.
105
L-lysine given orally inhibits herpesviral protein synthesis and restricts virus replication
by antagonizing the growth promoting effect of arginine. In vitro, FHV-1 replication
was significantly reduced when lysine was present in the growth medium.
179
It is optimal when used early in infection, or as a means to prevent recrudescence
during stress, where it has been shown to reduce viral shedding in latently infected
cats.
181
However, studies evaluating its usefulness in preventing upper respiratory tract disease
(URTD) in multicat settings, such as shelters, have shown no positive effect from
daily lysine supplementation.
243
In fact, one study actually found increased viral shedding and severity of signs of
URTD in shelter cats fed lysine supplements.
62
In another study evaluating the effectiveness of dietary lysine supplementation in
shelter cats with enzootic upper respiratory disease, mean disease scores were higher
for cats fed the lysine-supplemented diet.
183
However, food intake (and therefore lysine intake) decreased when lysine was added
to the diet. In addition, cats in the study were group housed and group fed so that
individual lysine intake could not be monitored. Despite this, oral administration
as a bolus (250 to 500 mg/cat/day) for acute infections and as a supplement for prophylaxis
in cats with recurrent signs has been recommended.
182
Lysine administration to cats appears to be safe, though the effects of long-term
administration on plasma arginine concentrations are not known.
183
In one study, plasma arginine concentrations declined in lysine-supplemented cats
during a 52-day monitoring period, leading the authors to recommend monitoring of
plasma arginine in cats receiving long-term lysine supplementation.
183
In experiments, bovine lactoferrin has been shown to inhibit virus attachment and
entry, and may eventually be available as an antiviral treatment for FHV-1.
17
An immune-enhancing probiotic, Enterococcus faecium SF68, used as a dietary supplement
has been shown to reduce evidence of clinical disease associated with chronic infection.
160
Although the study size was small (12 cats), the findings warrant further clinical
evaluation. At least one study has shown improvement in adult cats with chronic rhinitis
by administration of liposomal complexes containing interleukin-2 (IL-2) DNA as an
immunotherapeutic.
298
Another approach under investigation is the use of ribonucleic acid interference to
inhibit FHV-1 replication.
305
Prevention and Control
Protection following recovery is not long-lived, and reinfections may occur. Antigenic
variation is not a significant problem with feline herpesvirus; thus the antigenic
coverage of available vaccines is adequate. Vaccines do not prevent infection or production
of the carrier state. They do offer protection from disease, however, and FHV-1 is
considered a core component of feline vaccines.50, 249, 284 The nonadjuvanted modified
live vaccines that contain FHV-1 in combination with other agents have been shown
to be both efficacious and safe when administered as directed. In multicat situations
where FHV-1 infection is endemic, intranasal vaccination may be used in kittens for
early protection from clinical disease and decreased viral shedding.
159
In addition, response to intranasal vaccination is not affected by the presence of
maternal antibody. More information on FHV-1 vaccination is found in Chapter 8.
Feline Calicivirus
Feline calicivirus (FCV) is a highly contagious respiratory pathogen of cats. In addition
to the classic respiratory disease, FCV is associated with several other disease syndromes,
including polyarthritis, gingivostomatitis, and systemic vasculitis. The virus is
classified as a Vesivirus in the family Caliciviridae. It is a small nonenveloped
virus, making it very hardy in the environment, and it is easily spread by fomites,
including pet owners and hospital staff.
133
The viral genome is single-stranded RNA, giving it a significant mutation rate, much
higher than that of FHV-1. This may lead to changes in antigenicity (many strains
that vary antigenically exist) as well as virulence.
The gene encoding the capsomer protein, the major structural protein, has variable
regions that distinguish strains of FCV. These regions also contain important immunologic
epitopes; thus antigenic variability among strains is common, and has an impact on
vaccine efficacy. For most vaccines, there is sufficient antigenic overlap to allow
cross protection to heterologous strains following immunization with one strain of
FCV, but protection against all field strains may not be equal. Genetic variability
may also have an impact on disease phenotype, but does not segregate with antigenicity;
that is, differences in disease manifestations do not correlate with differences in
antigenicity. This, too, has an impact on vaccine design and development.
Transmission and Pathogenesis
FCV is shed in secretions from the oropharynx, conjunctiva, and nose. Transmission
is most efficient by direct cat-to-cat contact and by fomites. Aerosol transmission
is less important, because sneezed macrodroplets do not travel far (less than 4 feet).
A major source of infection is asymptomatic carrier cats that shed virus continuously.
Unlike FHV-1, FCV shedding is not influenced by stress. There is a high prevalence
of FCV in healthy cats (up to 24%, depending on the assay). Carrier cats may shed
for months to years (even lifelong),
302
although one study showed that 50% of infected cats ceased shedding within 75 days.
86
Long-term analysis of FCV shedding patterns in five naturally infected colonies revealed
three distinct patterns of shedding in individuals: cats that shed virus consistently,
cats that shed virus intermittently, and cats that never shed virus.
45
Re-infection after recovery is possible.
Feline calicivirus primarily targets epithelia of the upper respiratory tract, oral
cavity, and conjunctiva. Unlike FHV-1, it is not associated with corneal infection
and ulceration. The most common lesion associated with FCV infection is oral ulceration.
In general, clinical signs begin as vesicular lesions in the mouth, and are commonly
seen on margins of the tongue (Figure 33-10
).
239
As the overlying epithelia necroses, the lesions ulcerate and become inflamed. Feline
calicivirus may also target alveolar epithelia of the lower respiratory tract. Some
strains appear to be quite pneumotropic, leading to severe interstitial pneumonia.
FIGURE 33-10
The most common lesion associated with feline calicivirus infection is oral ulceration,
commonly on the margins of the tongue.
Infection with FCV also produces a transient viremia, leading to widespread distribution
of the virus.
239
In most cases, this dissemination does not manifest clinically. Uncommonly, disease
beyond the respiratory tract may occur. Lameness associated with acute synovitis may
occur, and although the precise mechanism of disease remains unclear, viral antigen
associated with joint macrophages has been identified.
239
Rarely, a virulent systemic (VS-FCV) manifestation may occur, and may appear as an
outbreak within a population.132, 223, 247, 260 This syndrome involves widespread
vasculitis and multiorgan failure and has occurred in vaccinated animals.
223
Epithelial infection and necrosis occurs in skin as well as mucous membranes, leading
to ulceration that often involves the ears, face, and paws (Figures 33-11
).
239
The mortality rate of this syndrome is quite high.
FIGURE 33-11
Epithelial necrosis associated with virulent systemic calicivirus infection occurs
in skin as well as mucous membranes, leading to ulceration that often involves the
ears (A), face (B), and paws.
(Courtesy Dr. Patricia Pesavento, University of California, Davis, Calif.)
The underlying pathogenesis of this virulent clinical manifestation appears to involve
viral mutations leading to hypervirulence, though the precise mutation remains unknown.
In each documented outbreak where data is available, the virulent strain seems to
have appeared spontaneously by mutation from caliciviruses already present in the
group. Each isolate has been genetically unique. VS-FCV isolates are not members of
a single clade.
212
Instead, these mutant viruses are emerging from several different lineages intermixed
with other field strain FCVs. In addition, the emergence of these variants seems to
involve host and environmental conditions as well. Thus far, no common mutation has
been identified; however, at least one report describes point mutations leading to
an additional glycosylation site in the capsomer protein of some hemorrhagic isolates.
2
Interestingly, most of the outbreaks associated with this form of FCV have arisen
in shelter or rescue situations. One theory is that in these settings, FCV infection
may be endemic in the population; in these situations, rapidly replicating virus that
can attain high titers in a relatively short period of time is selected for because
of the immunity of the endemically infected population.
239
When introduced into a population, this rapidly replicating, “hot” variant may lead
to systemic dissemination and disease.
Host parameters have also been speculated to play a role in VS-FCV cases. In particular,
immunopathologic mechanisms may contribute to the disease production.
74
Local modulation of cytokine levels have been found associated with lesions, and may
contribute to the vasculitis and increased vascular permeability seen.
Clinical Signs
Clinical presentations with FCV infection can vary from mild upper respiratory tract
disease to viral pneumonia to lethal systemic disease. The typical presentation is
similar to FHV infection; though the ocular discharge generally remains serous, corneal
ulcers do not occur and oral ulcers are common. Typically, cats present with vesicular
and ulcerative lesions of the oral cavity that may also involve the lips, nares, and
even paronychial skin. Sneezing, hypersalivation, serous ocular and nasal discharge,
and fever are seen. Ocular lesions include conjunctival hyperemia, chemosis, and blepharospasm.
133
The majority of infections are mild and self-limiting. Acute lameness with joint and
muscle pain may be seen in kittens associated with either FCV vaccine strains or field
virus.
219
Affected cats may be febrile, and about 25% have oral ulceration. Clinical signs resolve
quickly, usually within 72 to 96 hours.
239
Feline calicivirus has also been associated with chronic lymphoplasmacytic gingivostomatitis.
61
However, other pathogens and host factors likely also play a role in this syndrome.
239
For virulent systemic FCV (VS-FCV) infection, disease is typically more severe in
adults than kittens. Clinicopathologic abnormalities associated with VS-FCV are generally
nonspecific, such as neutrophilia, hyperglobulinemia, and elevated liver enzymes.
Characteristic clinical signs that have been described include subcutaneous edema,
particularly of the head and limbs, ulceration of pinna and footpads, and crusting
lesions of the face, ears, and limbs.133, 239 In addition, signs such as jaundice,
dyspnea, vomiting, and diarrhea, may be observed. However, mild or subclinical infections
may also occur, and asymptomatic cats are able to transmit fatal disease.
133
Mortality rates have been reported as high as 60%.
228
On necropsy, affected cats commonly have hepatocellular necrosis, interstitial pneumonia,
and fluid in body cavities.133, 228
Persistent infections following recovery from acute disease are not uncommon. Unlike
FHV, persistent FCV infections are not latent and shedding is continuous. These asymptomatic
shedders are important sources of the virus in a population and may be the source
of new variants. Infected cats may continue to shed the virus throughout their lifetime,
but most shed for periods of weeks to a few months.
Diagnosis
The presence of severe oral ulcerations is an important clinical indicator of FCV
infection, even in cases of VS-FCV. Confirmation of a diagnosis of FCV, as with FHV,
relies primarily on detection of the virus, because the majority of cats are seropositive
for FCV. Viral identification is particularly important in multicat settings. Virus
isolation is the gold standard, because it detects replicating virus. Virus can be
isolated from conjunctival and nasals swabs, but the highest success rate is achieved
with oropharyngeal swabs. Samples should be shipped cooled (e.g., with ice packs)
overnight to the testing laboratory. Antigen detection on slides made from swabs of
the same sites, as for virus isolation, can also be done but is generally of lower
sensitivity. As with FHV, detection of FCV nucleic acid by PCR is being used more
frequently for diagnosis and is done on the same samples as for virus isolation.
3
The drawback of PCR testing for FCV not observed with FHV is the genetic variation
of FCV, potentially leading to false-negative results. At least one report has identified
a highly conserved genetic region of the virus that can be targeted for detection
of the majority of field strains.3, 4 However, it is possible that PCR assays may
also detect vaccine virus in addition to field strains.
157
It is recommended that samples submitted for PCR NOT be frozen; refrigeration and
shipment on an ice pack is suggested.
157
None of the assays described can distinguish the virus of virulent systemic disease
from those causing more classic disease; this classification is currently based on
clinical presentation. In cases of suspected VS-FCV, samples from the same sites as
for typical presentations should be collected. In addition, tissue samples from those
animals that die should be submitted for histopathology and immunohistochemistry or
PCR. These samples should include parenchymal organs and ulcerated lesions (e.g.,
skin, foot pads, lingual areas).
Interpretation of positive results for each of these ante mortem assays must be done
in light of the fact that asymptomatic carrier states are not uncommon; thus finding
the virus in an ill cat does not necessarily prove causation of the current disease.
Treatment
Treatment of FCV infection primarily involves symptomatic and supportive care. Fluids
and nutritional support (e.g., esophagostomy or gastrostomy tube feeding) are important
for anorectic cats, and oxygen therapy for dyspneic cats is critical. Broad-spectrum
antibiotics should be used if bacterial infection is suspected. Recombinant feline
interferon has demonstrated antiviral activity in vitro, but in vivo effectiveness
is unclear.
209
Currently, no specific antiviral medication for FCV exists. A recent study showed
efficacy of virus-specific compounds in blocking FCV replication in vivo.
270
This technology, which is referred to as phosphorodiamidate morpholino oligomer (PMO),
uses virus-specific nucleic acid sequences that bind to viral RNA, preventing translation
of viral proteins. In at least one study, it was safe and reduced disease development,
virus shedding, and mortality.
270
As this technology is developed, a commercially produced medication may become available.
For cats with VS-FCV, intensive care using parameters described above are needed,
and corticosteroids for the immunopathologic component may be beneficial.133, 239
Oral interferon-alpha has also been used in these cases, though it is not clear if
it contributed to survival.
133
Prevention and Control
Vaccination is the main means of control, and, as with FHV, prevents disease but not
infection nor the carrier state. Calicivirus is considered a core component of feline
vaccines.50, 239, 249 Most vaccines contain a single strain, typically strain F9 or
strain 225, and these strains have been shown to be broadly cross-reactive based on
neutralization studies.
234
Traditional calicivirus vaccines, however, do not appear to be protective against
virulent systemic disease. Manufacturers are investigating the utility and inclusion
of additional strains in vaccines to increase the spectrum of protection. Newer vaccine
strains appear to induce neutralizing antibodies against a higher proportion of calicivirus
field strains.129, 235 A vaccine containing a virulent systemic strain is available,
although the ability of this vaccine to protect against future outbreaks of VS-FCV
disease is unknown. A bivalent vaccine containing two strains with broad cross-antigenicity
based on in vitro cross-neutralization evaluation was found to provide protection
against heterologous strains.
235
This study validated the use of cross-neutralization tests to evaluate cross-protection
of vaccine strains. It is important to bear in mind that inclusion of two or more
strains isolated from different disease manifestations does not necessarily insure
broad protection against the varied pathogenic phenotypes. Rather, neutralization
assays are critical for assessing the protective spectrum of any new vaccine. It will
be difficult to achieve a vaccine that provides protection against all strains in
circulation because of the antigenic variability of FCV, and continued evaluation
of prevalent strains and their antigenic relatedness to vaccine strains will be critical.
In a clinical setting, if vaccine breakthroughs are occurring within a cat population,
boosting with a different strain of FCV may enhance the protection of the population.
More information on calicivirus vaccines is found in Chapter 8.
Environmental decontamination is also important for control in multicat situations,
including veterinary clinics. Because of the environmental hardiness of the virus,
detergent alone will not inactivate FCV. The virus can persist for days to weeks in
the environment, and disinfection requires products with oxidizing activity, such
as 5% sodium hypochlorite diluted 1 : 32 and potassium peroxymonosulfate.
239
Quaternary ammonium products are not effective against FCV.
69
Thus decontamination following examination or housing of any cat with URT infection
should include cleaning with a detergent to remove organic matter, followed by disinfection.
133
During outbreaks of virulent disease because of FCV, stringent quarantine measures
and barrier nursing are required to prevent the spread of the virus. All affected
and exposed cats should be strictly isolated, and if possible, treatment away from
the veterinary hospital is ideal.
239
Additional and more detailed control measures can be found elsewhere.133, 239
Influenza Virus
Influenza virus is an uncommon pathogen of cats, but several occurrences have been
documented. The virus known as highly pathogenic avian influenza H5N1 (HPAI H5N1)
was found to infect cats in 2004 in Southeast Asia, while the human pandemic strain
of 2009 (H1N1) was transmitted from a human to a cat in 2009. Because of these occurrences,
it is important that veterinarians understand the virus and its pathogenesis not only
for patient care but, perhaps, even more importantly for communication with the public.
Influenza viruses are members of the Orthomyxoviridae family. These viruses are enveloped
viruses with a genome of single-stranded RNA. The majority of influenza viruses are
classified antigenically as type A (based on internal viral proteins). Subtypes of
the virus are based on antigenicity of the two viral glycoproteins embedded in the
viral envelope, the hemagglutinin (H) and neuraminidase (N) proteins, and are designated
by numbers (H1-16; N1-9). In addition to antigenicity, the hemagglutinin also affects
virulence of the virus, and certain subtypes are associated with more pathogenic strains,
notably H5 and H7. Another important characteristic of this family is the segmentation
of the genome, with each virus containing seven to eight separate genetic segments
encoding individual viral proteins. This allows for a unique form of viral mutation
called reassortment. As with all RNA viruses, the mutation rate of the genome is quite
high, and generally manifests as small point mutations, which lead to relatively minor
amino acid changes in the viral proteins. Reassortment involves the exchange of entire
gene segments when one or more distinct influenza viruses infect the same cell. This
is often the mechanism of significant changes in antigenicity, virulence, or host/tissue
tropism of influenza viruses. For example, the 2009 pandemic H1N1 influenza is a quadruple
reassortant, having gene segments from four distinct influenza viruses, two mammalian
and two avian in origin.
24
Reassortment is often referred to as “antigenic shift,” reflecting the relatively
large change in the viral genome, while “antigenic drift” refers to the smaller point
mutations observed from season to season within a single strain.
The natural reservoirs of influenza viruses are birds, primarily waterfowl. The most
common mammalian species affected are pigs, horses, and humans; more recently, dogs
have experienced infection with a variant derived from equine influenza virus H3N8.
Cats are only rarely infected with influenza virus.
In 1997, outbreaks of the HPAI H5N1 occurred in poultry in Southeast Asia. Subsequent
spread of H5N1 strains in birds has occurred in Europe, the Middle East, and Africa.
Sporadic cases of H5N1 in humans have also occurred with relatively high mortality.
In 2004, the first report of H5N1 in domestic cats in Thailand was made by the World
Health Organization.
287
Subsequent occurrences in domestic cats, as well as tigers and leopards, have been
documented in Turkey, Iraq, China, Germany, and Austria.
18
In the majority of cases, exposures occurred from contact with infected poultry. HPAI
H5N1 has not occurred in North or South America in either birds or mammals, to date.
In 2009, a new strain of H1N1 spread to humans causing a worldwide pandemic. This
virus is a reassortant that has infected a number of species, including turkeys, ferrets,
and swine. Infection of a domestic cat in the United States was documented in 2009,
with infection occurring from an infected person to the pet cat in the household.
274
Transmission and Pathogenesis
Oral infection of cats, particularly with avian influenza (e.g., by consumption of
infected bird carcasses) can occur. In addition, aerosol and direct contact may be
a means of transmission (i.e., spread of human H1N1 to cats by contact with infected
owners). Finally, indirect contact, for example, with feces from birds infected with
HPAI H5N1, may occur. Infections may be subclinical or may manifest with mild to severe
disease ending in death. Factors such as dose of virus, strain virulence, and host
factors may have an impact on the severity of disease. Prevalence of influenza infection
in cats is very low, including in areas where HPAI H5N1 occurs, and cats are not believed
to be important in maintenance or transmission of influenza virus for humans.
187
In fact, transmission of the virus from cats to humans has never been documented.186,
187 It is currently not known how well HPAI H5N1 can spread from cat to cat under
natural conditions, although it has been shown to occur in experimental settings.152,
296
Natural and experimental infections with HPAI H5N1 lead to viral replication in the
upper respiratory and gastrointestinal tracts.
285
Spread to the lower respiratory tract with viral replication in type II pneumocytes
may occur leading to alveolar damage.
286
This may manifest as severe pneumonia.186, 286 With HPAI H5N1, viremia may also occur,
leading to spread to other tissues. In fact, in addition to pneumonia, hepatic necrosis
is a common finding and contributes to the pathogenesis of this virus in cats.
150
In addition, neurologic disease associated with a nonsuppurative encephalitis has
been found in natural infection with HPAI H5N1.
285
Infected cats may shed the virus in respiratory secretions and feces.
186
Clinical Signs
In general, the incubation period for influenza in cats is quite short, usually 2
to 3 days. Typical signs, whether HPAI H5N1 or human pandemic H1N1, are fever, decreased
appetite and activity, and respiratory signs such as dyspnea.18, 285 Conjunctivitis
may also be observed.
285
With HPAI H5N1, signs of systemic spread may include icterus, hemorrhagic lesions,
and neurologic signs such as seizures and ataxia.
285
Diagnosis
Diagnosis may be established by virus detection or serology for virus-specific antibodies.
For the former, virus isolation as well as genetic detection by PCR may be performed
on oropharyngeal swabs or tissues post mortem.186, 285 In addition, immunohistochemistry
for viral antigen may be performed on tissues post mortem.
285
Treatment and Control
Treatment using human antiviral medication, such as oseltamivir (Tamiflu, Genentech,
South San Francisco, Calif.) has not been clinically evaluated and is not recommended.
18
Supportive treatment, including oxygen therapy as needed, is generally all that is
recommended. No vaccine is currently commercially available for any influenza of cats,
although experimental vaccines have been designed. Control is by and large aimed at
preventing exposure, including avoiding access to uncooked poultry.18, 186 Additional
recommendations may be found elsewhere.18, 186
Feline Panleukopenia
Feline panleukopenia is caused by feline parvovirus (FPV), and remains a significant
disease of cats. In addition to FPV, the newer canine variants of canine parvovirus
(CPV), specifically CPV-2a, CPV-2b, and CPV-2c reacquired the ability to replicate
and cause disease in cats. All of these variants are closely related, sharing approximately
99% DNA homology. Parvoviruses are small nonenveloped viruses with a single-stranded
DNA genome. A notorious property of the parvoviruses is their extreme hardiness in
the environment. They are shed in feces of infected animals and may remain infectious
in the environment for months, or even years, when protected by organic matter.
101
Parvoviruses are unique among most DNA viruses in that they have a significant mutation
rate, more similar to that of RNA viruses; thus mutations occur in circulating field
virus. Feline parvovirus is in evolutionary stasis as compared with CPV.
55
Canine parvovirus-2 is believed to be ancestrally related to FPV. It emerged in 1978,
and as it adapted to dogs, additional variants arose with relatively minor amino acid
changes in the capsomer protein genes. The original CPV-2 is now believed to be extinct,
and CPV-2b is the most prevalent variant in circulation. In recent years, additional
variants have emerged, and differ from CPV-2b by just a few amino acid residues, with
some leading to antigenic differences. The nomenclature of these variants is confusing
and has led to the reporting of several distinct CPV-2c isolates. These variants have
been identified in Asia, Europe, South America, and most recently, the United States.55,
124, 134 One of these variants contains a mutation at amino acid residue 426 of the
major capsid protein, an important antigenic epitope of CPV, leading to substitution
of an aspartic acid residue with glutamic acid.
56
This mutant has been reported to be replacing CPV-2b in Italy and is present in dogs
in the United States. The disease associated with these newer variants appears to
be similar to that seen with earlier strains, including vomiting, diarrhea that may
be hemorrhagic, and leukopenia. The mortality rate thus far does not seem to be significantly
different from that of previous isolates. Interestingly, the new canine variants that
emerged from the original variant, CPV-2 (which lacked the ability to infect cats),
have all reacquired the ability to infect and cause disease in cats.54, 85, 134 This
includes both CPV-2b and CPV-2c, which are currently the most prevalent variants in
circulation. Thus when we discuss feline panleukopenia, it is important to bear in
mind that the infecting agent may be either feline or canine in origin.
Transmission and Pathogenesis
FPV is shed from all body secretions during active disease but is most consistently
found in feces. Replication of the virus in intestinal epithelia leads to fecal shedding
of the virus, which is at very high levels in the acute phase of disease (≥109 TCID50/g).
The period of viral shedding is usually only a few days, but recovered cats can shed
virus in urine and feces for as long as 6 weeks.
49
Infection with FPV occurs through the oral cavity, where the virus initially replicates
in local lymphoid tissue. From there, the virus disseminates via lymphatics and blood
to many tissues. As discussed below, successful viral replication leading to cell
lysis occurs only in those cells that are actively replicating. Destruction of intestinal
crypt cells leads to blunting or complete loss of intestinal villi, while bone marrow
infection leads to profound leukopenia. In addition, destruction of lymphoid tissues
can contribute to the virus-induced immunodeficiency.
All parvoviruses share a tropism for cells of high mitotic index; that is, these viruses
can only complete their replication cycle in cells that are rapidly dividing. With
its small genomic coding capacity, much of the replication machinery for the virus
must be provided by the infected cell. Parvoviruses, unlike larger DNA viruses, such
as adenoviruses, have no ability to “push” cells into the cell cycle; thus cells must
be actively dividing to support parvovirus replication. In kittens and adult cats,
this includes cells of lymphoid tissue, blood cell precursors in the bone marrow,
and intestinal crypt epithelia. In the neonate, this also includes tissues such as
the cerebellum and myocardium. The virus may also target a wide variety of cells in
the developing embryo or fetus, causing reproductive loss. The virus causes a lytic
infection in target cells, leading to their destruction. The typical clinical presentation
in kittens reflects the bone marrow and intestinal epithelia involvement. For the
former, because of the shorter half-life of white blood cells compared with red blood
cells, this destruction generally manifests as a severe leukopenia, though anemia
can occur. Anemia can also occur as a consequence of blood loss in the intestines.
Clinical Signs
The clinical presentation of FPV infection includes profound depression, a consequence
of the bone marrow depletion, anorexia, and fever. Signs referable to the intestinal
infection may not be evident initially or may only include vomiting, but diarrhea
that may be hemorrhagic is a hallmark sign in most infections.42, 293 Kittens quickly
become dehydrated and may be moribund with subnormal body temperatures. The classic
disease presentation is most common in kittens at the time that maternal immunity
wanes and mortality is high. A study of kitten mortality in the United Kingdom revealed
25% of kitten deaths were due to FPV.
37
Infection of kittens in late gestation or in the neonatal period may result in myocardial
or cerebellar destruction. The latter syndrome manifests as permanent ataxia and intention
tremors.
293
Myocardial infection has been postulated to contribute to cardiomyopathy development,
but a causal association has not been proven.
193
Diagnosis
Diagnosis of feline panleukopenia is generally based on clinical presentation, the
presence of severe leukopenia (often <2000 cells/µL), and virus detection, which is
often done in-house at veterinary clinics using commercial fecal enzyme-linked immunosorbent
assay (ELISA) kits. Most kits use monoclonal antibodies, specific for a single epitope
of the virus, to detect the virus in fecal samples. Typically, fecal ELISA test kits
designed to detect CPV-2 variants of dogs will also detect FPV.1, 203 Evaluation of
ELISA results must be interpreted in light of vaccination history, especially in shelter
situations. It has been shown that some ELISA kits may detect vaccine virus for as
long as 2 weeks postvaccination.
218
Commercial ELISA kits currently available have shown good sensitivity and specificity
for detection of virus shedding in the unvaccinated animal.
Other diagnostic options include electron microscopy to visualize the virus in fecal
samples, which is typically only available at laboratories affiliated with academic
institutions, and PCR for genetic detection of the virus. Electron microscopy offers
the advantage of being nonspecific—that is, it is an assay for any virus that may
be causing enteritis, and it can detect agents such as coronavirus, rotavirus, or
other viral enteric pathogens. The PCR assay is very sensitive and may detect vaccine
virus or subclinical parvovirus infections; thus positive results by PCR must be interpreted
in light of other relevant clinical data. Virus isolation, as well as histopathology
and immunohistochemistry, can also be performed on tissues collected postmortem.
156
Histopathologic examination reveals crypt necrosis with villus blunting in the small
intestines and cellular depletion in bone marrow and lymphoid tissues (Figure 33-12
).
156
FIGURE 33-12
Feline panleukopenia virus infection in the small intestine. Photomicrograph of small
intestine with radiomimetic type injury of cryptal necrosis. Crypts are dilated and
lined by a reduced number of attenuated epithelial cells (H&E stain, 200×).
(Courtesy Dr. Robert Foster, Ontario Veterinary College and Yager-Best Histovet, Guelph,
Ontario, Canada.)
Treatment
Treatment of panleukopenia is directed at supportive care. Strict isolation and barrier
nursing must be used when treating affected cats in a clinic setting. Fluids to combat
dehydration, and restoration of electrolyte and acid–base balance are critical in
the treatment of panleukopenia.
293
Colloids, plasma, or whole blood transfusion may be required in hypoproteinemic cats
(protein <5 g/dL). B-vitamin supplementation should be given parenterally because
of decreased food intake and loss in diuresis. A platelet count and activated coagulation
time should be evaluated for signs of disseminated intravascular coagulopathy (DIC).
Initially, oral intake of food should be avoided to lessen vomiting and slow the bowel
mitotic activity necessary for viral replication. Antiemetics may be necessary to
control persistent vomiting. In addition to dehydration, a major concern is secondary
bacterial septicemia resulting from the leukopenia and intestinal epithelial necrosis;
thus parenteral broad-spectrum antibiotics with activity against gram-negative and
anaerobic bacteria (e.g., amoxicillin/clavulanic acid with an aminoglycoside, fluoroquinolone,
or cephalosporin) are an important management tool. Return to enteral nutrition is
vital once vomiting ceases.
293
Feline recombinant interferon-omega has been shown to inhibit viral replication in
vitro, and may be beneficial clinically.
293
Its administration has also been recommended in pregnant queens and neonatal kittens
prior to introduction to a potentially contaminated environment in order to enhance
antibody production.
215
The antiviral medication oseltamivir (Tamiflu) has been proposed as part of the treatment
regimen for CPV infection in dogs.
258
This drug, designed to combat influenza virus, inhibits neuraminidase enzyme activity.
Parvovirus encodes no neuraminidase function; therefore this medication has no direct
effect on the virus. Proponents of its use indicate it is beneficial because of its
effect on bacterial neuraminidase enzymes. The efficacy and, more importantly, the
safety of this medication in cats have not been evaluated, and its use is not recommended
for panleukopenia cases.
Prevention and Control
Panleukopenia is most common in kittens and is uncommon in adults. Despite the ability
of CPV-2a, CPV-2b, and CPV-2c to infect cats, FPV remains the most common cause of
panleukopenia in cats.
55
Panleukopenia is a major concern in shelter and rescue situations where it may accumulate
and survive disinfection. Thorough cleaning with a detergent to remove all organic
matter, followed by disinfection with an appropriate product with oxidizing activity
(e.g., 6% sodium hypochlorite, potassium peroxymonosulfate), is needed to inactivate
the virus.
69
The virus survives disinfection with 70% alcohol and quaternary ammonium compounds.69,
101 Contaminated fomites and caretakers can be an important mode of transmission,
and stringent precautions to prevent spread must be taken.
Passive immunization with serum from vaccinated or recovered cats is very effective,
even after exposure, as long as clinical signs are not present. Serum donors should
be selected with the same care as blood donors (see Chapter 25). Products containing
immunoglobulins against parvovirus are available in some European countries for cats
and are marketed for prophylactic and therapeutic use. Cats cannot be vaccinated with
a modified live virus (MLV) product for 3 weeks after administration of immunoglobulin
to avoid neutralization of vaccine virus. Repeated treatment should be avoided or
anaphylactic reactions may occur.
293
Immunity after recovery is likely lifelong.
42
Vaccination is recommended for every cat, given the severity of disease and the ability
of the virus to persist in the environment.50, 249, 293 The modified live vaccine
is recommended as early as 6 weeks of age and continuing through 16 weeks to ensure
that maternally derived immunity has not interfered with vaccine response.
249
In the face of an outbreak, kittens can be vaccinated as early as 4 weeks with a MLV
vaccine to provide rapid onset of immunity. Current guidelines recommend re-vaccination
at 1 year of age followed by vaccination every 3 years. Vaccination of pregnant queens
or neonates (<4 weeks) with a MLV vaccine is not recommended, because the live attenuated
virus may infect and produce lesions in the fetus or neonate.
Feline Coronavirus
Appearing for the first time in the 1950s, feline infectious peritonitis (FIP) continues
to be a significant disease in domestic cats. Approximately 1 out of every 200 new
feline cases seen at veterinary medical teaching hospitals are cats diagnosed with
FIP.
252
The pathogenesis of FIP is complex, involving feline coronavirus (FCoV) and an inappropriate
humoral response to the virus. A minority of FCoV-infected cats develops the lethal
disease, and both host and virus genetic factors are believed to play a role.
Feline coronavirus is a member of the Coronaviridae, and is antigenically related
to canine enteric coronavirus as well as transmissible gastroenteritis virus of swine.
It is an enveloped virus, which is unusual for an enteric pathogen. There is a relatively
large amount of glycoprotein embedded in the envelope in the form of peplomers, such
as the spike protein, and this may contribute to the virus’ stability. The virus may
survive in the environment for up to 7 weeks under dry conditions
264
but is readily inactivated by common detergents and disinfectants.
The spike protein is used for cellular attachment and may play a role in cellular
tropism of the virus as well as the pathogenesis of FIP. The genome of FCoV is single-stranded
RNA and is one of the largest RNA genomes of the animal viruses. The coronaviruses
have a high mutation rate, including point mutations, deletions, and recombination
with heterologous coronaviruses. For example, FCoV serotype 2 is a recombinant between
FCoV and canine enteric coronavirus, specifically, in the gene encoding the spike
protein. Thus this serotype of FCoV is more antigenically related to canine coronavirus
than to FCoV serotype 1.195, 300
As alluded to above, there are two antigenically distinct serotypes of FCoV, based
primarily on the antigenicity of the viral spike protein. Viruses capable of causing
FIP may be of either serotype; however, the majority of field strains are serotype
1.
19
Feline coronaviruses are also characterized according to virulence, referred to as
virus biotype. The most common biotype is that of mild or no disease associated with
enteric infection by the virus, and it is often referred to as feline enteric coronavirus
(FECV). This is actually a misnomer, because even in asymptomatic infections, the
virus can spread systemically, albeit at relatively low levels. The biotype associated
with FIP (FIPV) occurs in only a small percentage of infected cats. The viral properties
responsible for the difference in biotype are the subject of intense research.
Virus factors are important to disease development, because virus strains vary in
virulence. It has been theorized that a viral mutation is responsible for the change
in biotype of the virus, leading to disease production. Speculation on the genomic
locale of this mutation has involved the gene encoding the spike protein, as well
as genes encoding several nonstructural proteins including 3c, 7a, and 7b. However,
no consistent genetic difference between virulent and avirulent biotypes has been
found. In fact, one study found 100% homology in the 3-prime one third of the genome
when comparing the enteric and nonenteric forms of the virus from a cat with FIP.
65
Recently, genetic analysis of 56 isolates from cases of FIP (n=8) and asymptomatic
FCoV infection (n=48) revealed biotype-specific genotypes in the gene encoding the
membrane (M) protein.
30
In addition, phylogenetic clustering of virulent isolates was observed when based
upon the genes encoding the spike structural protein and 7b nonstructural protein.
These researchers concluded that based on their analyses, cases of FIP arise from
infection with a distinct strain rather than in vivo mutation.
Other studies have shown that the product of the nonstructural 3c gene may also play
a role in pathogenesis.38, 225 One research group found deletions within this gene
occurring in the majority of FIPV isolates examined (n=28) but intact in all FECV
isolates (n=27).
38
They speculate that these deletions lead to poor replication of the virus in the intestines
of cats and may explain, at least in part, why FIP outbreaks are uncommon. Another
research group had similar findings when analyzing the virus in eight cats that died
of FIP, in that extraintestinal virus from FIP lesions in the majority of cases (74%)
had deletional mutations in the 3c gene, leading to truncation of the protein, while
fecal virus in all cats had an intact 3c gene and presumably functional 3c gene product.
225
One phenotypic change in the virus associated with FIP disease production appears
to be efficiency of replication in monocytes and macrophages, in that viruses causing
FIP have acquired significant tropism for macrophages. Although FECV may spread beyond
the intestines, it does so at relatively low levels, probably because of a poor ability
to replicate in monocytes and macrophages.144, 192, 269 The virus of FIP, on the other
hand, replicates at high levels in macrophages and may disseminate throughout the
body. Macrophage tropism appears to reside in a region of the spike protein.
254
Quantitative differences in viral RNA levels in the blood of cats with and without
FIP have been found.
143
Rising amounts of viral RNA in the blood seen in end-stage disease may indicate enhanced
viral replication and disease progression. This increased viral replicative capacity
may be a key element of FIP pathogenesis. It is likely that the viral properties responsible
for development of FIP do not lie in a single or, even necessarily, the same mutation
in all cases, but instead lie in the high mutability of the virus and multiple genetic
changes. It is also likely that each virulent isolate arises individually.
Transmission and Pathogenesis
Feline enteric coronavirus is spread by the fecal–oral route because the virus is
primarily shed in feces and rarely in saliva or other body fluids. Virus may infect
intestinal epithelial cells from the lumen after ingestion. From there, systemic spread
by infection of monocytes/macrophages may occur. In multicat environments, kittens
are infected at a young age, typically at 4 to 6 weeks as maternally derived antibodies
wane.
8
However, infection as young as 2 weeks of age has been documented.
176
Fecal shedding occurs within 1 week following infection and may continue for weeks,
months, or even lifelong. Two types of shedding patterns are observed: cats that shed
virus almost continuously and cats that shed virus only intermittently.
77
In addition, a small number of cats are seropositive for FCoV, but never shed virus
in feces, apparently having a high degree of immunity.
77
Chronic carriers are an important source of the virus for other cats within the household.
Virus persists primarily in the colon; it may also persist in tissue macrophages,
giving rise to recurrent viremia.
147
It is important to note that although FECV (the benign biotype) is highly infectious,
FIPV (the virulent biotype) is infrequently spread in a horizontal manner.
221
FIPVs are strongly cell-associated and tissue-associated so that shedding into feces
would not normally be possible.
Enzootic disease is common in multicat environments, such as catteries, where losses
are sporadic and unpredictable. Overall mortality during a period of years is usually
less than 5%.
221
Very occasionally, epizootics with high mortality have been reported that generally
last less than 12 months. Epizootics are probably multifactorial, involving factors
such as population stresses, overcrowding, high kitten birth rates, and genetically
predisposed breeding cats. Risk factors for FIP in catteries include individual cat
age, individual cat coronavirus titer, overall frequency of fecal coronavirus shedding,
and the proportion of cats in the cattery that are chronic shedders.
78
In addition to changes in viral properties causing the shift from a benign to virulent
biotype, the pathogenesis of FIP also involves host factors. Genetic predisposition
along familial lines has been observed, and breeds in certain countries or areas appear
to have a predisposition for FIP development.75, 206, 229 However, the incidence of
FIP in cat breeds can vary greatly among countries, suggesting that susceptibility
to disease is more related to bloodlines than the breed itself.
221
These host factors may manifest in the immune response of the cat to systemic spread
of FCoV. In cats that develop FIP, a strong humoral response to infection occurs,
with inadequate cell-mediated response by cytotoxic T lymphocytes.
220
The antibody production is ineffective in clearing the virus and contributes to the
immune-mediated disease.
138
The factors responsible for this unsuccessful immune response are unknown, but various
mechanisms appear to be at work. As stated above, they seem to involve the immune
response to FCoV infection, in particular, a shift from a T-helper lymphocyte type
I (Th1) to a T-helper lymphocyte type 2 (Th2) response to the infection. The former
is important in coordinating cell-mediated immunity, which is protective against FIP,
while the latter is important in humoral response. This shift results in an exaggerated
humoral response that is not protective, and, in fact, actually enhances the disease
progression as the virus-specific antibody opsonizes the virus for phagocytosis by
monocytes and macrophages.
Another finding in cats with FIP is lymphocyte depletion, particularly T lymphocytes,
106
through apoptosis. The resultant depletion of T lymphocytes contributes to enhanced
viral replication, because these cells are important in cell-mediated immunity. At
least one group of investigators propose that the virus-driven T-lymphocyte depletion
occurring in infected cats that do not mount a quick and effective cell-mediated immune
response leads to loss of immune control and unchecked viral replication.
51
The virus does not replicate in lymphocytes; so, some other mechanism must be responsible
for this process.
Because lymphocytes are not target cells of FCoV, it is theorized that secreted factors,
including cytokines, are critical to these lymphocyte effects, including the Th2 response
and T-lymphocyte depletion. In fact, the T-lymphocyte response appears to be the decisive
factor in disease progression. Monocytes and macrophages are major cytokine producers
and are the target of FIPV infection. The cytokine secretion patterns from these cells
thus determine the magnitude and direction of the immune response. Cytokines associated
with cell-mediated immunity, such as IL-10, IL-12, and IFN-gamma have been found to
decrease in cats that develop FIP. Elevations in cytokines IL-1beta and IL-6 have
also been found in affected cats, which may contribute to the humoral response.
79
An increase in tumor necrosis factor-alpha (TNF-alpha) has been observed in some studies,
and may contribute to the T-lymphocyte apoptosis.
282
A recent study has shown that FCoV-infected macrophages produce factors that promote
B-lymphocyte differentiation into plasma cells.
281
This may contribute to the exaggerated humoral response.
Much focus has been placed on interferon-gamma, because of its role in enhancing the
cell-mediated immune response. Although serum interferon-gamma concentrations were
not found to differ between cats with FIP and healthy cats with feline coronavirus
in catteries with a low incidence of FIP, higher serum concentrations were seen in
healthy cats with feline coronavirus compared with cats with FIP in catteries with
a high prevalence of FIP.
91
In addition, higher interferon-gamma concentrations were associated with FIP lesions,
indicating that, at least at the tissue level, cell-mediated immunity may contribute
to lesion development.
91
In particular, it indicates that local activation of macrophages by interferon-gamma
may be occurring, leading to enhanced viral replication.
22
In contrast, a systemic increase in interferon-gamma concentrations, as indicated
by elevated expression in blood, may protect infected cats from disease.89, 91
Clinical Signs
The disease of FIP is predominantly immune mediated. Lesions are distributed along
the vasculature, particularly along veins.
146
Vasculitis is the hallmark lesion of FIP, whether the effusive or noneffusive form.
Emigration of infected monocytes/macrophages from blood vessels into perivascular
regions incites local inflammatory responses. Type II and type III hypersensitivity
responses occur with complement activation and cellular destruction. This may occur
widely throughout an infected cat's tissues, leading to increased vascular permeability,
extensive pyogranulomatous lesions, and the classic signs of the effusive, or wet,
form of FIP. Alternatively, focal lesions may be confined to one or more organ systems
in the noneffusive, or dry, form of FIP. The cells involved in the inflammatory process
are primarily macrophages and neutrophils; however, B lymphocytes play a critical
role in producing disease.
145
The incubation period for FIP is unknown, but is probably weeks or months, in some
cases, even years.
221
The cat with FIP generally presents with weight loss, fever, and inappetence. The
fever may wax and wane and is not responsive to antibiotics. Kittens are often underweight
and unthrifty compared with normal littermates (Figure 33-13
). Icterus may be seen with both effusive and noneffusive forms (Figure 33-14
). Abdominal palpation of affected cats may reveal thickened bowel loops, mesenteric
lymphadenopathy, or irregular serosal surfaces of abdominal organs. Cats with the
effusive form characteristically present with significant abdominal ascites. In fact,
FIP is the leading cause of ascites in young cats, proving a more common cause than
cardiac disease, neoplasia, and hepatic or renal disease.
307
The enlarged abdomen can contain a surprising amount of fluid and may be mistaken
for pregnancy by owners of female cats. Typically, the abdominal distension is nonpainful,
and a fluid wave can be palpated. Effusion in the thorax and/or pericardial sac may
also occur. If pleural effusion occurs, the primary clinical signs may include dyspnea,
tachypnea, open-mouth breathing, and cyanotic mucous membranes. Heart sounds will
be muffled on thoracic auscultation.
FIGURE 33-13
Kittens with FIP are often underweight and unthrifty compared with normal littermates.
Pleural effusion may cause dyspnea (A), and ascites may cause abdominal enlargement
(B).
FIGURE 33-14
A Burmese kitten with noneffusive FIP. Icterus may be seen with both effusive and
noneffusive forms of FIP.
With the noneffusive form, signs may be referable to virtually any organ, singly or
in combination (Table 33-2
). Thoracic or abdominal effusions are either absent or too scant to be appreciated
clinically. Granulomatous lesions may occur in the eye, including retinal changes,
iritis, an irregular pupil, and uveitis with hyphema, hypopyon, aqueous flare, miosis,
and keratic precipitates.
58
Ocular disease may be the sole manifestation of FIP in affected cats, or it may be
combined with CNS or abdominal involvement. CNS lesions may be single or multifocal
and may involve the spinal cord, cranial nerves, or meninges, causing seizures, ataxia,
nystagmus, tremors, depression, behavior or personality changes, paralysis or paresis,
circling, head tilt, hyperesthesia, or urinary incontinence.
149
FIP is the most common inflammatory disease of the CNS in cats
28
and is a leading cause of spinal disease.
185
Affected cats are typically young (less than 2 years old) and come from multicat environments.
76
In one study of 24 cats with FIP and neurologic involvement, 75% had hydrocephalus
at necropsy.
149
The occurrence of seizures indicates extensive brain damage and is an unfavorable
prognostic sign.
288
TABLE 33-2
Variability in Clinical Signs of Noneffusive Feline Infectious Peritonitis
Clinical Signs Referable to Involvement of:
% of Affected Cats
Peritoneal cavity
32.0
CNS
23.0
Eyes
15.0
CNS and eyes
8.5
Peritoneal cavity and eyes
7.4
Peritoneal and pleural cavities
4.3
Peritoneal and pleural cavities, CNS
3.2
Peritoneal and pleural cavities, eyes
2.1
Peritoneal cavity, CNS, eyes
2.1
Pleural cavity
1.1
Pleural cavity, CNS, eyes
1.1
Adapted from Table 2 in Pedersen NC: A review of feline infectious peritonitis virus
infection: 1963-2008, J Feline Med Surg 11:225, 2009.
Abdominal involvement with FIP may include granulomas in mesenteric lymph nodes, kidneys
or liver, as well as adhesions throughout the omentum and mesentery that may be palpable
as masses and visible with ultrasonography (Figure 33-15
). With intramural intestinal involvement, diarrhea and vomiting may be observed.
Focal granulomas may be found in the ileum, ileocecocolic junction, or colon. Involvement
of the cecum and colon produces a distinct form of FIP with signs of colitis (soft
stools containing blood and mucus).
116
FIGURE 33-15
Abdominal involvement with FIP may include granulomas on the serosal surface of the
intestines (A); in mesenteric lymph nodes, kidneys, or liver (B); as well as adhesions
throughout the omentum and mesentery (B) and accumulation of straw-colored fluid (C).
Uncommon manifestations of noneffusive FIP include cutaneous lesions, such as intradermal
papules.
57
Skin lesions resulting from coronavirus-induced vasculitis have been reported in a
cat with FIP and concurrent feline immunodeficiency virus infection.
33
Scrotal enlargement may occur because of extension of the peritonitis to the tunics
surrounding the testes or because of chronic fibrinous necrotizing orchitis (Figure
33-16
).81, 268
FIGURE 33-16
A Siamese kitten with FIP. Scrotal enlargement may occur because of extension of the
peritonitis to the tunics surrounding the testes or because of chronic fibrinous necrotizing
orchitis.
In addition, a combination of effusive and noneffusive forms may occur, and transition
between the two can occur in any given cat with FIP. The onset of FIP may be acute
or insidious. For the former, rapid development of effusion may occur, and the disease
course may be short. For the latter, a subclinical state may exist for sometime or
may be preceded by months or even years of vague illness and poor growth.
221
Diagnosis
Diagnosis of FIP can be challenging, especially for the noneffusive form. Clinical
signs of FIP, particularly the noneffusive form, are often vague; in addition, changes
in clinical parameters are not pathognomonic for FIP. The effusive form of FIP is
the easiest to diagnose, but only about 50% of cats that present with effusions will
have FIP. The most common diseases that produce effusions similar to FIP include lymphocytic
cholangitis and malignancies.
273
Feline coronavirus infection is common, thus evidence of infection is not diagnostic
for FIP. Though diagnosis of FIP is critical, given the poor prognosis, ante mortem
diagnosis of FIP can be a challenge, requiring a combination of evidence gathered
from patient signalment, medical history, physical examination, imaging, and laboratory
findings. There is no single test, other than histopathology and immunohistochemistry,
that will confirm a diagnosis of FIP.
Diagnosing FIP starts with obtaining an animal's history and noting its signalment.
Most cases occur in young cats (usually <1 year of age); it occurs more frequently
in purebred than it does in mixed-breed cats; and affected cats usually originate
from or are currently housed in multicat situations.
9
In breeding catteries, examination of records may reveal a genetic connection among
cases. A history of a stressful event, such as spay or neuter, adoption from a shelter,
or trauma, may precede the onset of signs by several weeks. An event that qualifies
as a stressor may also be more subtle, such as a change of social hierarchy within
the population.
Imaging, such as radiography and ultrasonography are useful to rule out other diseases
and identify effusions, especially in cats with abdominal enlargement or dyspnea.
A recent study of abdominal ultrasonographic findings in 16 cats with FIP identified
a variety of nonspecific changes, such as renomegaly, irregular renal contour and
hypoechoic subcapsular echogenicity, abdominal lymphadenopathy, peritoneal or retroperitoneal
effusion, and diffuse changes within the intestines.
171
However, a normal abdominal ultrasonograph does not exclude a diagnosis of FIP.
For cats with effusion, evaluation of this fluid can be informative. Tests on effusions
have greater diagnostic reliability than tests on blood or serum. Therefore the first
step should be evaluation of the patient for evidence of effusion using radiographs
and/or ultrasonography if necessary (Figure 33-17
). The fluid has been described as straw-colored (Figure 33-18
) and is usually viscous because of the high-protein content (Box 33-2
). It usually has a relatively low cellular content that is pyogranulomatous (macrophages
and neutrophils—usually no toxic changes in the latter) in nature. Detection of feline
coronavirus antigen by immunofluorescence within inflammatory cells (macrophages)
in effusive fluid correlates with a diagnosis of FIP.112, 217 Viral antigen detection
by immunofluorescence is offered by many diagnostic laboratories and can be performed
on sediment from submitted abdominal fluid. RT-PCR has been shown to differentiate
FIP effusions from effusions because of other causes.
112
High levels of protein and a low albumin to globulin ratio in the fluid are also indicative
of FIP.112, 217
FIGURE 33-17
A, A thoracic radiograph of the kitten with pleural effusion shown in Figure 33-13,
A
.
B, An abdominal radiograph of the kitten with ascites shown in Figure 33-13, B
.
FIGURE 33-18
The effusion characteristic of FIP is straw to golden yellow in color, viscous, clear
(A) to slightly cloudy (B), depending on cell count, often frothy when shaken.
BOX 33-2
Characteristics of the Effusion Found in Feline Infectious Peritonitis217
•
Nonseptic exudate
•
Straw to golden yellow color, viscous, clear to slightly cloudy, frothy when shaken
•
High specific gravity (1.017 to 1.047)
•
High protein (typically >3.5 g/dL, often 5 to 12 g/dL)
•
Albumin : globulin ratio less than 0.45
•
Low to moderate cellularity (<5000 cells/µL)
The Rivalta test is a simple and inexpensive supportive test on effusions in the diagnosis
of FIP. It distinguishes between exudates and transudates. A test tube is filled with
distilled water and one drop of 98% acetic acid is added, followed by one drop of
effusion sample. If the effusion drop dissipates in the solution, the test is negative
and not supportive of FIP. If the drop retains its shape, the test is positive and
supportive of FIP. In one large retrospective study, the positive predictive value
of the Rivalta test was 86%, and the negative predictive value was 97%.
112
Serum chemistry profiles reveal that many cats with FIP have elevated serum total
protein concentrations, because of the high globulin concentrations; however, even
with normal total protein concentrations, a decreased albumin to globulin ratio may
be evident. As this ratio approaches 0.5, a diagnosis of FIP becomes more likely (Table
33-3
).
112
Other abnormalities may be evident depending on the tissues involved (e.g., elevated
hepatic enzyme activities, azotemia, hyperbilirubinemia, hyperbilirubinuria).271,
273
TABLE 33-3
Specificity, Sensitivity, Positive Predictive Value, Negative Predictive Value, and
Optimum Cutoff Value of Different Total Protein Concentrations, Gamma-Globulin Concentrations,
and Albumin to Globulin Ratios in Effusions
Total Protein
Gamma-Globulin
Albumin to Globulin Ratio
Total Protein (g/dL)
SP
SE
PPV
NPV
Gamma-Globulin (g/dL)
SP
SE
PPV
NPV
Albumin to Globulin Ratio
SP
SE
PPV
NPV
5.0
0.10
1.00
0.56
1.00
0.5
0.47
0.94
0.67
0.87
0.5
0.89
0.62
0.86
0.76
6.0
0.33
0.88
0.60
0.71
0.1*
0.83
0.82
0.84
0.80
0.6
0.85
0.67
0.83
0.70
7.0
0.53
0.82
0.66
0.72
1.5
0.93
0.65
0.91
0.70
0.7
0.82
0.69
0.81
0.71
8.0*
0.90
0.55
0.78
0.62
2.0
0.97
0.44
0.94
0.61
0.8
0.79
0.78
0.80
0.68
9.0
0.93
0.32
0.84
0.55
2.5
0.99
0.35
0.98
0.57
0.9*
0.74
0.86
0.79
0.82
10.0
0.95
0.23
0.85
0.52
3.0
1.00
0.26
1.00
0.55
1.0
0.65
0.94
0.75
0.91
11.0
0.98
0.12
0.87
0.50
12.0
0.99
0.07
0.89
0.49
SP, Specificity; SE, sensitivity; PPV, positive predictive value; NPV, negative predictive
value.
*
Optimum cutoff value as determined by differential positive rate analysis.
Adapted from Table 3 in Hartmann K, Binder C, Hirschberger J et al: Comparison of
different tests to diagnose feline infectious peritonitis, J Vet Intern Med 17:781,
2003.
Complete blood count (CBC) results are variable and nonspecific but may include neutrophilia
with a mild left shift, lymphopenia (<1500/µl), and anemia of chronic disease.214,
271, 273 Lymphopenia may be present in the face of an elevated total white blood cell
count. Immunophenotyping shows that the T lymphocytes, in particular, are depleted;
in fact, a normal T-lymphocyte count has a significant negative predictive value for
FIP. Immunophenotyping or flow cytometry is often offered by laboratories associated
with academic institutions.
51
Results of serum chemistries and CBC may also be normal in cats with FIP.
In addition to high serum globulin concentrations, elevation in acute phase proteins
also occurs. Elevations in alpha-1 acid glycoprotein (AGP) in serum have been noted
in cats with FIP and may aid diagnosis. In one study that evaluated the usefulness
of measuring AGP to diagnose FIP, it was found that high AGP concentrations (>1.5 g/L)
in serum, plasma, or effusion samples are a discriminating marker for FIP.64, 216
Measurement of AGP can be specifically requested from some but not all commercial
labs and is more commonly available in Europe than North America. However, it must
be remembered that many other inflammatory conditions, such as lymphoma and FIV, can
lead to an increase in serum AGP; so, it is not diagnostic for FIP by itself.
FIP is one of the most frequent causes of neurologic disease in the cat, especially
in cases with multifocal clinical signs. Examination of cerebrospinal fluid from cats
with neurologic FIP reveals a marked pleocytosis (>100 cells/mL) primarily consisting
of neutrophils, high protein content (>200 mg/dL), and coronavirus antibody titer
greater than 1:25.
241
Magnetic resonance imaging (MRI) is useful to confirm the presence of inflammatory
disease and demonstrate abnormalities consistent with FIP, such as periventricular
contrast enhancement, ventricular dilatation, and hydrocephalus.76, 202
Serum Antibody and Virus Detection Assays
Feline coronavirus-specific assays can generally be categorized as FCoV-specific antibody
measurement or virus detection assays. Because of the inability to identify a consistent
viral mutation correlating with FIP, no FIP virus-specific test exists. Serologic
analysis detects only antibody to the coronavirus and does not reflect the virus’
biotype. Unfortunately, some commercial diagnostic laboratories use the misnomer “FIP
test” for coronavirus antibody titer. Although a high antibody titer is consistent
with a diagnosis of FIP, it is not confirmatory; in addition, some cats with FIP have
low antibody titers or are seronegative.
9
This latter situation may occur in fulminant cases or may be due to high virus levels
that bind antibody, making it undetectable in the serologic assay. Therefore serology
should only be used as an aid to rule in or rule out the possibility of FIP, and a
diagnosis of FIP should never be made on antibody titers alone.
Serologic assays for antibody to a single virus-specific protein (as opposed to antibody
to multiple virus proteins) have been developed. In particular, a serologic test for
antibody to the 7b protein has been offered as a diagnostic aid to FIP. This protein
is a viral nonstructural protein whose function is unknown, but, as described above,
it may play a role in disease development. It has been theorized that this protein
is not expressed in all feline coronavirus infections; when expression does occur,
perhaps because of a viral mutation allowing 7b expression, FIP may develop. Cats
with high concentrations of antibody to the 7b protein would, by definition, be infected
with the FIP viral biotype. However, subsequent studies have shown that 7b expression
occurs in most infections; 7b-specific antibodies, although consistently present at
high concentrations in cats with FIP, are also present in healthy cats with feline
coronavirus.
142
Thus, although 7b seronegative status would lessen the likelihood of a diagnosis of
FIP, this test cannot be used to confirm FIP.
Because of the problems associated with serology, it is difficult to use FCoV antibody
testing to control or eliminate FIP from catteries.
221
In most cases, it is not possible to interpret the results of FCoV testing cats in
catteries. Most catteries with an active breeding program, and having at least six
cats, will have endemic FECV, and 50% or more of the cats will have FCoV titers of
1 : 100 or greater at any given time.
221
Unfortunately, antibody titers do not provide the type of information the breeder
requires, such as whether any cats have FIP, whether a particular cat will develop
FIP, and which cats are shedding FECV.
Virus detection assays also suffer from a lack of specificity for FIP virus. That
is, finding the virus by antigen detection (e.g., immunofluorescent staining of ascitic
macrophages) or genetic detection (e.g., real-time polymerase chain reaction testing
of whole blood) is consistent with a diagnosis of FIP but is not necessarily confirmatory.
At least one commercial laboratory (Auburn University College of Veterinary Medicine)
offers a RT-PCR assay that quantitates the level of viral messenger RNA (mRNA) in
the monocytes of cats. Although it is not known precisely how the cutoff levels were
determined, high levels of viral mRNA do reflect efficient viral replication in circulating
monocytes.
269
However, in a recent study, FCoV mRNA was detected in 14 of 26 blood samples, yet
only one of these cats had clinical signs compatible with FIP.
32
As stated above, high viral loads in the blood are consistent with FIP, especially
in the end stage; however, high viral loads in the blood are also found in healthy
cats in endemically infected populations.148, 192 In addition, absence of circulating
virus detectable by PCR has been observed in noneffusive, localized forms of FIP (Dr.
Alfred Legendre, personal communication). Virus detection and quantitation is thus
not confirmatory for FIP but does offer diagnostic information. In general, results
of any single assay claiming specificity for the virus of FIP must be interpreted
with great caution.
The gold standard for FIP diagnosis remains histopathology and immunohistochemistry
for feline coronavirus antigen.221, 283 Granulomatous lesions are vascular and perivascular,
primarily involving small and medium veins. Cellular composition is mainly monocytes
and macrophages with a minority of neutrophils. B lymphocytes and plasma cells may
be found at the periphery of lesions, while T lymphocytes are few. Detection of viral
antigen (immunohistochemistry) or nucleic acid (in situ hybridization) in infected
cells within lesions is found and is confirmatory; this testing is offered by some
pathology laboratories.
Treatment
In the past, treatment has focused on two areas: suppressing the immune response or
modulating the immune response. The former generally involves administering immunosuppressive
drugs to inhibit the immune response, while the latter attempts to enhance the cell-mediated
response through the administration of cytokines such as interferon. Immunosuppression
by using prednisolone or cyclophosphamide will sometimes slow disease progression
but will not provide a cure.
114
Antibiotics are not justified unless neutropenia occurs as a result of cytotoxic drug
therapy. Good nutritional support and avoidance of stressors are also recommended.
Although human and feline recombinant interferon has been shown to inhibit feline
coronavirus replication in vitro, in vivo studies have shown no effect on survival
time or quality of life. Recombinant feline interferon-omega (Virbagen Omega, Virbac,
Carros, France) had showed some initial promise in a small, uncontrolled clinical
trial.
135
However, a larger placebo-controlled double-blind trial found no statistically significant
difference in the survival time of cats treated with recombinant feline interferon-omega
versus a placebo.
250
Recently, a new drug tested in three cats with the dry form of FIP demonstrated efficacy
in prolonging life and alleviating signs.
162
The drug, a polyprenyl immunostimulant, is an investigatory veterinary biologic and
acts by upregulating mRNA expression of T-helper lymphocytes responsible for effective
cell-mediated immunity. In this study, two cats with FIP were still alive 2 years
after diagnosis, while one cat survived 14 months. As of this writing, further studies
are underway to assess its potential for FIP treatment.
Finally, it is rarely necessary to isolate a cat with FIP from other cats in the home,
particularly if the other cats are healthy adults. Transmission of FIP directly from
cat to cat is the exception, not the rule. Isolation of an already sick kitten or
young cat simply provides another stressor that may further impair the immune response.
Prevention and Control
Preventing FIP is challenging, because the only effective means of control is preventing
infection with feline coronavirus. The widespread nature of the virus and its ease
of transmission, as well as the existence of persistent infections, make this difficult
in a multicat situation. If one cat in a multicat population dies of FIP, the other
members are likely already infected with the circulating virus. The likelihood that
other cats in the population will develop FIP is not high, but it can occur, especially
if there are genetic links to the affected cat. There may be some risk to introducing
a new cat to this population, but generally, outbreaks of FIP are not observed. In
most pet cat homes, where the number of cats is small, there should be little risk
to introduction of a new cat after a resident cat has died of FIP. To decrease the
risk, owners should consider adopting older (greater than 16 weeks) rather than younger
kittens, or even a young adult cat.
Various strategies have been used to eliminate or prevent feline coronavirus infection
in a cat population (Box 33-3
). In breeding catteries, isolating pregnant queens nearing parturition and queens
and kittens after parturition, as well as early weaning at 5 to 6 weeks of age, has
been advocated (Table 33-4
).5, 6 This prevention method, which requires strict quarantine measures and low (<5)
numbers of cats in the population, is designed to delay infection until the kitten
is older and can more easily eliminate the virus after exposure. One of the most important
measures that can be used in a breeding cattery is to maintain complete breeding records.
Heritability of FIP susceptibility is known to exist; thus continued breeding of parents,
particularly sires that have produced kittens that developed FIP, is not recommended.
BOX 33-3
Methods for Control of Feline Infectious Peritonitis in Multicat Environments221
1
Eliminate overcrowding: maintain no more than six breeding cats, keep cats in stable
small groups
2
Maintain cats 3 years and older as a larger proportion of the population
3
Manage litter boxes properly: have adequate numbers of litter boxes, limit spread
of litter and dust, scoop boxes regularly, empty and disinfect boxes at least weekly
4
Have a selective breeding program: produce the least number of kittens necessary,
do not use any tom cat in a breeding program that has produced kittens that have developed
feline infectious peritonitis, preferably do not use such queens either
TABLE 33-4
Protocol for Early Weaning and Isolation to Prevent Coronavirus Infection of Kittens
Step
Description
Prepare kitten room
1
Remove all cats and kittens 1 week before introducing new queen.
2
Disinfect room using 1:32 dilution of sodium hypochlorite (bleach).
3
Dedicate separate litter trays and food and water bowls to this room, and disinfect
with sodium hypochlorite.
4
Introduce single queen 1-2 weeks before parturition.
Practice barrier nursing
1
Work in the kitten room before tending other cats.
2
Clean hands with disinfectant before going into kitten room.
3
Have shoes and coveralls dedicated to the kitten room.
Wean and isolate kittens early
1
Test queen for FCoV antibodies either before or after she gives birth.
2
If queen is seropositive, she should be removed from the kitten room when the kittens
are 5-6 weeks old.
3
If the queen is seronegative, she can remain with the kittens until they are older.
Test kittens
1
Test kittens for FCoV antibodies after 10 weeks of age.
Adapted from Table 11-5 in Addie DD, Jarrett O: Feline coronavirus infections. In
Greene CE, editor: Infectious diseases of the dog and cat, ed 3, St Louis, 2006, Saunders
Elsevier, p 101.
Other means of control involve removing chronic shedders from the population. Detection
of virus in the feces by using PCR testing is the optimal method for identifying viral
shedding in multicat environments. PCR testing without quantitation is offered at
many commercial laboratories. Testing multiple samples from an animal over time can
identify chronic shedding.
120
Because these animals may shed the virus intermittently, at least two fecal samples
(preferably more), collected at weekly to monthly intervals should be tested. An example
regimen would be three samples collected daily, followed by three samples daily 1
month later. Some laboratories may offer pooling of samples to reduce costs. Serology
may also be helpful, because cats that maintain high antibody levels are likely shedding
high levels of virus.
10
However, it may be almost impossible to maintain a group of cats free of FCoV without
strict quarantine measures and barrier nursing techniques that are typically beyond
the capabilities of most breeding catteries.
At least one commercially available vaccine for feline coronavirus exists. It is an
intranasal vaccine containing a temperature-sensitive mutant of feline coronavirus
allowing replication in the upper respiratory tract but not systemically. The vaccine
is given as two doses, 3 or more weeks apart, but is not started until 16 weeks of
age or older. Although this vaccine appears to be safe, its efficacy has been questioned.
A small reduction in the number of FIP cases was noted in one study when the vaccine
was given to seronegative cats.
244
However, in cats with preexisting antibody, the vaccine showed no protection. In another
field study, the vaccine failed to prevent FIP in kittens with preexisting FCoV antibodies
in a cattery.
72
In households in which feline coronavirus is endemic or in which FIP has occurred,
most cats are seropositive and thus not aided by vaccination. Kittens at highest risk
for FIP are those born into colonies in which the virus is endemic, where infection
often occurs by 4 to 6 weeks of age. However, the vaccine is not given until 16 weeks
of age; thus the vaccine is of dubious usefulness in those situations in which the
risk is greatest. It may provide some protection for seronegative cats entering an
infected population, but currently, this vaccine is not recommended as part of core
vaccines for routine use.5, 50, 249
Rabies
Rabies is a member of the Rhabdoviridae family and belongs to the Lyssavirus genus
along with European bat lyssaviruses 1 and 2. Rabies virus particles (rhabdovirions)
are a characteristic bullet shape because of the cylindrical form of the nucleocapsid
core. Rabies is an enveloped single-stranded RNA virus. Although all warm-blooded
animals are susceptible to infection with rabies, mammals are the only known vectors
and reservoirs. Species susceptibility varies considerably; for example, cats, foxes,
and raccoons are highly susceptible while domestic dogs, horses, and goats are moderately
susceptible, and birds have low susceptibility. Younger animals are generally more
susceptible than older animals. Rabies virus is neurotrophic, traveling quickly to
the CNS after infection. Salivary glands have high concentrations of virus, thus allowing
efficient transmission through bites or saliva-contaminated scratches. An infected
cat will be able to transmit the disease in saliva about 3 days before clinical signs
appear. Environmental transmission by fomites is rare and infected animals are not
viremic, so blood is not infectious. As an enveloped virus, rabies is inactivated
by many disinfectants and labile when exposed to ultraviolet light and heat. The virus
can remain viable in a carcass for several days or longer, depending on temperature.
Large parts of Europe are now rabies-free because of wildlife vaccination programs.
Strict quarantines have kept several countries free of rabies, such as Japan and the
United Kingdom. Worldwide, the majority of human rabies cases are due to dog bites,
because dog rabies is endemic in many developing countries. In Canada and the United
States, domestic dogs have been effectively eliminated as a reservoir. However, rabies
virus continues to be a concern for cat owners; in 2008, 294 cases of rabies in cats
were reported in the United States and Puerto Rico compared with 75 cases in dogs.
27
The risk of exposure to outdoor cats from infected wildlife is significant. Raccoons,
skunks, and bats are the main reservoirs in the United States, but other species such
as foxes, coyotes, and bobcats may also be infected. In addition, importation of rabies
infected animals from areas of endemic infection, such as Africa, poses a risk and
requires practitioners to be aware of potential cases, even in rabies-free areas.
Following exposure an incubation period of weeks to months may follow, but once symptoms
appear, death occurs within days. The typical incubation period in cats is 2 to 24
weeks (average 4 to 6 weeks) before CNS signs appear.
102
Once rabies virus enters the CNS, damage to lower motor neurons (LMN) causes the typical
ascending paralysis. After replicating in the CNS, the virus spreads via peripheral,
sensory, and motor nerves. Virus reaches the salivary glands via cranial nerves. Virtually
any tissue may be infected, but spread outside the CNS does not occur in every case.
Classically, rabies has been divided into two clinical presentations—furious and paralytic.
However, rabies is variable in its presentation and atypical signs are common. Usually
the initial history includes a bite wound. The prodromal phase in cats lasts up to
2 days and is characterized by behavior changes, erratic behavior, and fever spikes.
In the furious form, cats show erratic and unusual behavior, aggression, restlessness,
muscle tremors, and weakness or incoordination. The paralytic phase typically follows
as LMN paralysis progresses. Mandibular and laryngeal paralysis is less common in
cats than dogs. However, increased frequency of vocalization and a change in voice
pitch are common in cats.
73
Ascending paralysis terminates in coma and death, usually after as little as 3 to
4 days.
255
There is no effective therapy for animals with rabies, and supportive care is not
recommended. Clinically normal cats with suspected exposure to rabies should be quarantined
as recommended by local authorities. Postexposure vaccination is forbidden in most
countries.
Rabies should be considered as a differential diagnosis in any cat with profound behavior
changes and/or LMN paralysis, particularly if there is a history of contact with wildlife.
The definitive diagnostic test is demonstration of rabies virus antigen by direct
fluorescent antibody testing of brain tissue. No ante mortem tests are considered
sensitive enough for rabies diagnosis. Handling live cats suspected of rabies must
be done with extreme care, using heavy protective gloves, cages, catchpoles, and other
equipment. The animal must be humanely euthanized and the head removed and refrigerated
until the brain can be examined. Specimens should be transported according to the
specifications of the individual laboratory and should always be identified as hazardous.
Rabies titer testing may be required to export a pet to a rabies-free country. Although
no “protective” titer is known in animals, a titer of less than or equal to 0.5 IU/mL
detected by the fluorescent antibody virus neutralization (FAVN) method is accepted
by most countries. Depending on the country, other requirements must be fulfilled,
such as identification with microchip or tattoo.
Virus neutralizing antibody is critical for protection against rabies following exposure.
Rabies is considered a core vaccination in countries where the disease is endemic.50,
82, 249 Current vaccines provide excellent protection; the presence of neutralizing
antibody at the time of exposure eliminates the virus prior to neuronal infection.
In the unvaccinated cat, this immune response occurs too late to prevent neuronal
spread. Rarely, rabies can occur in vaccinated animals; thus any animal exhibiting
signs compatible with rabies should be handled as such, regardless of vaccination
history.
199
Any cat dying from neurologic disease for which antemortem diagnosis was not obtained
should be submitted for rabies testing.
Feline Retroviruses
The feline retroviruses, feline leukemia virus (FeLV) and feline immunodeficiency
virus (FIV), are members of the Retroviridae and are among the most common and important
infectious diseases of cats. FeLV and FIV are found worldwide, with variable seroprevalence
depending on geography and risk factors (Table 33-5
). Although infected cats may remain clinically well for prolonged periods (especially
with FIV infection), retroviruses are associated with a wide variety of clinical problems,
such as anemia, lymphoma, chronic inflammatory diseases, and secondary and opportunistic
infections. Testing for FeLV and FIV should be part of the minimum database for all
sick cats, even if previously tested negative.
TABLE 33-5
Seroprevalence of FeLV and FIV in Selected Areas and Populations of Cats
Location
FeLV%
FIV%
Population
Japan137
N/A
28.9
3,323 cats
Belgium59
3.8
11.3
346 stray cats
Istanbul308
5.8
22.3
103 owned, outdoor cats
United Kingdom196
3.5
10.4
517 stray cats
Finland278
1.0
6.6
196 stray cats
Germany92,94
3.7
3.2
17,462 cats
South Africa259
12.3
22.2
454 sick cats;3.5% co-infected
Australia205
N/A
8
340 owned/feral cats
United States170
2.3
2.5
18,038 cats;0.3% co-infected
Canada172
3.4
4.3
11,144 cats;0.5% co-infected
FeLV, Feline leukemia virus; FIV, feline immunodeficiency virus; N/A, not available.
Certain risk factors for infection are common to both FeLV and FIV worldwide. Sick
cats are more likely to be seropositive than healthy cats, with sick feral cats having
the highest risk. Other risk factors include age (>6 months), male gender, and access
to outdoors. Low-risk groups include juvenile cats (<6 months) and spayed or neutered
cats.94, 170, 172, 196 However, in one large study in the United States, seroprevalence
in healthy feral cats was similar to that of healthy outdoor pet cats.
170
An important risk factor is bite wounds. In a study of over 900 cats with bite wounds
or abscesses, 19.3% of cats were seropositive for one or both viruses (FeLV 8.8%,
FIV 12.7%, co-infected 2.2%) at the time of treatment.
95
FeLV and FIV share several important properties. They are single-stranded diploid
RNA viruses with a cone-shaped capsid made up of the core protein. They possess a
lipid envelope in which the glycoproteins needed for attachment and entry into the
host cell are embedded. Outside of the host animal, these viruses are very labile,
lasting only minutes in the environment; thus direct contact between animals is the
most efficient mode of spread.
During replication of the retroviruses, the RNA genome is converted into double-stranded
DNA (provirus) by the viral enzyme reverse transcriptase. This enzyme has no proofreading
ability and is mistake-prone. As a result, the retroviruses have a high mutation rate,
and even within a host, the population is heterologous, differing slightly from one
another; thus each animal is infected with a cloud of variants, rather than a single
genotype. These mutations may lead to changes in phenotype, which will be discussed
with the individual viruses, as well as antigenicity. After conversion to DNA, the
viral genome becomes incorporated into the host cell DNA. This integration is permanent;
thus for total elimination of the virus, all infected cells must be removed. This
viral DNA then serves as the template for new viral RNA genomes, which are ultimately
packaged and released from the infected cell.
Feline Leukemia Virus
Feline leukemia virus was first described in 1964 in a cat with lymphoma and was formerly
classified in the subfamily Oncovirinae, referring to its oncogenic ability. The subfamilies
of the Retroviridae were renamed, and FeLV is now classified as a gammaretrovirus.
Within the gammaretroviruses, FeLV is classified into A, B, C, and T subgroups based
on antigenicity and host cell target (Table 33-6
). Subgroup A viruses are generally mildly pathogenic and are the forms horizontally
transmitted. Subgroups B, C, and T arise by point mutations of subgroup A members,
and in the case of subgroup B, by recombination with endogenous retroviruses. All
cats have endogenous retroviral genetic material that is normally present in the genome
and is inherited. These pieces of endogenous DNA are not pathogenic themselves and
do not produce infectious virus particles. However, they can recombine with exogenous
retroviruses, such as FeLV-A, and increase the pathogenicity of the infecting virus.
TABLE 33-6
Classification of FeLV Subgroups
Viral Subgroups
Frequency of Isolation in FeLV-Positive Cats
Associated Disease
Comparison by Species of In Vitro Replication
A
100% viremic cats, mildly pathogenic but highly contagious, mildly cytopathogenic
Hematopoietic neoplasia, experimentally may cause hemolysis
Cat, rabbit, pig, mink, human
B
Occurs with subgroup A in 50% or more of cats with neoplastic disease (lymphoma)
Not pathogenic alone, virulent in recombination with subgroup A, noncontagious
Cat, dog, cow, hamster, pig, human
C
Rarely isolated, arises by mutation from FeLV subgroup A
Nonregenerative anemia and erythremic myelosis, nonreplicating and noncontagious
Cat, dog, guinea pig, human
T*
Highly cytopathic, T-cell tropic virus; affinity for two host cell proteins: Pit1
and FeLIX; evolved from FeLV subgroup A
Lymphopenia, neutropenia, fever, diarrhea
Cat
*
Subgroup T is a variant of subgroup A. Changes in the envelope protein result in increased
cytopathogenicity of T strains.
Adapted from Table 13-2 in Hartmann K: Feline leukemia virus infection. In Greene
CE, editor: Infectious diseases of the dog and cat, ed 3, St Louis, 2006, Saunders
Elsevier, p 107. Modified from Jarrett O: Feline leukemia virus subgroups. In Hardy
WD, Essex M, McClelland AJ, editors: Feline leukemia virus, New York, 1990, Elsevier;
and Nakata R, Myiazawa T, Shin YS, et al: Reevaluation of host ranges of feline leukemia
virus subgroups, Microbes Infect 5:947-950, 2003.
Although FeLV was only “discovered” in 1964, genomic analysis has determined that
it evolved from a virus in an ancestor of the rat.
21
This event likely took place up to 10 million years ago in the North African desert,
an area where both cats and rats lived.
Transmission and Pathogenesis
Viremic FeLV-infected cats shed virus in many body fluids, including saliva, feces,
milk, and urine. FeLV transmission occurs through sustained close contact among cats.
Behaviors such as mutual grooming, sharing of food and water bowls and litter boxes,
and fighting can contribute to transmission, primarily through saliva. Resistance
to persistent infections increases with age, although the degree of natural resistance
is unknown. Kittens less than 16 weeks of age are most likely to remain persistently
infected after exposure. However, adult cats may be susceptible to FeLV infection
after long-term exposure.
100
FeLV can be transmitted to kittens by various routes from infected queens. Infected
pregnant queens may suffer reproductive loss; kittens that survive to term are generally
born viremic and fade quickly. Up to 20% of vertically infected kittens may survive
to become persistently infected adults.
111
Transmission to kittens may also occur through the milk from an infected queen or
through saliva when the queen cleans the kittens.
111
FeLV subgroups are associated with distinct pathologies: Subgroup B is associated
with lymphomas, C with nonregenerative anemia, and T with immunosuppression. This
reflects the distinct syndromes that may be seen with FeLV infection—proliferative
(cancer), degenerative (blood cell line depletion), and immunosuppression. The pathogenesis
of FeLV infection can be thought of as occurring in six stages:
1
Virus enters through the oral cavity (e.g., by mutual grooming), where it infects
and replicates in mononuclear white blood cells in the tonsils.
2
Transient cell-associated lymphatic and viremic spread of the virus to regional lymphatics
occurs.
3
Spread of the virus to systemic lymphoid tissue occurs.
4
Infection of the blood cell precursors in the bone marrow occurs.
5
Secondary viremia disseminates the virus.
6
Virus replicates in many epithelial cells, including those of salivary glands, intestines,
and conjunctiva.
In the past, it was thought that about one third of cats would become persistently
viremic and two thirds would eventually clear infection.
125
Depending upon several factors, including immune status, age, dose, and strain of
the virus, infection may be eliminated in the first three stages. Once bone marrow
infection occurs, it becomes much less likely that the cat will clear the virus.
Evaluation of the FeLV-host relationship has been evaluated using real-time PCR, which
provided new insight and evolving ideas on infection with FeLV.
289
This technology detects viral genetic material and can be designed to detect viral
RNA or DNA (provirus—the DNA-integrated form of the virus). Researchers examined FeLV
infection in vaccinated and unvaccinated cats and were able to define four separate
classes of infection: abortive, regressive, latent, and progressive (Table 33-7
):
1
Abortive infections are those in which the exposed cat produces an effective and early
immune response preventing viral replication and eliminating virus-infected cells.
These cats are negative for circulating viral antigen (core protein) and viral genetic
material.
2
Regressive infections are those in which viral replication is limited, and a small
population of virus-infected cells remain. These cats are also antigen negative, but
viral genetic material can be detected in a small percentage of blood cells by PCR.
These cats may go on to eliminate the virus completely. Regressively infected cats
are not viremic (and therefore not contagious), but proviral DNA may be infectious
through blood transfusion.
39
3
Latent infection refers to those in which a moderate amount of proviral-infected cells
remain. These cats are antigen negative but PCR positive. These latently infected
cells have the potential for reactivation of virus replication but are not contagious
as long as the infection remains latent.
4
Progressive infections are those in which virus replication is not eliminated; both
viral antigen and genetic material can be detected in the blood of these cats, and
they are actively shedding virus primarily in saliva and feces.96, 98 These cats are
likely to become ill with FeLV-related disease.
TABLE 33-7
Outcomes of Feline Leukemia Virus Infection
Outcome of FeLV Exposure
FeLV p27 Antigen in Blood
Viral Blood Culture
Viral Tissue Culture
Viral RNA in Blood
Proviral DNA in Blood
Viral Shedding
FeLV-Associated Disease
Progressive infection
Positive
Positive
Positive
Positive
Positive
Positive
Likely
Regressive infection
Negative or transiently positive
Negative or transiently positive
Negative or transiently positive
Transiently or persistently positive
Positive
Negative
Unlikely
Abortive exposure
Negative
Negative
Negative
Not tested
Negative
Negative
Unlikely
Focal infection
Negative
Negative
Positive
Not tested
Not tested
Variable
Unlikely
Adapted from Table 1 in Levy J, Crawford C, Hartmann K et al: 2008 American Association
of Feline Practitioners’ feline retrovirus management guidelines, J Feline Med Surg
10:300, 2008.
In this study, these classifications were attained in the exposed cats within 4 to
8 weeks post-infection; however, these classifications are likely dynamic, especially
in the intermediate stages. Interestingly, vaccination was not found to prevent provirus
integration; thus vaccinated cats that are exposed to FeLV may become latently infected.
Finally, focal infections were reported in early studies, describing FeLV infection
restricted to certain tissues.
117
These and other results suggest that many cats may remain infected with FeLV for life
following exposure but may revert to a regressive state.97, 122, 227 One study of
597 Swiss cats found that 10% of cats negative on ELISA for p27 antigen were positive
for FeLV provirus by PCR.
122
The provirus is integrated into the cat's genome, and so, it may not be possible to
clear infection.
36
The clinical significance of antigen-negative, PCR-positive cats is unclear. One study
evaluated 152 necropsied cats, with various disorders, that were negative for viral
antigen but positive for FeLV provirus in bone marrow. A significant association with
anemia, panleukopenia, and purulent inflammation, but not lymphosarcoma, was found.
280
Clinical Signs
Following exposure, cats may exhibit mild clinical signs, such as fever and malaise,
or may remain asymptomatic. For cats that remain persistently infected, this acute
phase is followed by a period of asymptomatic infection that may last months or years.
Ultimately, persistently infected cats develop one of several FeLV-associated disorders
(Box 33-4
).
BOX 33-4
Retrovirus-Associated Illnesses in Cats
•
Common illnesses associated with feline leukemia virus (FeLV) infection
•
Hematologic disease: anemia (most commonly nonregenerative), neutropenia, thrombocytopenia
•
Lymphoma: common sites include mediastinum, eye, and multicentric forms
•
Myelopathy: gradually progressive neurologic dysfunction; abnormal vocalization and
behavior, hyperesthesia, paresis progressing to paralysis
•
Common illnesses associated with FIV infection
•
Stomatitis: variable severity, often refractory to conservative treatment
•
Neoplasia: most commonly lymphoma, but also other tumor types, including sarcomas
and carcinomas
•
Ocular disease: most commonly uveitis and chorioretinitis
•
Central and peripheral neurologic disease: abnormal behavior, nystagmus, ataxia, seizures,
paresis, and paralysis
•
Hematologic disease: anemia and leukopenia; often more than one cell line involved
•
Renal disease: similar to nephropathy in human immunodeficiency virus (HIV) patients
•
Common secondary diseases in retrovirus-infected cats
•
Systemic infections: Toxoplasma, Cryptococcus, Mycoplasma haemofelis, feline infectious
peritonitis
•
Gastrointestinal: stomatitis/gingivitis, parasitism (Giardia, coccidia, Cryptosporidia),
bacterial infection (Salmonella, Campylobacter), chronic diarrhea
•
Dermatologic: Demodex, ringworm
•
Respiratory/ocular: herpesvirus keratitis, chronic upper respiratory infections/sinusitis,
uveitis, chorioretinitis, spastic pupil syndrome (FeLV associated)
•
Urinary tract: pyelonephritis, bacterial cystitis
The B subgroup variants, which as stated above, arise in about 50% of infected cats
by recombinational mutation between the infecting A subgroup with endogenous retroviruses,
are oncogenic primarily by insertional mutagenesis. The provirus integration into
the host cell genome activates a cellular oncogene or disrupts a tumor suppressor
gene.
84
Some of these genomic loci for cellular integration have been identified, such as
those for lymphomas,
84
the most common tumor of cats. The most common malignancies associated with FeLV are
lymphomas and leukemias, but nonhematopoietic malignancies are occasionally seen.
Prior to the 1980s, about 80% of feline lymphomas were FeLV-related. A dramatic shift
has occurred, where now only a small percentage of cats with these malignancies are
FeLV-positive. For example, only 8% of cats with lymphoma treated at the Animal Medical
Center in New York between 1988 and 1994 were FeLV positive.
44
PCR detection of proviral DNA in tumor tissue may uncover more cases than FeLV antigen
testing alone.111, 303a Lymphomas are classified based on anatomic locale as mediastinal
(thymic; Figure 33-19
), alimentary, multicentric (lymph nodes), or extranodal (kidneys, CNS, skin). Leukemias
are generally classified as to the cellular origin (e.g., erythroid, granulocytic,
myelocytic).
FIGURE 33-19
Radiograph of a mediastinal mass in a young cat with FeLV.
Anemias, mainly nonregenerative, are one of the most common clinical problems in FeLV-infected
cats. Occasionally, regenerative anemia associated with M. haemofelis or immune-mediated
destruction is seen. FeLV-infected cats may also develop anemia of chronic disease.
The C subgroup variants are rare and are associated with fatal red cell aplasia. These
variants arise from mutations in the envelope glycoprotein gene of the infecting subgroup
A virus. This mutation leads to a change in cell receptors used by the virus from
the thiamine transporter to the heme exporter.
265
This switch in host receptors is believed to disrupt early erythropoiesis, leading
to a nonregenerative anemia, typically with a hematocrit less than 15%, that is resistant
to therapy.
Immunosuppression is one of the most common manifestations of FeLV infection, and
is very complex. Some viral proteins, particularly the transmembrane protein p15e,
are directly immunosuppressive. The p15e protein affects the interleukin 2 signaling
pathway.155, 191 In addition, FeLV infection may lead to lymphopenia, especially a
decrease in CD8+ cytotoxic T lymphocytes, which are critical for viral immunity. Granulocytopenia
may also occur, as well as effects on neutrophil function. The result is recurrent
or chronic infections with other pathogens (e.g., poxvirus, M. haemofelis, Cryptococcus,
Toxoplasma gondii), including agents that are usually of little clinical significance,
such as Salmonella or Listeria.175, 240 Concurrent infection with feline coronavirus
may lead to FIP development. Other infections, such as abscesses, rhinitis, and stomatitis,
may be slow to resolve.
175
FeLV may be neuropathogenic.
60
Neurologic disease not associated with malignancy has been described and manifests
clinically as anisocoria (Figure 33-20
) and mydriasis, Horner syndrome, urinary incontinence, abnormal vocalization, hyperesthesia,
as well as paresis and paralysis.29, 34
FIGURE 33-20
FeLV may cause neurologic disease not associated with malignancy that may manifest
as anisocoria.
Diagnosis
Diagnosis of FeLV-related disorders is multifaceted. Clearly, confirmation of FeLV
infection is of primary importance, but since FeLV-infected cats may be concurrently
infected with other pathogens that are treatable, such as M. haemofelis, identification
of any concomitant pathogen is critical as well. A minimum database (CBC, serum chemistry
panel, urinalysis) is important for the investigation of any sick cat, including cats
that may have retroviral infections. Low neutrophil and thrombocyte levels are commonly
seen in FeLV-infected cats, as well as anemia.92, 93 No consistent abnormalities are
seen in serum chemistry panels from FeLV-infected cats.
Confirmation of FeLV infection relies on detection of the virus. There are several
in-clinic screening ELISA-based kits available that detect the core protein of the
virus (p27). These tests vary in sensitivity and specificity, but most have high negative
and positive predictive values.113, 256 In-clinic kits may be used with anticoagulated
whole blood, serum, or plasma, although the test kit should be checked for the manufacturer's
recommendations. Most cats will test positive for soluble FeLV antigen with ELISA
early in primary viremia, within 30 days of exposure. The exception is those ELISA
tests using saliva and/or tears; these tests do not detect viral antigen until the
epithelial cells are infected, at stage 6, and are thus not ideal for routine screening.
As well, they are known to have a high rate of false results.
165
Because ELISA tests for FeLV detect viral antigen, and not antibody to the virus,
maternal immunity will not interfere with testing. Vaccination generally does not
interfere with testing; however, blood samples drawn immediately following vaccination
may contain detectable FeLV vaccine antigen.
166
It is unknown how long this type of test interference lasts; FeLV testing should always
be performed before vaccination. Confirmation of a positive result obtained by ELISA
is recommended, particularly in healthy cats. False-positive results are possible,
and may be due to a number of factors, including improper testing or kit storage and
hemolyzed samples. A false-negative test result can occur if the cat is tested too
early in the course of infection for detection of soluble antigen (less than 4 weeks).
In addition, because ELISA testing on serum can detect early infection, it does not
distinguish transient from persistent infection. The confirmatory test recommended
is the immunofluorescence assay (IFA), which detects virus infected cells, primarily
neutrophils. It is best performed on a smear prepared from fresh whole blood, because
anticoagulants can interfere with results.
15
This assay can detect infection only after the blood cell precursors in the bone marrow
have been infected (stage 4), 6 to 8 weeks after exposure. Thus an IFA positive result
indicates that the cat is likely persistently infected. False-negative IFA results
may occur in leukopenic cats. False-positive results may occur if the smear is too
thick, if background fluorescence is high, or if the test is performed and interpreted
by inexperienced personnel.
166
Early in infection a cat may be ELISA positive and IFA negative; these cats should
be rechecked with ELISA in 1 to 3 months to determine their status. If the ELISA result
remains positive, a second IFA test should be performed to confirm. Uncommonly, a
cat may remain discordant (ELISA positive, IFA negative); the reason for this is unclear
but may be seen in a latently infected cat that is periodically antigenemic. In these
cases, PCR may be used to detect proviral DNA. PCR can also be used to detect provirus
DNA in antigen-negative cats that are regressively or latently infected. PCR is recommended
only for cats that are to be used as blood donors, cats with persistently discordant
ELISA/IFA results, or antigen-negative cats that are believed to have a FeLV-related
disorder, like lymphoma.
Recently, a novel PCR for detection of FeLV viral RNA in saliva has been described.
97
The diagnostic sensitivity and specificity, as well as positive and negative predictive
values for the PCR, were very high when compared with conventional ELISA. In situations
where the cost of testing is a barrier, such as shelters and multicat households,
it is possible that pooled saliva samples could be used for screening. The method
is sensitive enough to detect one infected cat in a pool of up to 30 samples.
98
Treatment
Illness in the FeLV-infected cat requires prompt attention for accurate diagnosis
and institution of appropriate treatment. Because of the immunosuppression associated
with FeLV, identification of secondary infections and treatment, which may be prolonged
compared with noninfected cats, is required. Immunosuppressive drugs, such as corticosteroids,
should be avoided unless specifically indicated.
175
For FeLV-associated anemias, transfusions may be necessary. Treatment of FeLV-associated
neoplasia should follow established regimens. Symptomatic and supportive treatment
may also be required for FeLV-associated diseases.
Immunomodulatory treatment has been investigated for the FeLV-infected cat. Staphylococcus
protein A (SPA), a cell wall component of the bacterium with immunoenhancing activity
has been evaluated in FeLV-infected cats. In at least one study, although subjective
assessment of owners indicated improvement with SPA treatment, objective parameters
did not differ from those in cats given the saline control.
190
Several other treatments, such as acemannan and Proprionibacterium acnes, have been
evaluated and either failed to demonstrate efficacy or suffer from poorly-designed
studies.
Interferon, an important antiviral cytokine has also been evaluated in FeLV-infected
cats. The effects on the virus in cell culture were induction of apoptosis in infected
but not uninfected cells, decreasing the amount of viral replication overall.
41
In vivo studies have had conflicting results; at least one study showed no improvement.
190
However, this study used human recombinant interferon. Treatment with feline recombinant
interferon (Virbagen Omega, Virbac) has shown evidence of improved clinical picture
and survival, but evaluation of virologic parameters was not performed in these studies.52,
189 A suggested treatment protocol is 1 million U/kg, SC, every 24 hours for 5 consecutive
days.
Lymphocyte T-cell immunomodulator (LTCI; ProLabs, St. Joseph, Mo.) is a product of
the thymic stromal epithelial cells that is now commercially available for feline
retrovirus-infected cats. It enhances interleukin-2 and interferon production by T-helper
lymphocytes, which, in turn, enhances cytotoxic T-lymphocyte activity.
90
LTCI is supplied in 1-mL single dose vials for SC injection, and the recommended protocol
is an initial three-dose regimen given at weekly intervals, with further treatments
as necessary. LTCI is reported to improve clinical and hematologic parameters. However,
controlled clinical trials have not been published.
The antiretroviral drug 3′-azido-2′3′-dideoxythymidine (AZT) has shown some positive
effects but can have serious side effects at higher dosages (recommended dose is 5
to 10 mg/kg, PO, every 12 hours).
175
Careful monitoring of the patient's CBC is necessary, because AZT can cause bone marrow
suppression, especially anemia. Many other antiretroviral drugs are too toxic for
use in the cat or are not effective against FeLV or FIV.
FeLV-infected cats that are otherwise healthy can be maintained, sometimes for years,
without problems. Data on survival of retroviral infected cats indicate that the lifespan
of FeLV-infected cats is generally shorter than that of uninfected cats. In one study
conducted in the United States, records of 67,963 cats that were tested for FeLV and
FIV in 2000, and that had outcome information available 6 years later, were analyzed.
169
Survival of infected cats was compared with age-matched and sex-matched uninfected
cats. The 6-year survival rates were 90% for uninfected cats, 65% for FIV-positive
cats, and 51% for FeLV-positive cats. Most deaths in cats with FeLV or FIV occurred
in the first year after diagnosis, probably because of the illness that prompted the
original veterinary visit or because of euthanasia for purposes of infection control.
A study of 17,289 cats in Germany tested for FeLV and FIV from 1993 to 2002 included
survival data on 100 randomly selected cats: 19 FIV positive, 18 FeLV positive, and
63 uninfected.
94
The mean survival time of FeLV-positive cats (312 days) was significantly shorter
than that of FeLV-negative cats (732 days).
Owners should be advised that certain precautions should be instituted with FeLV-infected
cats, including isolation from uninfected cats (Box 33-5
). This protects not only the uninfected cats from FeLV, but it also serves to limit
the risk of exposure of the FeLV-infected cat to other feline pathogens.
175
Given that many retrovirus-infected cats will survive for years after diagnosis, veterinarians
should be familiar with guidelines for management of infected cats.166, 175 Wellness
exams should be performed every 6 to 12 months to detect problems early (Box 33-6
). Otherwise healthy retrovirus-infected cats require routine veterinary care, including
surgical sterilization and dental prophylaxis. Simple precautions in the veterinary
hospital will enable these patients to receive appropriate care safely (Box 33-7
). FeLV is not considered a zoonotic disease; one study of 204 veterinarians and others
with potential exposure to retroviruses, including needle sticks, failed to detect
retrovirus infection using serologic and molecular methods.
31
BOX 33-5
Client Education for Owners of Retrovirus-Infected Cats
•
Confine retrovirus-infected cats indoors to prevent disease transmission to other
cats and to protect the infected cat from trauma and infectious disease.
•
Spay and neuter intact cats.
•
Whenever possible, isolate infected cats from uninfected cats to prevent disease transmission.
•
Feline leukemia virus (FeLV) is primarily spread by close, intimate contact (i.e.,
between friendly cats); vaccination of any FeLV-negative in-contact cats is recommended.
•
Feline immunosuppressive virus (FIV) is primarily spread by bite wounds (i.e., between
unfriendly cats); transmission is unlikely in socially stable households, and a decision
to vaccinate any FIV-negative in-contact cats should be taken with care because of
vaccine interference with testing.
•
Feed a high-quality commercial diet.
•
Avoid raw meat and eggs, and unpasteurized milk as potential sources of bacterial
or parasitic infections.
•
Monitor infected cats closely for potential signs of illness, such as
•
Changes in social interactions with people or other pets.
•
Changes in activity level and sleeping habits.
•
Changes in food or water consumption.
•
Unexpected weight loss or weight gain.
•
Bad breath odor.
•
Consult a veterinarian promptly at the earliest sign of illness.
BOX 33-6
Wellness Examination Procedures for Retrovirus-Infected Cats
•
Obtain a detailed medical, dietary and behavior history.
•
Perform a thorough physical examination, with special attention to the lymph nodes,
skin, eyes, and oral cavity.
•
Weigh the patient accurately.
•
Perform a complete blood cell count, serum chemistries, and urinalysis (cystocentesis
collection) at least once yearly.
•
Feline leukemia virus (FeLV)-infected cats should have a complete blood cell count
at least every 6 months.
•
Perform fecal examinations if the patient is at risk of intestinal parasite infection
or has signs of gastrointestinal disease.
BOX 33-7
Prevention of Retrovirus Transmission in Veterinary Hospitals
•
Feline leukemia virus (FeLV) and feline immunosuppressive virus (FIV) are fragile
viruses that do not persist in the environment and are susceptible to all common detergents
and disinfectants.
•
Ensure routine infection-control measures are in place.
•
Ensure routine handwashing.
•
Disinfect equipment, cages, instruments, food/water bowls, litter boxes, and so forth.
•
Do not re-use dental or surgical instruments without sterilization.
•
Do not re-use needles/syringes or share bags of intravenous fluids among patients.
•
Avoid multidose vials of medication and vaccines.
•
Feed all cats individually; do not share dishes of food.
•
Carefully handle/dispose of infected body fluids (blood, urine, saliva, feces).
•
House infected cats individually but not in special isolation or contagious disease
areas.
•
Screen blood donors appropriately for blood type and infectious diseases.
The necessity of vaccination of healthy FeLV-infected cats with core vaccines should
be evaluated on an individual basis. Inactivated vaccines are often recommended because
modified live virus vaccines have a theoretical risk of reversion to virulence in
an immunosuppressed animal. However, definitive clinical evidence to support this
recommendation is not available. FeLV vaccination is of no benefit and should not
be administered to FeLV-infected cats.
Prevention and Control
FeLV testing may be performed for a variety of reasons (Box 33-8
). The American Association of Feline Practitioners (AAFP) has stated that the retrovirus
status of all cats should be known because the consequences of infection are important
to the patient and any in-contact cats.
166
Preventing exposure of healthy cats to FeLV-infected cats by test and removal or isolation
is an important way to prevent spread of the disease and is not replaced by vaccination
as a control method.
253
BOX 33-8
Summary of Feline Leukemia (FeLV) and Feline Immunosuppressive Virus (FIV) Testing
Recommendations
1
Cats that should be tested for FeLV and FIV include
a
At-risk cats: sick cats, cats with bite wounds or oral disease, cats with known exposure
to a retrovirus-infected cat, cats in multicat environments where the status of all
cats is not known, cats entering shelters or rescue organizations
–
Sick cats should be tested regardless of a negative FeLV or FIV test result in the
past
b
Newly acquired cats and kittens
c
Cats about to be vaccinated for FeLV or FIV
2
Test for FeLV antigen and FIV antibody at presentation with in-clinic or referral
laboratory enzyme-linked immunosorbent assay (ELISA)
a
Cats that test positive for FeLV and/or FIV
–
If FeLV positive, confirm with immunofluorescence assay (IFA)
–
If FIV positive and greater than 6 months of age
i
If not FIV vaccinated, confirm with Western blot
ii
If known or possibly FIV vaccinated, confirm with an alternative test methodology,
such as a validated polymerase chain reaction (PCR) test
–
If FIV positive and less than 6 months of age, re-test at intervals of 30 days until
the kitten tests negative or is greater than or equal to 6 months of age
b
Cats that test negative for FeLV and FIV
–
Ideally, all cats should have confirmatory testing performed to ensure negative status;
however, it is most important for sick cats and cats with bite wounds
i
Although FeLV retesting alone can be performed in a minimum of 30 days, it is may
be more practical and cost effective to re-test for both viruses in a minimum of 60
days with in-clinic or referral laboratory ELISA
3
Cats at ongoing risk of infection (e.g., cats with access to outdoors) should be tested
annually for FeLV and for FIV, if not FIV vaccinated, with in-clinic or referral laboratory
ELISA
4
Cats used for blood or tissue donation in practice or in shelters should have negative
screening tests for FIV antibody, as well as FeLV antigen and FeLV provirus by serology
and real-time PCR, respectively
Kittens can be tested for FeLV at any age, because passively acquired maternal antibody
does not interfere with testing for viral antigen. Newborn kittens infected from FeLV-positive
queens may not test positive for weeks to months after birth. Although it may be tempting
to test only a queen and not her kittens in an attempt to conserve resources in shelter
or rescue settings, it is inappropriate to test one cat as a representative for others.
Even young kittens may be exposed to cats other than the dam; for example, feral queens
often share mothering of kittens. If a queen or any one of her kittens tests FeLV
positive, all should be considered potentially infected and isolated, with follow-up
testing to resolve status.
111
If a queen or one kitten in a litter tests negative, it cannot be guaranteed that
the others are also negative. Shelters or rescue groups sometimes test pooled blood
samples from litters of kittens in order to save money; the reliability of this method
is unknown and cannot be recommended.
Certain populations of cats require tailored recommendations for control of retrovirus
infections. Retrovirus testing and management for multicat environments such as shelters
is discussed in Chapter 46. Breeding catteries have a low prevalence of FeLV infections,
since the advent of test and removal programs over 30 years ago. However, these multicat
environments require ongoing disease surveillance because factors such as group living
and introduction of new cats favor transmission of infectious diseases. The retrovirus
status of all cats in a breeding cattery should be known, and ideally negative test
results should be confirmed. Infected cats should be removed from the cattery. Additional
recommendations for breeding catteries are found in Box 33-9
.
BOX 33-9
Retrovirus Infection Prevention Recommendations for Breeding Catteries
•
Any newly acquired cats should be isolated and tested before introduction into the
population.
•
Queens sent outside the cattery for breeding should only be mated to toms known to
be retrovirus negative. Upon return, the queen should be isolated and tested in 60
days.
•
Cats that have left the cattery for a cat show do not need to be re-tested, because
cat shows are very low-risk environments for retrovirus transmission.
•
Catteries that maintain retrovirus-negative status do not require vaccination of cats
against feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV), as long
as no cats have access to outdoors.
•
Catteries that rely heavily on sending queens to an outside stud service should consider
FeLV vaccination of queens in addition to testing.
•
Vaccination against FIV is not recommended because FIV is uncommon in catteries and
vaccination interferes with common testing methods.
Adapted from Levy J, Crawford C, Hartmann K et al: 2008 American Association of Feline
Practitioners’ feline retrovirus management guidelines, J Feline Med Surg 10:300,
2008.
Vaccination against FeLV is not considered a core vaccine but is recommended for cats
at risk of exposure50, 175, 249 (e.g., cats with access to outdoors, cats living with
known FeLV-infected cats, multicat environments where the status of all cats is not
known). In addition, vaccination of all kittens has been recommended,
249
because a kitten's status (indoor vs. outdoor; low risk vs. high risk) may change,
and susceptibility to persistent infection is highest in kittenhood. Several vaccines
are available, including whole inactivated virus, subunit, and recombinant canarypox
vector vaccines (which may be administered subcutaneously or intradermally). Testing
of cats prior to vaccination is recommended to ensure negative status. Inadvertent
use of FeLV vaccine in a cat infected with FeLV is not harmful, but it is also of
no benefit. However, vaccination of a cat that is unknowingly retrovirus-infected
gives false expectations to the owner and will give rise to unnecessary questions
of vaccine efficacy when the infection is eventually discovered.
The efficacy of the available vaccines is controversial.
272
Many of the published efficacy trials have been conducted or supported by the vaccine
manufacturer, and most studies do not evaluate more than one vaccine. Other factors
hamper interpretation of vaccine efficacy, such as lack of standard challenge and
testing protocols, and the difficulty of infecting adult cats for a trial. Generally,
inactivated whole virus vaccines have been recommended. In addition, a recombinant
FeLV vaccine provided protection against persistent antigenemia equivalent to an efficacious
inactivated whole virus vaccine.
104
One study using whole inactivated virus vaccines found that, after challenge, vaccinated
cats had no detectable viral antigen, RNA, proviral DNA, or infectious virus.
290
Other studies have shown that vaccines do not prevent the persistence of proviral
DNA following exposure.
123
Despite these findings, several current vaccines are efficacious at preventing persistent
virus persistence and replication, as well as FeLV-associated disease.
121
Feline Immunodeficiency Virus
Feline immunodeficiency virus (FIV) was discovered in 1986 in a California cattery
where cats had immunodeficiency-like illnesses.
224
FIV is a member of the Retroviridae, along with FeLV, but is classified in a different
subfamily, Lentivirinae, along with HIV, equine infectious anemia virus, and ovine
progressive pneumonia/caprine arthritis encephalitis viruses. The immunodeficiency
viruses of domestic cats are classified into several subtypes or clades, designated
A to E, based on the antigenicity of the envelope glycoprotein, gp120. Some authorities
also recognize a sixth clade (F) that is found predominantly in Texas. Prevalence
of the various clades varies geographically, although most field isolates belong to
clades A or B. In the United States, clades A, B, C, and F have been identified, with
clade B being predominant.
303
In Canada, clades A, B and C have been identified.
246
In the United Kingdom, only clade A is found, and in Japan, all clades have been identified.
In general, clade A is thought to be less pathogenic than clades B and C. Within a
clade, variations in genotype as well as phenotype may occur, including emergence
of more pathogenic subtypes.53, 230 Recombination between two distinct isolates may
also occur with co-infection, leading to new strains as well.
118
Infection with lentiviruses related to FIV has also been documented in many nondomestic
cat species around the world, such as the lion, puma, and Florida panther. In general,
the isolates from nondomestic cats are less pathogenic than domestic cat FIV. This
suggests that nondomestic cats have been living with the virus for a long time and
that infection of domestic cats is more recent. Domestic cats can be infected with
isolates from nondomestic felids, but do not develop the same clinical and immunologic
abnormalities found in FIV-infected cats.292, 297
Variations in the envelope glycoprotein affect cross-reactivity and cross-protection
among virus strains. The virus structure, stability, genomic characteristics, and
replication at the cellular level are similar to FeLV. One of the main target cells
of FIV is the CD4+ T-helper lymphocyte, which is essential for both cell-mediated
and humoral immunity. Dysfunction and destruction of these cells are critical to the
pathogenesis of disease. But FIV has a relatively broad cell tropism, and it is not
restricted to cells expressing CD4; it may also use chemokine receptors for cellular
attachment and entry. The virus also replicates in B lymphocytes, monocytes and macrophages,
salivary gland epithelia, and fibroblast and neural cell lines.
FIV has a high mutation rate because of an error-prone reverse transcriptase enzyme,
leading to the circulation of many heterologous strains, even within a single host.
Some of these mutations may lead to changes in virulence or antigenicity.53, 230 This
tremendous variation has an impact on diagnostics, therapeutics, and vaccine development.
Transmission and Pathogenesis
The virus is present in saliva of infected cats, and FIV infection is most likely
to occur in male cats and free-roaming cats, reflecting the efficient transmission
by bite wounds. Queens may be infected during mating if bitten by an infected tom
cat. However, transmission through sustained contact among infected and uninfected
cats, as with FeLV, may occur.
7
In addition, in utero and lactogenic transmission to kittens from queens may occur,
especially if the queen is experiencing high levels of viremia.12, 208
In utero transmission may lead to fetal resorption, abortion, or stillbirth and is
likely due to placental inflammation.
40
However, experimental evidence suggests that not all kittens in a litter will acquire
infection in utero from an FIV-infected queen.207, 208, 251 When the pregnant queen
is acutely infected and has a high viral load, most of the kittens will become infected.
However, when the pregnant queen is chronically infected and healthy, with low a viral
load, few kittens will become infected. Complicating the picture is the fact that
some kittens born to FIV-infected queens have FIV provirus detected in tissues, but
not blood, and are negative for FIV antibody in blood.
11
In experiments, queens can be infected through semen, but it is unknown how important
this mode of transmission is in nature.
139
After inoculation of FIV, the virus replicates in T-helper (CD4+) lymphocytes, which
are critical cells for appropriate and adequate immune responses to infecting pathogens.
The virus binds through CD134 molecules and may also use a chemokine receptor (CXCR4)
for attachment on the cell surface.
68
CD134 protein is upregulated on activated T lymphocytes, thus making these cells the
primary target of FIV. Viral infection of these cells leads to disruption of normal
function, as well as cell death. In addition, during the acute phase of infection,
infection of a subset of T-helper cells, the T-regulatory lymphocytes, contributes
to the disease process. These cells have an immunosuppressor function. It has been
shown that infection of these cells with FIV leads to activation, and, by definition,
immunosuppression. This may contribute to the ineffective FIV clearance with resultant
chronic infection, as well as immunodeficiency.
194
In addition to T lymphocytes, the virus infects macrophages and dendritic cells.
Following cellular infection, as part of the replication cycle, viral RNA is transcribed
to double-stranded DNA by the viral enzyme reverse transcriptase. The DNA product
then integrates into the cellular DNA as a provirus. In activated lymphocytes, viral
RNA is transcribed using the DNA template by the cellular RNA polymerase. This is
followed by viral protein synthesis, assembly of the virion, and release of the infectious
virus. In nonactivated cells, the replication cycle may stop at the provirus stage;
this is referred to as a latent infection, which may be reactivated with activation
of the lymphocyte, allowing completion of the viral replication cycle.
126
This ability of the virus to persist integrated into the cellular genome makes treatment
as well as prevention through vaccination challenging.
Most infected cats will mount an immune response to the virus, which leads to decreased
virus replication and viral load in infected cats, but not elimination of infection.
This generally occurs within 1 to 3 months postinfection, and the cat will then enter
an asymptomatic phase. Virus replication continues, but at very low levels. This phase
may last for months or years. Initially, levels of both CD4+ and CD8+ lymphocytes
decline. As the cat mounts an immune response, a rebound of CD8+ lymphocytes above
preinfection levels occurs. This causes an inversion of the CD4+:CD8+ lymphocyte ratio
(the normal ratio is 2 : 1) that is persistent. Over time, the level of both CD4+
and CD8+ lymphocytes may gradually decline, ultimately leading to immunodeficiency
in the infected cat.
Clinical Signs
FIV infection can be categorized into clinical stages similar to HIV infection, and
various schemes for staging cats have been devised.99, 136, 222 A simplified and useful
categorization for the practicing clinician is as follows, bearing in mind there may
not be clear distinction between phases and not all cats will demonstrate each phase:
1
Acute phase: Clinically, cats may present in the acute phase of infection with signs
such as depression, anorexia, fever, and lymphadenopathy. Some cats, however, remain
asymptomatic immediately following infection.
2
Clinically latent phase: A significant period of asymptomatic infection follows that
may last for months or years. During this asymptomatic stage, however, changes in
blood cell values may occur. Although hematologic abnormalities are less common than
in FeLV-infected cats, FIV infection of bone marrow cells may lead to peripheral cytopenia
of one or more cell lines.83, 93 In addition, FIV-infected cats have higher serum
total protein and globulin concentrations than uninfected cats. In one study, FIV-infected
cats also had lower serum aspartate transaminase (AST) and glutamate dehydrogenase
than uninfected cats.
93
3
Acquired immunodeficiency syndrome (AIDS)-related complex (ARC) phase: As the cat
progresses to the immunodeficient state, secondary infections may occur. In addition,
immune-mediated diseases resulting from immune cell activation may also occur. These
manifestations generally occur later in life, perhaps years after initial FIV infection.
Cats may present with single or combinations of infectious agents, including viral,
bacterial, fungal, protozoal, and parasitic, and clinical signs may involve any system.
Infections may be chronic or intermittent/recurring in nature.
4
Acquired immunodeficiency syndrome (AIDS) phase: This terminal phase of infection
is characterized by neurologic disorders, neoplasia, multiple concurrent infections,
and serious opportunistic infections. Survival time is no more than a few months.
The clinical signs and illnesses associated with FIV are varied and nonspecific (see
Box 33-4) and are usually not a direct effect of the virus but resulting from secondary
infections that may be treatable, such as Demodex-associated skin disease (Figure
33-21
). One of the most common clinical presentations is chronic gingivostomatitis (Figure
33-22
),
126
though the precise pathogenic mechanisms at work are unclear. Histologic findings
include lymphocytes, plasma cells, and variable neutrophilic and eosinophilic infiltrates.
Ocular disease has been well characterized in cats with FIV, with abnormalities in
both the anterior (uveitis [Figure 33-23
], glaucoma) and posterior (pars planitis, retinal degeneration, retinal hemorrhage)
segments.70, 158, 306 Neoplasia is also common in cats with FIV and includes various
tumors, such as lymphomas (primarily B lymphocyte) and leukemias. FIV may infect neural
tissue, causing neurologic disease, affecting central or peripheral nerves. Clinical
signs reported include seizures, behavior changes, cognitive difficulties, and paresis.
126
Renal disease has also been associated with FIV infection and may be similar to HIV-associated
nephropathy. Affected cats have glomerular and tubulointerstitial lesions, elevations
in BUN and creatinine, and proteinuria.232, 233 In one group of 155 cats with FIV,
azotemia and proteinuria were more common than in age-matched uninfected cats.
164
In an Australian case-control study of 73 cats with chronic kidney disease (CKD) and
69 control cats, cats less than 11 years of age with CKD were significantly more likely
to be FIV positive than cats of similar age without CKD.
304
FIGURE 33-21
Secondary causes of disease are common in FIV-infected cats, such as this cat with
alopecia and pruritus (A). Skin scrapings revealed infection with Demodex cati
(B).
FIGURE 33-22
One of the most common clinical presentations in cats with FIV is chronic gingivostomatitis.
FIGURE 33-23
Ocular disease has been well characterized in cats with FIV, such as the anterior
uveitis seen in this cat.
Diagnosis
Routine diagnosis of FIV infection currently relies on detection of virus-specific
antibody. Rapid screening for viral antigen is not possible, because the amount of
circulating virus is low after the acute stage of infection. FIV produces a persistent,
lifelong infection so that the detection of antibodies is sufficient for diagnosis
as long as the cat has not been vaccinated for FIV. Detection of FIV-specific antibodies
is initially performed using a point-of-care ELISA or immunochromatography kits. Using
these kits, most cats will have detectable FIV antibody within 60 days of infection,
but some cats take up to 4 months to seroconvert.
15
Comparison of several diagnostic kits that are commercially available indicate a high
sensitivity and specificity and significant (>90%) negative and positive predictive
values in cats with no history of FIV vaccination.113, 168 Despite these results,
confirmation of positive ELISA results when screening a healthy cat is recommended.
Although virus culture is considered the gold standard for FIV infection, it is not
readily available in many countries, and it is time-consuming and labor-intensive.
A different soluble antibody test has been recommended as a confirmatory test,
166
but to date, only one FIV antibody test is commercially available in Canada and the
United States. Western blot and immunofluorescent antibody assays are available in
many countries. These assays detect antibodies against an increased number of viral
antigens and are suggested as confirmatory tests in seropositive cats with no history
of FIV vaccination.
Kittens born to infected or FIV-vaccinated queens may acquire FIV antibodies in colostrum.
In a study of such kittens, FIV antibodies persisted past 8 weeks of age in more than
50% of kittens (n=55) born to FIV-vaccinated queens (n=12), but were no longer detectable
at 12 weeks of age.
177
In another study, passively acquired antibodies in five kittens from infected queens
declined to undetectable levels only by 17 weeks of age.
237
None of the routine testing methods can distinguish passively acquired maternal antibodies
from antibodies produced by infected kittens; thus kittens less than 6 months of age
testing positive using these assays should be retested when maternal antibodies wane.
For example, kittens can be rested at intervals of 30 days until negative for FIV
antibody. Though infection of kittens, even those born to infected queens, is uncommon,
one must assume a kitten testing positive is contagious until a negative result is
achieved. Kittens greater than 6 months of age with FIV antibodies are more likely
to be infected. Because of concerns regarding detection of passively acquired FIV
antibodies, it is tempting to delay testing kittens for FIV until after 6 months of
age. Because they are a low-risk group, most kittens test negative and can reliably
be considered clear of infection. However, infected kittens could be a source of infection
for other cats if they are not identified and isolated. Compliance of both owners
and veterinarians with retroviral testing recommendations was low in one published
study so that delaying testing of newly acquired kittens until 6 months of age would
potentially result in many cats that never undergo FIV testing at all.
95
The recent development of a vaccine for FIV has complicated testing in countries where
it is available (e.g., Canada, United States, Australia, New Zealand, and Japan, but
not Europe), because the current technology used for screening tests cannot distinguish
natural infection from vaccination.
168
Antibodies derived from vaccination persist for more than 1 year, and possibly for
more than 4 years.166, 168 In some cats, it may be difficult to determine if a positive
FIV antibody test means the cat is truly infected with FIV, is vaccinated against
FIV but not infected, or is vaccinated against FIV and also infected. Detection of
viral nucleic acid by PCR has been proposed as an alternative testing method for vaccinated
cats. However, both false-negative and false-positive results may occur.25, 46 For
the former, the most common cause is the inherent genetic variability of FIV strains,
making development of a genetic assay that can detect all strains challenging. False-positive
results have been observed in vaccinated cats.
46
In one study, the sensitivity and specificity of PCR testing for FIV varied tremendously
among laboratories. The most accurate test was the real-time PCR, but it had a sensitivity
of only 76%.
46
Newer PCR technologies, such dual-emission fluorescence resonance energy transfer
(FRET) real-time PCR, may prove more reliable for discrimination of FIV-vaccinated
from FIV-infected cats.
301
Because of the limited sensitivity of currently available assays, PCR is not useful
as a screening tool for FIV and will not replace in-clinic or referral laboratory
ELISA tests. Rather, PCR testing should be reserved for FIV antibody–positive cats
that have an unknown vaccination history or that have been vaccinated against FIV
but where infection is still suspected. PCR test results must be interpreted with
caution. A positive FIV PCR result from a laboratory with stringent quality control
should confirm FIV infection and should not be affected by FIV vaccination. However,
a negative FIV PCR result does not rule out infection, but may reflect a level of
viral nucleic acid below the limit of detection, or a strain of FIV that is not detected
by the test.
Recently, a study has shown that cats vaccinated for but not infected with FIV may
not produce antibodies to all FIV epitopes. The process of inactivation of the virus
for vaccine production leads to alteration of the native structure of some virus proteins.
154
This alteration leads to loss of certain viral epitopes. As a result, cats infected
with FIV would have antibody able to recognize these epitopes, while vaccinated cats
would not, which has been shown in one study.
167
Use of these viral proteins to distinguish vaccine response from FIV infection may
become commercially available.
Treatment
As for FeLV infection, sick FIV-infected cats require prompt attention to diagnosis
and appropriate treatment. Retrovirus-infected cats may respond to treatment as well
as uninfected cats, although in some cases, longer or more intensive courses of therapy
may be needed. It is important for both the veterinarian and owner to allow enough
time for response to treatment and not become discouraged too quickly. Treatment of
the ill FIV cat requires a full health evaluation, including a minimum database (CBC,
chemistry panel, urinalysis) and identification of any secondary infecting agent.
When secondary infections are identified, institution of appropriate treatment (e.g.,
doxycycline for M. haemofelis infection) may resolve the clinical problem. Supportive
treatment may also be indicated depending on the severity of the illness. Treatment
of chronic stomatitis with corticosteroids is controversial because of adverse effects
with long-term use. Griseofulvin should never be used in FIV-infected cats, because
it causes bone marrow suppression
266
; newer azole drugs are safe and effective for treatment of fungal infections.
Treatment of the FIV infection itself has focused primarily on drugs developed against
HIV. Reverse transcriptase (RTase) inhibitors, such as AZT (zidovudine; Retrovir,
GlaxoSmithKline), have been used in cats, both alone and in combination with other
drugs. Reduced viral load and improved clinical status have been observed with AZT
treatment (5 mg/kg, PO, every 12 hours).
126
Side effects are possible, including nonregenerative anemia, and cats should be monitored
carefully during treatment, including complete blood cell counts. One study has shown
that AZT alone or in combination with another inhibitor of RTase was effective in
preventing infection after exposure (treated cats that were exposed to the virus did
not become infected), but did not have therapeutic value in chronically infected cats.
14
Another study showed in vitro viral replication was inhibited by AZT in combination
with other nucleoside analogs.
26
AZT is best reserved for treatment of severe stomatitis/gingivitis or neurologic disease.
166
Another RTase inhibitor, stampidine, has shown antiretroviral activity in FIV-infected
cats and is well tolerated.294, 295
Other drugs that may potentially be valuable for FIV treatment but have not yet been
tested in cats include other reverse transcriptase inhibitors, as well as inhibitors
of viral protease, integrase, and envelope fusion.47, 210, 257 A selective antagonist
(AMD3100) to the cellular co-receptor for FIV (chemokine receptor CXCR4) has shown
in vitro and in vivo activity against the virus, leading to reduced viral load.
115
In addition, side effects were not observed. A protease inhibitor that showed in vitro
activity against FIV (TL-3) was shown to prevent and even counteract changes in the
CNS from FIV.
131
As research continues, additional medications may become available and useful for
FIV treatment.
Immune modulation has also been attempted for the FIV-infected cat. Cytokines, such
as granulocyte colony–stimulating factor (G-CSF) and erythropoietin have been used
to stimulate blood cell production in cases of neutropenia and anemia, respectively.
As they are human in origin, antibodies to these cytokines are produced in treated
cats, reducing the drugs’ effectiveness within a few weeks.
231
Interferons, both human and feline origin, have also been used in FIV-infected cats.
To date, only one study has been published on the use of recombinant feline interferon
(rFeIFN; Virbagen Omega, Virbac) for FIV, and the study population consisted of 24
cats co-infected with FeLV.
52
In this multicenter, double-blind, placebo-controlled trial, rFeIFN-treated cats (1
million U/kg/day SC for 5 days in three courses: days 0 to 4, days 14 to 18, days
60 to 64) had improved clinical scores in the first 4 months, minor improvement in
hematologic parameters, and lower rates of mortality. However, evaluation of virologic
parameters was not performed and the study is difficult to interpret, because the
data was not broken down by infection type (FeLV-infected only versus FeLV/FIV-infected).
Ironically, one study evaluating human interferon (10 IU/kg, PO, once daily using
a 7-day on, 7-day off treatment schedule) in 24 FIV-infected cats did show clinical
improvement and improved survival in infected cats compared with six placebo-treated
cats despite no change in viral loads.
226
However, the control group was small, and all cats were treated with antiparasitic
drugs and antibiotics as needed.
To modulate the lymphocyte activation and proliferation, which may play a role in
chronic inflammation associated with FIV (e.g., stomatitis), the antiinflammatory
product bovine lactoferrin may affect lymphocyte proliferation and cytokine production,
and may provide clinical improvement.
151
Investigation of in vivo effects is ongoing.
As for FeLV, lymphocyte T-cell immunomodulator (LTCI; ProLabs) has been evaluated
in cats with FIV. Limited data from placebo-controlled trials in small groups of cats
has been published, reporting increased lymphocyte counts, more rapid recovery from
respiratory infections, and reduced viral load in LTCI-treated cats.
90
Data on survival of retroviral infected cats indicate that the lifespan of FIV-infected
cats appears similar to that of uninfected cats. FIV-infected cats may have a long
disease-free period, especially if wellness care is provided and exposure to other
infectious diseases is limited. In one study conducted in the United States, records
of 67,963 cats that were tested for FeLV and FIV in 2000, and that had outcome information
available 6 years later, were analyzed.
169
The 6-year survival rates were 90% for uninfected cats and 65% for FIV-positive cats.
Most deaths in cats with FIV occurred in the first year after diagnosis, probably
because of the illness that prompted the original veterinary visit or because of euthanasia
for purposes of infection control. A study of 17,289 cats in Germany tested for FeLV
and FIV from 1993 to 2002 included survival data on 100 randomly selected cats, including
19 FIV-positive cats. There was no statistically significant difference in the mean
survival time of FIV-positive cats (785 days) compared with FIV-negative cats (625
days).
94
In a study of 1,205 cats tested for FeLV and FIV in western Canada, FIV-positive/FeLV-negative
cats were compared with randomly selected, age-matched and sex-matched FIV/FeLV-negative
cats. The median survival time for FIV-positive cats (n=39, 3.9 years) was not significantly
different from that of FIV-negative cats (n=22, 5.9 years).
242
Management of the FIV-infected cat is similar to the FeLV-infected cat, including
client education about isolation (again, not only to prevent spread of FIV, but to
protect the FIV-infected cat from infectious agents carried by other cats) and other
management issues (see Box 33-5). Guidelines for management of retrovirus-infected
cats have been published.126, 166 Wellness exams should be performed every 6 to 12
months to allow early detection, diagnosis, and treatment of health problems (see
Box 33-6). FIV-infected cats will require hospitalization both for treatment of illness
and for routine wellness care (e.g., surgical sterilization, dental prophylaxis);
simple infection control precautions should be instituted (see Box 33-7). Administration
of perioperative broad-spectrum antibiotics should be considered for surgical and
dental procedures. As for FeLV, FIV is not considered a zoonotic disease, and one
study of 204 veterinarians and others with potential exposure to retroviruses failed
to detect infection using serologic and molecular methods.
31
Vaccination of healthy FIV-infected cats against core diseases should be evaluated
on a case-by-case basis, taking into account individual risk factors. As for FeLV,
inactivated vaccines are often recommended but no data exist to support the recommendation.
Healthy cats with FIV have adequate immune responses to vaccination.48, 163 Concern
exists that activation of infected lymphocytes by vaccinations may increase viral
replication
48
; however, the clinical significance is unclear.
126
FIV vaccination is of no benefit and should not be administered to FIV-infected cats.
Prevention and Control
Control of FIV is aimed primarily at preventing infection. FIV testing may be performed
for a variety of reasons (see Box 33-8), including identification of infected cats
to prevent disease transmission. It has been recommended that the retrovirus status
of all cats should be known.
166
Neutering may limit aggressive behavior, thus limiting spread by fighting and bite
wounds. Restricting contact with cats outside the household, especially feral cats
that are at risk for FIV infection, is the ideal method of prevention.
A vaccination for FIV is commercially available, and contains inactivated whole virus
isolates from clades A and D with an adjuvant. It has been found to induce antibodies
as well as cell-mediated responses.
211
Studies of the currently available vaccine (Fel-O-Vax FIV; Boehringer Ingelheim Vetmedica,
Inc.) conducted by the inventor or manufacturer have demonstrated efficacy when vaccinated
cats were challenged with subtypes A and B.127, 128, 153, 236 One independent study
showed that the vaccine was not able to protect cats when they were challenged by
a subtype A field strain from the United Kingdom.
63
Although it offers some protection to some cats at high risk, its use remains controversial,
and it is listed as noncore or not recommended by the major vaccine advisory groups.50,
126, 249 An informed decision to use the vaccine requires local knowledge about prevalent
FIV subtypes, which is typically not available to the practitioner, as well as better
evaluation of vaccine efficacy against FIV field strains. Another important concern
is that current screening/testing methods cannot distinguish naturally infected from
vaccinated cats. In addition, because high-risk cats are those that are free roaming,
these animals may be more likely to be seized by animal control authorities. Without
identification and access to vaccination records, these cats may be inappropriately
euthanized if tested FIV positive at the receiving facility.
Cats should be tested for FIV infection prior to vaccination. The AAFP guidelines
recommend clients be informed of the difficulties interpreting FIV test results in
vaccinated cats, the lack of knowledge about vaccine efficacy, and that vaccinated
cats should be permanently identified, such as with a microchip, tattoo, and/or collar.
166
Microchip databases can be used to record FIV vaccination histories.
As for FeLV, certain populations of cats require tailored recommendations for control
of FIV. Retrovirus testing and management for multicat environments is discussed in
Chapter 46. Although FIV is uncommon in breeding catteries, the retrovirus status
of all breeding cats should be known. Vaccination against FIV is generally not required
in catteries. Additional recommendations for control of retrovirus infections in breeding
catteries are found in Box 33-9.
Miscellaneous Viruses
Other Viral Enteritis Agents
Agents of viral enteritis in cats other than coronavirus include astrovirus, rotavirus,
reovirus, enterovirus, and calicivirus/norovirus.* These agents, all nonenveloped
RNA viruses, may survive for extended periods in contaminated environments. They are
transmitted orally, and unlike parvoviruses, infect the intestinal epithelia from
the lumen. They target mature epithelia at the villus tips, leading to intestinal
villus atrophy. Disease, which manifests as diarrhea without blood, is typically only
seen in very young animals, where turnover/replacement of intestinal epithelia is
slower than in adults. The most serious consequence of disease in affected kittens
is dehydration. Because these are not systemic infections, changes in leukocyte levels
and other signs of systemic disease, such as depression and fever, may not be seen.
Diagnosis can generally only be accomplished using electron microscopy. Treatment
is supportive, with fluids being the key component. Environmental decontamination
involves cleaning with a detergent to remove all organic matter followed by disinfection
with an appropriate product with oxidizing activity (e.g., 6% sodium hypochlorite,
potassium peroxymonosulfate). Zoonotic transmission of rotavirus and perhaps norovirus
is possible; thus owners should take appropriate precautions when handling affected
cats.43, 263
Bornavirus
Borna disease was named after a town in Saxony, Germany where, in 1895, an outbreak
of fatal neurologic disease occurred in horses. The causative virus was identified
in 1925 and named Bornavirus. Since that report, Bornavirus has been identified in
a number of species, including cattle, donkeys, dogs, wild birds, and ostriches, and
occurs virtually worldwide.
140
It is a cause of encephalomyelitis in many species. In the mid-1990s, Bornavirus was
isolated from cats experiencing a neurologic disease in Sweden called “staggering
disease.”
174
Since that report, evidence of potential Bornavirus-associated disease has been described
in cats in Australia, the United Kingdom, and Japan.141, 201, 213, 245 Evidence of
infection with Bornavirus, but not necessarily disease, has been found in several
countries. FIV-infected cats may have a higher prevalence of infection.119, 130
Bornavirus is a single-stranded RNA virus in the family Bornaviridae with a helical
capsid and a lipid envelope. Its genome is nonsegmented and approximately 9000 bases
in length. Interestingly, the virus does not appear to be cytolytic. In affected animals,
the disease is a nonsuppurative meningoencephalitis, and pathology includes an inflammatory
response in the CNS and demyelinating lesions.
103
Asymptomatic infection has also been documented.
204
The most characteristic clinical sign is hindlimb paraparesis and ataxia (staggering);
other clinical signs include behavioral changes, lumbosacral pain, anorexia, hypersalivation,
hypersensitivity to light and sound, visual impairment, seizures, and inability to
retract the claws.
103
The clinical signs progress over 1 to 4 weeks until the patient either deteriorates
to the point of death or euthanasia, or stabilizes. Recovered cats may be permanently
affected with motor dysfunction or personality changes.
103
The mode of transmission of Bornavirus is unclear, though vectorborne transmission
has been postulated because of its seasonality, with most cases occurring in spring
and summer.
103
Transmission by bodily fluids has also been proposed, and rodents and birds have been
postulated to be reservoirs.
103
The virus is believed to reach the CNS from its site of entry by axonal migration.
The immune response is believed to play a role in disease development and is primarily
mediated by CD8+ T lymphocytes.
23
Diagnosis is problematic and controversial, because the presence of antibody is not
confirmatory and virus is present at low levels, even in affected tissue. Ante mortem,
it is a diagnosis by elimination of other causes. As well as postmortem examination,
histopathology, and immunohistochemistry of CNS gray matter for Bornavirus antigen
may be required for diagnosis. Treatment is largely supportive; however, given the
immunopathologic component, corticosteroids may be beneficial.
Papillomavirus
Papillomaviruses are members of the Papovaviridae family and cause cutaneous warts
in a number of animal species, including domestic and nondomestic cats. They are small,
nonenveloped DNA viruses that are highly species specific, although there is one report
in the literature of a feline papilloma associated with human papillomavirus type
9.
198
In cats, though infection appears to be infrequent, papillomaviruses have been associated
with papillomas, fibropapillomas, and squamous cell carcinomas.* Papillomavirus skin
lesions have also been reported in a cat with FIV infection.
66
Papillomas most likely develop after introduction of the virus through skin lesions
or abrasions. The papillomaviruses have a specific tropism for squamous epithelial
cells. Lesions in cats appear distinct from those in other species and are locally
extensive, often multiple, and can appear on the skin or in the oral cavity.
279
Oral papillomas are small, soft, light pink, oval, slightly raised, flat, and appear
on the ventral lingual surface.
279
Cutaneous papillomas may be rough, raised, pigmented or nonpigmented, scaly plaques
(Figure 33-24
).
279
Histologic examination reveals pigmented, hyperplastic epidermal plaques without evidence
of inflammation.
67
Papillomavirus DNA has been identified in plaques and invasive squamous cell carcinomas.
The virus causes hyperplasia of epithelia and contributes to epithelial proliferation
in cutaneous neoplasms.
197
FIGURE 33-24
Papillomavirus lesions in cats appear distinct from those in other species and are
locally extensive, often multiple, and can appear on the skin or in the oral cavity.
Cutaneous papillomas may be rough, raised, pigmented (A) or nonpigmented (B), scaly
plaques.
(A courtesy Kelly St. Denis. B courtesy Lisa Henderson, Veterinary Information Network.)
The histology of feline fibropapillomas is very similar to equine sarcoid, and in
one report, 17 of 19 tumors were positive for a papillomavirus most similar to bovine
papillomavirus type 1.108, 261 Fibropapillomas appear to be most common in outdoor
cats living in rural areas and cats with known exposure to cattle. Like equine sarcoids,
local recurrence after excision is common and metastasis has not been reported.
Definitive diagnosis of feline papillomatosis is by immunohistochemical staining of
tissue obtained during biopsy or surgical resection. PCR can also be used to demonstrate
viral DNA in lesions. No specific treatment has been identified; surgical excision
is rarely warranted. Spontaneous regression has occurred in other species, such as
dogs.
Poxvirus
Cats are most commonly infected with cowpox,
200
an orthopoxvirus in the Poxviridae family that is only found in Europe and Asia. Orthopoxviruses
are enveloped DNA viruses that are relatively stable in the environment, surviving
under dry conditions for months to years. They are readily inactivated by common disinfectants.
The reservoir hosts are small rodents, such as voles and wood mice. Cowpox infection
is seen primarily in rural cats that hunt rodents, and cases are typically seasonal,
occurring in the summer and fall.
20
The virus is probably inoculated under the skin through a bite wound. The virus replicates
locally, producing a skin lesion, and then spreads systemically, causing more widespread
skin lesions within 1 to 3 weeks. The skin lesions are small nodules at first, but
form well-circumscribed ulcers that become scabbed.
20
The lesions gradually exfoliate after 4 to 5 weeks, and new hair growth occurs, although
some lesions may result in permanent bald patches. Signs of systemic illness occur
early in infection in some cats; they are generally mild and include pyrexia, anorexia,
and depression. Severe or fatal disease is rare and is typically associated with immunosuppression,
such as from retrovirus infection or administration of immunosuppressive drugs.20,
262
Feline cowpox virus infection is diagnosed by culturing dried scab material, electron
microscopy, or PCR. Serum antibodies can also be detected. Histologic examination
of lesions reveals epithelial hyperplasia, vesicle formation and ulceration. Infected
cells may contain intracytoplasmic eosinophilic inclusion bodies. No specific treatment
has been identified; therapy is primarily supportive, such as broad-spectrum antibiotics
for secondary bacterial infections. Corticosteroids should be avoided.
Cat-to-cat and cat-to-human transmission has been documented.16, 71, 107, 262 Human
cowpox infection is rare in the United Kingdom, but more than half of cases are due
to transmission from cats.
16
Cowpox causes skin lesions in humans, as well as systemic infections. Basic hygiene
precautions will help prevent transmission from infected cats to humans, and euthanasia
of infected cats is not warranted.
References
1
Abd-Eldaim
M
Beall
M
Kennedy
M
Detection of feline panleukopenia virus using a commercial ELISA for canine parvovirus
Vet Ther
10
2009
E1
2
Abd-Eldaim
M
Potgieter
L
Kennedy
M
Genetic analysis of feline caliciviruses associated with a hemorrhagic-like disease
J Vet Diagn Invest
17
2005
420
16312232
3
Abd-Eldaim
MM
Wilkes
RP
Thomas
K
Development and validation of a TaqMan real-time reverse transcription-PCR for rapid
detection of feline calicivirus
Arch Virol
154
2009
555
19253013
4
Reference deleted in pages.
5
Addie
D
Belak
S
Boucraut-Baralon
C
Feline infectious peritonitis ABCD guidelines on prevention and management
J Feline Med Surg
11
2009
594
19481039
6
Addie
D
Jarrett
O
Control of feline coronavirus infections in breeding catteries by serotesting, isolation,
and early weaning
Feline Pract
23
1995
92
7
Addie
DD
Dennis
JM
Toth
S
Long-term impact on a closed household of pet cats of natural infection with feline
coronavirus, feline leukaemia virus and feline immunodeficiency virus
Vet Rec
146
2000
419
10811262
8
Addie
DD
Jarrett
O
A study of naturally occurring feline coronavirus infections in kittens
Vet Rec
130
1992
133
1313617
9
Addie
DD
Jarrett
O
Feline coronavirus infections
Greene
CE
Infectious diseases of the dog and cat
ed 3
2006
Saunders Elsevier
St Louis
88
10
Addie
DD
Paltrinieri
S
Pedersen
NC
Recommendations from workshops of the second international feline coronavirus/feline
infectious peritonitis symposium
J Feline Med Surg
6
2004
125
15123158
11
Allison
RW
Hoover
EA
Covert vertical transmission of feline immunodeficiency virus
AIDS Res Hum Retroviruses
19
2003
421
12804000
12
Allison
RW
Hoover
EA
Feline immunodeficiency virus is concentrated in milk early in lactation
AIDS Res Hum Retroviruses
19
2003
245
12689417
13
Andrew
SE
Immune-mediated canine and feline keratitis
Vet Clin North Am Sm Anim Pract
38
2008
269
14
Arai
M
Earl
DD
Yamamoto
JK
Is AZT/3TC therapy effective against FIV infection or immunopathogenesis?
Vet Immunol Immunopathol
85
2002
189
11943320
15
Barr
MC
FIV, FeLV, and FIPV: interpretation and misinterpretation of serological test results
Semin Vet Med Surg (Small Anim)
11
1996
144
8942210
16
Baxby
D
Bennett
M
Getty
B
Human cowpox 1969-93: a review based on 54 cases
Br J Dermatol
131
1994
598
7999588
17
Beaumont
SL
Maggs
DJ
Clarke
HE
Effects of bovine lactoferrin on in vitro replication of feline herpesvirus
Vet Ophthalmol
6
2003
245
12950656
18
Beeler
E
Influenza in dogs and cats
Vet Clin North Am Small Anim Pract
39
2009
251
19185192
19
Benetka
V
Kubber-Heiss
A
Kolodziejek
J
Prevalence of feline coronavirus types I and II in cats with histopathologically verified
feline infectious peritonitis
Vet Microbiol
99
2004
31
15019109
20
Bennett
M
Gaskell
CJ
Baxbyt
D
Feline cowpox virus infection
J Small Anim Pract
31
1990
167
21
Benveniste
R
Sherr
C
Todaro
G
Evolution of type C viral genes: origin of feline leukemia virus
Science
190
1975
886
52892
22
Berg
AL
Ekman
K
Belak
S
Cellular composition and interferon-gamma expression of the local inflammatory response
in feline infectious peritonitis (FIP)
Vet Microbiol
111
2005
15
16183217
23
Berg
AL
Johannisson
A
Johansson
M
Peripheral and intracerebral T cell immune response in cats naturally infected with
Borna disease virus
Vet Immunol Immunopathol
68
1999
241
10438323
24
Bi
Y
Fu
G
Chen
J
Novel swine influenze virus reassortants in pigs, China
Emerg Inf Dis
16
2010
1162
25
Bienzle
D
Reggeti
F
Wen
X
The variability of serological and molecular diagnosis of feline immunodeficiency
virus infection
Can Vet J
45
2004
753
15510684
26
Bisset
LR
Lutz
H
Boni
J
Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral
therapy in suppressing in vitro FIV replication
Antiviral Res
53
2002
35
11684314
27
Blanton
JD
Robertson
K
Palmer
D
Rabies surveillance in the United States during 2008
J Am Vet Med Assoc
235
2009
676
19751163
28
Bradshaw
J
Pearson
G
Gruffydd-Jones
T
A retrospective study of 286 cases of neurological disorders of the cat
J Comp Pathol
131
2004
112
15276850
29
Brightman
AH
2nd
Ogilvie
GK
Tompkins
M
Ocular disease in FeLV-positive cats: 11 cases (1981-1986)
J Am Vet Med Assoc
198
1991
1049
1851738
30
Brown
MA
Troyer
JL
Pecon-Slattery
J
Genetics and pathogenesis of feline infectious peritonitis virus
Emerg Infect Dis
15
2009
1445
19788813
31
Butera
ST
Brown
J
Callahan
ME
Survey of veterinary conference attendees for evidence of zoonotic infection by feline
retroviruses
J Am Vet Med Assoc
217
2000
1475
11128537
32
Can-Sahna
K
Soydal Ataseven
V
Pinar
D
The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR
J Feline Med Surg
9
2007
369
17478116
33
Cannon
MJ
Silkstone
MA
Kipar
AM
Cutaneous lesions associated with coronavirus-induced vasculitis in a cat with feline
infectious peritonitis and concurrent feline immunodeficiency virus infection
J Feline Med Surg
7
2005
233
16055009
34
Carmichael
KP
Bienzle
D
McDonnell
JJ
Feline leukemia virus-associated myelopathy in cats
Vet Pathol
39
2002
536
12243463
35
Carney
HC
England
JJ
Hodgin
EC
Papillomavirus infection of aged Persian cats
J Vet Diagn Invest
2
1990
294
1965634
36
Cattori
V
Tandon
R
Pepin
A
Rapid detection of feline leukemia virus provirus integration into feline genomic
DNA
Mol Cell Probes
20
2006
172
16488115
37
Cave
T
Thompson
H
Reid
S
Kitten mortality in the United Kingdom: a retrospective analysis of 274 histopathological
examinations (1986 to 2000)
Vet Rec
151
2002
497
12430997
38
Chang
HW
de Groot
RJ
Egberink
HF
Feline infectious peritonitis: insights into feline coronavirus pathobiogenesis and
epidemiology based on genetic analysis of the viral 3c gene
J Gen Virol
91
2010
415
19889934
39
Chen
H
Bechtel
MK
Shi
Y
Pathogenicity induced by feline leukemia virus, Rickard strain, subgroup A plasmid
DNA (pFRA)
J Virol
72
1998
7048
9696797
40
Coats
KS
The feline immunodeficiency virus-infected cat: a model for lentivirus-induced placental
immunopathology and reproductive failure [mini-review]
Am J Reprod Immunol
54
2005
169
16135008
41
Collado
VM
Gomez-Lucia
E
Tejerizo
G
Effect of type I interferons on the expression of feline leukaemia virus
Vet Microbiol
123
2007
180
17507184
42
Cook
AK
Feline infectious diarrhea
Top Companion Anim Med
23
2008
169
19081550
43
Cook
N
Bridger
J
Kendall
K
The zoonotic potential of rotavirus
J Infect
48
2004
289
15066329
44
Cotter
SM
Feline viral neoplasia
Greene
CE
Infectious diseases of the dog and cat
ed 2
1998
Saunders
Philadelphia
71
45
Coyne
KP
Dawson
S
Radford
AD
Long-term analysis of feline calicivirus prevalence and viral shedding patterns in
naturally infected colonies of domestic cats
Vet Microbiol
118
2006
12
16911860
46
Crawford
PC
Slater
MR
Levy
JK
Accuracy of polymerase chain reaction assays for diagnosis of feline immunodeficiency
virus infection in cats
J Am Vet Med Assoc
226
2005
1503
15882000
47
D’Ursi
AM
Giannecchini
S
Esposito
C
Development of antiviral fusion inhibitors: short modified peptides derived from the
transmembrane glycoprotein of feline immunodeficiency virus
Chembiochem
7
2006
774
16566046
48
Dawson
S
Smyth
NR
Bennett
M
Effect of primary-stage feline immunodeficiency virus infection on subsequent feline
calicivirus vaccination and challenge in cats
AIDS
5
1991
747
1652980
49
Dawson
S
Willoughby
K
Gaskell
RM
A field trial to assess the effect of vaccination against feline herpesvirus, feline
calicivirus and feline panleucopenia virus in 6-week-old kittens
J Feline Med Surg
3
2001
17
11716626
50
Day
MJ
Horzinek
MC
Schultz
RD
WSAVA guidelines for the vaccination of dogs and dats
J Small Anim Pract
51
2010
338
51
de Groot-Mijnes
JD
van Dun
JM
van der Most
RG
Natural history of a recurrent feline coronavirus infection and the role of cellular
immunity in survival and disease
J Virol
79
2005
1036
15613332
52
de Mari
K
Maynard
L
Sanquer
A
Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus
(FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic
cats
J Vet Intern Med
18
2004
477
15320583
53
de Rozieres
S
Mathiason
CK
Rolston
MR
Characterization of a highly pathogenic molecular clone of feline immunodeficiency
virus clade C
J Virol
78
2004
8971
15308694
54
Decaro
N
Buonavoglia
D
Desario
C
Characterisation of canine parvovirus strains isolated from cats with feline panleukopenia
Res Vet Sci
89
2010
275
20334885
55
Decaro
N
Desario
C
Miccolupo
A
Genetic analysis of feline panleukopenia viruses from cats with gastroenteritis
J Gen Virol
89
2008
2290
18753239
56
Decaro
N
Desario
C
Parisi
A
Genetic analysis of canine parvovirus type 2c
Virology
385
2009
5
19144369
57
Declercq
J
De Bosschere
H
Schwarzkopf
I
Papular cutaneous lesions in a cat associated with feline infectious peritonitis
Vet Dermatol
19
2008
255
18927951
58
Doherty
MJ
Ocular manifestations of feline infectious peritonitis
J Am Vet Med Assoc
159
1971
417
5107089
59
Dorny
P
Speybroeck
N
Verstraete
S
Serological survey of Toxoplasma gondii, feline immunodeficiency virus and feline
leukaemia virus in urban stray cats in Belgium
Vet Rec
151
2002
626
12479298
60
Dow
SW
Hoover
EA
Neurologic disease associated with feline retroviral infection
Kirk
R
Bonagura
J
Current veterinary therapy
1992
Saunders
Philadelphia
1010
61
Dowers
KL
Hawley
JR
Brewer
MM
Association of Bartonella species, feline calicivirus, and feline herpesvirus 1 infection
with gingivostomatitis in cats
J Feline Med Surg
12
2010
314
19959386
62
Drazenovich
TL
Fascetti
AJ
Westermeyer
HD
Effects of dietary lysine supplementation on upper respiratory and ocular disease
and detection of infectious organisms in cats within an animal shelter
Am J Vet Res
70
2009
1391
19878022
63
Dunham
SP
Bruce
J
MacKay
S
Limited efficacy of an inactivated feline immunodeficiency virus vaccine
Vet Rec
158
2006
561
16632531
64
Duthie
S
Eckersall
PD
Addie
DD
Value of alpha 1-acid glycoprotein in the diagnosis of feline infectious peritonitis
Vet Rec
141
1997
299
9330474
65
Dye
C
Siddell
SG
Genomic RNA sequence of feline coronavirus strain FCoV C1Je
J Feline Med Surg
9
2007
202
17363313
66
Egberink
HF
Berrocal
A
Bax
HA
Papillomavirus associated skin lesions in a cat seropositive for feline immunodeficiency
virus
Vet Microbiol
31
1992
117
1320786
67
Egberink
HF
Horzinek
MC
Feline viral papillomatosis
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Saunders Elsevier
St Louis
160
68
Elder
JH
Sundstrom
M
de Rozieres
S
Molecular mechanisms of FIV infection
Vet Immunol Immunopathol
123
2008
3
18289701
69
Eleraky
N
Potgieter
L
Kennedy
M
Virucidal efficacy of four new disinfectants
J Am Anim Hosp Assoc
38
2002
231
12022408
70
English
RV
Davidson
MG
Nasisse
MP
Intraocular disease associated with feline immunodeficiency virus infection in cats
J Am Vet Med Assoc
196
1990
1116
2158494
71
Essbauer
S
Pfeffer
M
Meyer
H
Zoonotic poxviruses
Vet Microbiol
140
2010
229
19828265
72
Fehr
D
Holznagel
E
Bolla
S
Placebo-controlled evaluation of a modified life virus vaccine against feline infectious
peritonitis: safety and efficacy under field conditions
Vaccine
15
1997
1101
9269053
73
Fogelman
V
Fischman
H
Horman
J
Epidemiologic and clinical characteristics of rabies in cats
J Am Vet Med Assoc
202
1993
1829
8320150
74
Foley
J
Hurley
K
Pesavento
P
Virulent systemic feline calicivirus infection: local cytokine modulation and contribution
of viral mutants
J Feline Med Surg
8
2006
55
16213763
75
Foley
J
Pedersen
N
The inheritance of susceptibility to feline infectious peritonitis in purebred catteries
Feline Pract
24
1996
14
76
Foley
JE
Lapointe
JM
Koblik
P
Diagnostic features of clinical neurologic feline infectious peritonitis
J Vet Intern Med
12
1998
415
9857333
77
Foley
JE
Poland
A
Carlson
J
Patterns of feline coronavirus infection and fecal shedding from cats in multiple-cat
environments
J Am Vet Med Assoc
210
1997
1307
9143535
78
Foley
JE
Poland
A
Carlson
J
Risk factors for feline infectious peritonitis among cats in multiple-cat environments
with endemic feline enteric coronavirus
J Am Vet Med Assoc
210
1997
1313
9143536
79
Foley
JE
Rand
C
Leutenegger
C
Inflammation and changes in cytokine levels in neurological feline infectious peritonitis
J Feline Med Surg
5
2003
313
14623200
80
Fontenelle
JP
Powell
CC
Veir
JK
Effect of topical ophthalmic application of cidofovir on experimentally induced primary
ocular feline herpesvirus-1 infection in cats
Am J Vet Res
69
2008
289
18241028
81
Foster
R
Caswell
J
Rinkardt
N
Chronic fibrinous and necrotic orchitis in a cat
Can Vet J
37
1996
681
8939335
82
Frymus
T
Addie
D
Belak
S
Feline rabies ABCD guidelines on prevention and management
J Feline Med Surg
11
2009
585
19481038
83
Fujino
Y
Horiuchi
H
Mizukoshi
F
Prevalence of hematological abnormalities and detection of infected bone marrow cells
in asymptomatic cats with feline immunodeficiency virus infection
Vet Microbiol
136
2009
217
19110384
84
Fujino
Y
Ohno
K
Tsujimoto
H
Molecular pathogenesis of feline leukemia virus-induced malignancies: insertional
mutagenesis
Vet Immunol Immunopathol
123
2008
138
18313764
85
Gamoh
K
Shimazaki
Y
Makie
H
The pathogenicity of canine parvovirus type-2b, FP84 strain isolated from a domestic
cat, in domestic cats
J Vet Med Sci
65
2003
1027
14532700
86
Gaskell
CJ
Gaskell
RM
Dennis
PE
Efficacy of an inactivated feline calicivirus (FCV) vaccine against challenge with
United Kingdom field strains and its interaction with the FCV carrier state
Res Vet Sci
32
1982
23
6283611
87
Gaskell
R
Dawson
S
Radford
A
Feline herpesvirus
Vet Res
38
2007
337
17296160
88
Gaskell
RM
Povey
RC
Experimental induction of feline viral rhinotracheitis virus re-excretion in FVR-recovered
cats
Vet Rec
100
1977
128
191978
89
Gelain
ME
Meli
M
Paltrinieri
S
Whole blood cytokine profiles in cats infected by feline coronavirus and healthy non-FCoV
infected specific pathogen-free cats
J Feline Med Surg
8
2006
389
16777454
90
Gingerich
D
Lymphocyte T-cell immunomodulator (LTCI): review of the immunopharmacology of a new
veterinary biologic
Intern J Appl Res Vet Med
6
2008
61
91
Giordano
A
Paltrinieri
S
Interferon-gamma in the serum and effusions of cats with feline coronavirus infection
Vet J
180
2009
396
18406642
92
Gleich
S
Hartmann
K
Feline immunodeficiency virus and feline leukemia virus—a retrospective study in 17462
cases
J Vet Intern Med
21
2007
578
93
Gleich
S
Hartmann
K
Hematology and serum biochemistry of feline immunodeficiency virus-infected and feline
leukemia virus-infected cats
J Vet Intern Med
23
2009
552
19645840
94
Gleich
SE
Krieger
S
Hartmann
K
Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned
cats and risk factors for infection in Germany
J Feline Med Surg
11
2009
985
19616984
95
Goldkamp
CE
Levy
JK
Edinboro
CH
Seroprevalences of feline leukemia virus and feline immunodeficiency virus in cats
with abscesses or bite wounds and rate of veterinarian compliance with current guidelines
for retrovirus testing
J Am Vet Med Assoc
232
2008
1152
18412524
96
Gomes-Keller
MA
Gonczi
E
Grenacher
B
Fecal shedding of infectious feline leukemia virus and its nucleic acids: a transmission
potential
Vet Microbiol
134
2009
208
18842363
97
Gomes-Keller
MA
Gonczi
E
Tandon
R
Detection of feline leukemia virus RNA in saliva from naturally infected cats and
correlation of PCR results with those of current diagnostic methods
J Clin Microbiol
44
2006
916
16517876
98
Gomes-Keller
MA
Tandon
R
Gonczi
E
Shedding of feline leukemia virus RNA in saliva is a consistent feature in viremic
cats
Vet Microbiol
112
2006
11
16303261
99
Goto
Y
Nishimura
Y
Mizuno
T
Quantification of viral ribonucleic acid in plasma of cats naturally infected with
feline immunodeficiency virus
Am J Vet Res
61
2000
1609
11131607
100
Grant
CK
Essex
M
Gardner
MB
Natural feline leukemia virus infection and the immune response of cats of different
ages
Cancer Res
40
1980
823
6258787
101
Greene
C
Addie
D
Feline parvovirus infections
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Saunders Elsevier
St Louis
78
102
Greene
C
Rupprecht
C
Rabies and other Lyssavirus infections
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Saunders Elsevier
St Louis
167
103
Greene
CE
Berg
AL
Chomel
BB
Miscellaneous viral infections
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Saunders Elsevier
St Louis
162
104
Grosenbaugh
DA
Leard
T
Pardo
MC
Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV)
vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously
Vet Ther
5
2004
258
15719325
105
Gutzwiller
ME
Brachelente
C
Taglinger
K
Feline herpes dermatitis treated with interferon omega
Vet Dermatol
18
2007
50
17222241
106
Haagmans
BL
Egberink
HF
Horzinek
MC
Apoptosis and T-cell depletion during feline infectious peritonitis
J Virol
70
1996
8977
8971027
107
Haenssle
HA
Kiessling
J
Kempf
VA
Orthopoxvirus infection transmitted by a domestic cat
J Am Acad Dermatol
54
2006
S1
16427982
108
Hanna
PE
Dunn
D
Cutaneous fibropapilloma in a cat (feline sarcoid)
Can Vet J
44
2003
601
12892294
109
Hargis
A
Ginn
P
Mansell
J
Ulcerative facial and nasal dermatitis and stomatitis in cats associated with feline
herpesvirus 1
Vet Dermatol
10
1999
267
110
Hartley
C
Aetiology of corneal ulcers: assume FHV-1 unless proven otherwise
J Feline Med Surg
12
2010
24
20123484
111
Hartmann
K
Feline leukemia virus infection
Greene
C
Infectious diseases of the dog and cat
ed 3
2006
Saunders Elsevier
St Louis
105
112
Hartmann
K
Binder
C
Hirschberger
J
Comparison of different tests to diagnose feline infectious peritonitis
J Vet Intern Med
17
2003
781
14658713
113
Hartmann
K
Griessmayr
P
Schulz
B
Quality of different in-clinic test systems for feline immunodeficiency virus and
feline leukaemia virus infection
J Feline Med Surg
9
2007
439
17604205
114
Hartmann
K
Ritz
S
Treatment of cats with feline infectious peritonitis
Vet Immunol Immunopathol
123
2008
172
18395801
115
Hartmann K, Stengel S, Klein D et al: Efficacy of the chemokine receptor inhibitor
1,1’-bis-1,4,8,11-tetraazacyclotetradekan against feline immunodeficiency virus infection
[abstract], Sixth International Feline Retrovirus Research Symposium, Amelia Island,
Fla, 2002, p 26.
116
Harvey
CJ
Lopez
JW
Hendrick
MJ
An uncommon intestinal manifestation of feline infectious peritonitis: 26 cases (1986-1993)
J Am Vet Med Assoc
209
1996
1117
8800260
117
Hayes
KA
Rojko
JL
Tarr
MJ
Atypical localised viral expression in a cat with feline leukaemia
Vet Rec
124
1989
344
2541530
118
Hayward
JJ
Rodrigo
AG
Recombination in feline immunodeficiency virus from feral and companion domestic cats
Virol J
5
2008
76
18559113
119
Helps
CR
Turan
N
Bilal
T
Detection of antibodies to Borna disease virus in Turkish cats by using recombinant
p40
Vet Rec
149
2001
647
11764326
120
Herrewegh
AA
de Groot
RJ
Cepica
A
Detection of feline coronavirus RNA in feces, tissues, and body fluids of naturally
infected cats by reverse transcriptase PCR
J Clin Microbiol
33
1995
684
7751377
121
Hofmann-Lehmann
R
Cattori
V
Tandon
R
How molecular methods change our views of FeLV infection and vaccination
Vet Immunol Immunopathol
123
2008
119
18295346
122
Hofmann-Lehmann
R
Huder
JB
Gruber
S
Feline leukaemia provirus load during the course of experimental infection and in
naturally infected cats
J Gen Virol
82
2001
1589
11413369
123
Hofmann-Lehmann
R
Tandon
R
Boretti
FS
Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular
assays
Vaccine
24
2006
1087
16198454
124
Hong
C
Decaro
N
Desario
C
Occurrence of canine parvovirus type 2c in the United States
J Vet Diagn Invest
19
2007
535
17823398
125
Hoover
EA
Mullins
JI
Feline leukemia virus infection and diseases
J Am Vet Med Assoc
199
1991
1287
1666070
126
Hosie
MJ
Addie
D
Belak
S
Feline immunodeficiency ABCD guidelines on prevention and management
J Feline Med Surg
11
2009
575
19481037
127
Huang
C
Conlee
D
Gill
M
Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective
immunity against heterologous challenge
J Feline Med Surg
12
2010
451
20167521
128
Huang
C
Conlee
D
Loop
J
Efficacy and safety of a feline immunodeficiency virus vaccine
Anim Health Res Rev
5
2004
295
15984343
129
Huang
C
Hess
J
Gill
M
A dual-strain feline calicivirus vaccine stimulates broader cross-neutralization antibodies
than a single-strain vaccine and lessens clinical signs in vaccinated cats when challenged
with a homologous feline calicivirus strain associated with virulent systemic disease
J Feline Med Surg
12
2010
129
19836282
130
Huebner
J
Bode
L
Ludwig
H
Borna disease virus infection in FIV-positive cats in Germany
Vet Rec
149
2001
152
11517984
131
Huitron-Resendiz
S
De Rozieres
S
Sanchez-Alavez
M
Resolution and prevention of feline immunodeficiency virus-induced neurological deficits
by treatment with the protease inhibitor TL-3
J Virol
78
2004
4525
15078933
132
Hurley
K
Pesavento
P
Pedersen
N
An outbreak of virulent systemic feline calicivirus disease
J Am Vet Med Assoc
224
2004
241
14736069
133
Hurley
K
Sykes
J
Update on feline calicivirus: new trends
Vet Clin North Am Sm Anim Pract
33
2003
759
134
Ikeda
Y
Nakamura
K
Miyazawa
T
Feline host range of canine parvovirus: recent emergence of new antigenic types in
cats
Emerg Infect Dis
8
2002
341
11971764
135
Ishida
T
Shibanai
A
Tanaka
S
Use of recombinant feline interferon and glucocorticoid in the treatment of feline
infectious peritonitis
J Feline Med Surg
6
2004
107
15123155
136
Ishida
T
Tomoda
I
Clinical staging of feline immunodeficiency virus infection
Nippon Juigaku Zasshi
52
1990
645
2166854
137
Ishida
T
Washizu
T
Toriyabe
K
Feline immunodeficiency virus infection in cats of Japan
J Am Vet Med Assoc
194
1989
221
2537270
138
Jacobse-Geels
HE
Daha
MR
Horzinek
MC
Isolation and characterization of feline C3 and evidence for the immune complex pathogenesis
of feline infectious peritonitis
J Immunol
125
1980
1606
7410847
139
Jordan
HL
Howard
JG
Bucci
JG
Horizontal transmission of feline immunodeficiency virus with semen from seropositive
cats
J Reprod Immunol
41
1998
341
10213322
140
Kamhieh
S
Flower
RL
Borna disease virus (BDV) infection in cats. A concise review based on current knowledge
Vet Q
28
2006
66
16841569
141
Kamhieh
S
Hodgson
JL
Bode
L
Borna disease virus: evidence of naturally-occurring infection in cats in Australia
APMIS Suppl
2008
50
18771098
142
Kennedy
MA
Abd-Eldaim
M
Zika
SE
Evaluation of antibodies against feline coronavirus 7b protein for diagnosis of feline
infectious peritonitis in cats
Am J Vet Res
69
2008
1179
18764691
143
Kipar
A
Baptiste
K
Barth
A
Natural FCoV infection: cats with FIP exhibit significantly higher viral loads than
healthy infected cats
J Feline Med Surg
8
2006
69
16213766
144
Kipar
A
Bellmann
S
Gunn-Moore
DA
Histopathological alterations of lymphatic tissues in cats without feline infectious
peritonitis after long-term exposure to FIP virus
Vet Microbiol
69
1999
131
10515283
145
Kipar
A
Bellmann
S
Kremendahl
J
Cellular composition, coronavirus antigen expression and production of specific antibodies
in lesions in feline infectious peritonitis
Vet Immunol Immunopathol
65
1998
243
9839877
146
Kipar
A
May
H
Menger
S
Morphologic features and development of granulomatous vasculitis in feline infectious
peritonitis
Vet Pathol
42
2005
321
15872378
147
Kipar
A
Meli
ML
Baptiste
KE
Sites of feline coronavirus persistence in healthy cats
J Gen Virol
91
2010
1698
20237226
148
Kiss
I
Kecskemeti
S
Tanyi
J
Preliminary studies on feline coronavirus distribution in naturally and experimentally
infected cats
Res Vet Sci
68
2000
237
10877969
149
Kline
K
Joseph
R
Averill
D
Feline infectious peritonitis with neurological involvement: clinical and pathological
findings in 24 cats
J Am Anim Hosp Assoc
30
1994
111
150
Klopfleisch
R
Wolf
PU
Uhl
W
Distribution of lesions and antigen of highly pathogenic avian influenza virus A/Swan/Germany/R65/06
(H5N1) in domestic cats after presumptive infection by wild birds
Vet Pathol
44
2007
261
17491066
151
Kobayashi
S
Sato
R
Aoki
T
Effect of bovine lactoferrin on functions of activated feline peripheral blood mononuclear
cells during chronic feline immunodeficiency virus infection
J Vet Med Sci
70
2008
429
18525162
152
Kuiken
T
Rimmelzwaan
G
van Riel
D
Avian H5N1 influenza in cats
Science
306
2004
241
15345779
153
Kusuhara
H
Hohdatsu
T
Okumura
M
Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with
heterologous subtype B FIV infected cats
Vet Microbiol
108
2005
155
15899558
154
Kusuhara
H
Hohdatsu
T
Seta
T
Serological differentiation of FIV-infected cats from dual-subtype feline immunodeficiency
virus vaccine (Fel-O-Vax FIV) inoculated cats
Vet Microbiol
120
2007
217
17141431
155
Lafrado
LJ
Lewis
MG
Mathes
LE
Suppression of in vitro neutrophil function by feline leukaemia virus (FeLV) and purified
FeLV-p15E
J Gen Virol
68
Pt 2
1987
507
3029288
156
Lamm
CG
Rezabek
GB
Parvovirus infection in domestic companion animals
Vet Clin North Am Small Anim Pract
38
2008
837
18501282
157
Lappin
MR
Infectious disease diagnostic assays
Top Companion Anim Med
24
2009
199
19945088
158
Lappin
MR
Marks
A
Greene
CE
Serologic prevalence of selected infectious diseases in cats with uveitis
J Am Vet Med Assoc
201
1992
1005
1330998
159
Lappin
MR
Sebring
RW
Porter
M
Effects of a single dose of an intranasal feline herpesvirus 1, calicivirus, and panleukopenia
vaccine on clinical signs and virus shedding after challenge with virulent feline
herpesvirus 1
J Feline Med Surg
8
2006
158
16442823
160
Lappin
MR
Veir
JK
Satyaraj
E
Pilot study to evaluate the effect of oral supplementation of Enterococcus faecium
SF68 on cats with latent feline herpesvirus 1
J Feline Med Surg
11
2009
650
19201238
161
Lee
M
Bosward
KL
Norris
JM
Immunohistological evaluation of feline herpesvirus-1 infection in feline eosinophilic
dermatoses or stomatitis
J Feline Med Surg
12
2010
72
20113951
162
Legendre
AM
Bartges
JW
Effect of polyprenyl immunostimulant on the survival times of three cats with the
dry form of feline infectious peritonitis
J Feline Med Surg
11
2009
624
19482534
163
Lehmann
R
Franchini
M
Aubert
A
Vaccination of cats experimentally infected with feline immunodeficiency virus, using
a recombinant feline leukemia virus vaccine
J Am Vet Med Assoc
199
1991
1446
1666101
164
Levy
J
CVT Update: feline immunodeficiency virus
Bonagura
J
Kirk's current veterinary therapy XIII: small animal practice
2000
Saunders
Philadelphia
291
165
Levy
J
FeLV and non-neoplastic FeLV-related disease
Ettinger
S
Feldman
E
Textbook of veterinary internal medicine
ed 5
2000
Saunders
Philadelphia
424
166
Levy
J
Crawford
C
Hartmann
K
2008 American Association of Feline Practitioners’ feline retrovirus management guidelines
J Feline Med Surg
10
2008
300
18455463
167
Levy
JK
Crawford
PC
Kusuhara
H
Differentiation of feline immunodeficiency virus vaccination, infection, or vaccination
and infection in cats
J Vet Intern Med
22
2008
330
18371028
168
Levy
JK
Crawford
PC
Slater
MR
Effect of vaccination against feline immunodeficiency virus on results of serologic
testing in cats
J Am Vet Med Assoc
225
2004
1558
15568388
169
Levy JK, Lorentzen L: Long-term outcome of cats with natural FeLV and FIV infection
[abstract], 8th International Feline Retrovirus Research Symposium, Washington, DC,
2006.
170
Levy
JK
Scott
HM
Lachtara
JL
Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection
among cats in North America and risk factors for seropositivity
J Am Vet Med Assoc
228
2006
371
16448357
171
Lewis
KM
O’Brien
RT
Abdominal ultrasonographic findings associated with feline infectious peritonitis:
a retrospective review of 16 cases
J Am Anim Hosp Assoc
46
2010
152
20439937
172
Little
S
Sears
W
Lachtara
J
Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection
among cats in Canada
Can Vet J
50
2009
644
19721785
173
Lozano-Alarcon
F
Lewis
TP
2nd
Clark
EG
Persistent papillomavirus infection in a cat
J Am Anim Hosp Assoc
32
1996
392
8875353
174
Lundgren
A-L
Zimmermann
W
Bode
L
Staggering disease in cats: isolation and characterization of the feline Borna disease
virus
J Gen Virol
76
1995
2215
7561758
175
Lutz
H
Addie
D
Belak
S
Feline leukaemia ABCD guidelines on prevention and management
J Feline Med Surg
11
2009
565
19481036
176
Lutz H, Gut M, Leutenegger C et al: Kinetics of FCoV infection in kittens born in
catteries of high risk for FIP under different rearing conditions, Proceedings of
the Second International Feline Coronavirus/Feline Infectious Peritonitis Symposium,
Glasgow, Scotland, 2002.
177
MacDonald
K
Levy
JK
Tucker
SJ
Effects of passive transfer of immunity on results of diagnostic tests for antibodies
against feline immunodeficiency virus in kittens born to vaccinated queens
J Am Vet Med Assoc
225
2004
1554
15568387
178
Maggs
D
Clarke
H
Relative sensitivity of polymerase chain reaction assays used for detection of feline
herpesvirus type 1 DNA in clinical samples and commercial vaccines
Am J Vet Res
66
2005
1550
16261828
179
Maggs
D
Collins
B
Thorne
J
Effects of l-lysine and l-arginine on in vitro replication of feline herpesvirus type-1
Am J Vet Res
61
2000
1474
11131583
180
Maggs
D
Lappin
M
Reif
J
Evaluation of serologic and viral detection methods for diagnosing feline herpesvirus-1
infection in cats with acute respiratory tract or chronic ocular disease
J Am Vet Med Assoc
214
1999
502
10029851
181
Maggs
D
Nasisse
M
Kass
P
Efficacy of oral supplementation with l-lysine in cats latently infected with feline
herpesvirus
Am J Vet Res
64
2003
37
12518876
182
Maggs
DJ
Update on pathogenesis, diagnosis, and treatment of feline herpesvirus type 1
Clin Tech Small Anim Pract
20
2005
94
15948423
183
Maggs
DJ
Sykes
JE
Clarke
HE
Effects of dietary lysine supplementation in cats with enzootic upper respiratory
disease
J Feline Med Surg
9
2007
97
17055313
184
Malik
R
Lessels
NS
Webb
S
Treatment of feline herpesvirus-1 associated disease in cats with famciclovir and
related drugs
J Feline Med Surg
11
2009
40
19154974
185
Marioni-Henry
K
Vite
CH
Newton
AL
Prevalence of diseases of the spinal cord of cats
J Vet Intern Med
18
2004
851
15638269
186
Marschall
J
Hartmann
K
Avian influenza A H5N1 infections in cats
J Feline Med Surg
10
2008
359
18619884
187
Marschall
J
Schulz
B
Harder Priv-Doz
TC
Prevalence of influenza A H5N1 virus in cats from areas with occurrence of highly
pathogenic avian influenza in birds
J Feline Med Surg
10
2008
355
18640861
188
Martella
V
Campolo
M
Lorusso
E
Norovirus in captive lion cub (Panthera leo)
Emerg Infect Dis
13
2007
1071
18214183
189
Maynard L, De Mari K, Lebreux B: Efficacy of a recombinant feline omega interferon
in the treatment of symptomatic FeLV- or FeLV- and FIV-positive cats, Proceedings
of the 10th Congress of the European Society of Veterinary Internal Medicine, Neuchatel,
Switzerland, 2000, p 122a.
190
McCaw
DL
Boon
GD
Jergens
AE
Immunomodulation therapy for feline leukemia virus infection
J Am Anim Hosp Assoc
37
2001
356
11450836
191
Mehrotra
S
Mishra
KP
Yadav
VS
Immunomodulation by peptide analogs of retroviral envelope protein
Peptides
24
2003
979
14499276
192
Meli
M
Kipar
A
Muller
C
High viral loads despite absence of clinical and pathological findings in cats experimentally
infected with feline coronavirus (FCoV) type I and in naturally FCoV-infected cats
J Feline Med Surg
6
2004
69
15123151
193
Meurs
K
Fox
P
Magnon
A
Molecular screening by polymerase chain reaction detects panleukopenia virus DNA in
formalin-fixed hearts from cats with idiopathic cardiomyopathy and myocarditis
Cardiovasc Pathol
9
2000
119
10867362
194
Mexas
AM
Fogle
JE
Tompkins
WA
CD4+CD25+ regulatory T cells are infected and activated during acute FIV infection
Vet Immunol Immunopathol
126
2008
263
18799222
195
Motokawa
K
Hohdatsu
T
Aizawa
C
Molecular cloning and sequence determination of the peplomer protein gene of feline
infectious peritonitis virus type I
Arch Virol
140
1995
469
7733820
196
Muirden
A
Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus
and feline coronavirus in stray cats sent to an RSPCA hospital
Vet Rec
150
2002
621
12046785
197
Munday
JS
Dunowska
M
De Grey
S
Detection of two different papillomaviruses within a feline cutaneous squamous cell
carcinoma: case report and review of the literature
N Z Vet J
57
2009
248
19649022
198
Munday
JS
Hanlon
EM
Howe
L
Feline cutaneous viral papilloma associated with human papillomavirus type 9
Vet Pathol
44
2007
924
18039907
199
Murray
KO
Holmes
KC
Hanlon
CA
Rabies in vaccinated dogs and cats in the United States, 1997-2001
J Am Vet Med Assoc
235
2009
691
19751164
200
Naidoo
J
Baxby
D
Bennett
M
Characterization of orthopoxviruses isolated from feline infections in Britain
Arch Virol
125
1992
261
1322655
201
Nakamura
Y
Watanabe
M
Kamitani
W
High prevalence of Borna disease virus in domestic cats with neurological disorders
in Japan
Vet Microbiol
70
1999
153
10596800
202
Negrin
A
Lamb
CR
Cappello
R
Results of magnetic resonance imaging in 14 cats with meningoencephalitis
J Feline Med Surg
9
2007
109
17052935
203
Neuerer
FF
Horlacher
K
Truyen
U
Comparison of different in-house test systems to detect parvovirus in faeces of cats
J Feline Med Surg
10
2008
247
18243743
204
Nishino
Y
Funaba
M
Fukushima
R
Borna disease virus infection in domestic cats: evaluation by RNA and antibody detection
J Vet Med Sci
61
1999
1167
10563298
205
Norris
JM
Bell
ET
Hales
L
Prevalence of feline immunodeficiency virus infection in domesticated and feral cats
in eastern Australia
J Feline Med Surg
9
2007
300
17409007
206
Norris
JM
Bosward
KL
White
JD
Clinicopathological findings associated with feline infectious peritonitis in Sydney,
Australia: 42 cases (1990-2002)
Aust Vet J
83
2005
666
16315663
207
O’Neil
LL
Burkhard
MJ
Diehl
LJ
Vertical transmission of feline immunodeficiency virus
Semin Vet Med Surg (Small Anim)
10
1995
266
8820602
208
O’Neil
LL
Burkhard
MJ
Hoover
EA
Frequent perinatal transmission of feline immunodeficiency virus by chronically infected
cats
J Virol
70
1996
2894
8627764
209
Ohe
K
Takahashi
T
Hara
D
Sensitivity of FCV to recombinant feline interferon (rFeIFN)
Vet Res Commun
32
2008
167
17909979
210
Oishi
S
Kodera
Y
Nishikawa
H
Design and synthesis of membrane fusion inhibitors against the feline immunodeficiency
virus
Bioorg Med Chem
17
2009
4916
19541488
211
Omori
M
Pu
R
Tanabe
T
Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype
FIV vaccine
Vaccine
23
2004
386
15530685
212
Ossiboff
RJ
Sheh
A
Shotton
J
Feline caliciviruses (FCVs) isolated from cats with virulent systemic disease possess
in vitro phenotypes distinct from those of other FCV isolates
J Gen Virol
88
2007
506
17251569
213
Ouchi
A
Kishi
M
Kobayashi
T
Prevalence of circulating antibodies to p10, a non-structural protein of the Borna
disease virus in cats with ataxia
J Vet Med Sci
63
2001
1279
11789604
214
Paltrinieri
S
Cammarata
MP
Cammarata
G
Some aspects of humoral and cellular immunity in naturally occuring feline infectious
peritonitis
Vet Immunol Immunopathol
65
1998
205
9839875
215
Paltrinieri
S
Crippa
A
Comerio
T
Evaluation of inflammation and immunity in cats with spontaneous parvovirus infection:
consequences of recombinant feline interferon-omega administration
Vet Immunol Immunopathol
118
2007
68
17521745
216
Paltrinieri
S
Giordano
A
Tranquillo
V
Critical assessment of the diagnostic value of feline alpha1-acid glycoprotein for
feline infectious peritonitis using the likelihood ratios approach
J Vet Diagn Invest
19
2007
266
17459855
217
Paltrinieri
S
Parodi
MC
Cammarata
G
In vivo diagnosis of feline infectious peritonitis by comparison of protein content,
cytology, and direct immunofluorescence test on peritoneal and pleural effusions
J Vet Diagn Invest
11
1999
358
10424653
218
Patterson
EV
Reese
MJ
Tucker
SJ
Effect of vaccination on parvovirus antigen testing in kittens
J Am Vet Med Assoc
230
2007
359
17269866
219
Pedersen
N
Laliberte
L
Ekman
S
A transient febrile “limping” syndrome of kittens caused by two different strains
of feline calicivirus
Feline Pract
13
1983
26
220
Pedersen
NC
Virologic and immunologic aspects of feline infectious peritonitis virus infection
Adv Exp Med Biol
218
1987
529
2829567
221
Pedersen
NC
A review of feline infectious peritonitis virus infection: 1963-2008
J Feline Med Surg
11
2009
225
19254859
222
Pedersen
NC
Barlough
JE
Clinical overview of feline immunodeficiency virus
J Am Vet Med Assoc
199
1991
1298
1666071
223
Pedersen
NC
Elliott
JB
Glasgow
A
An isolated epizootic of hemorrhagic-like fever in cats caused by a novel and highly
virulent strain of feline calicivirus
Vet Microbiol
73
2000
281
10781727
224
Pedersen
NC
Ho
EW
Brown
ML
Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like
syndrome
Science
235
1987
790
3643650
225
Pedersen
NC
Liu
H
Dodd
K
Significance of coronavirus mutants in feces and diseased tissues of cats suffering
from feline infectious peritonitis
Viruses
1
2009
166
21994544
226
Pedretti
E
Passeri
B
Amadori
M
Low-dose interferon-alpha treatment for feline immunodeficiency virus infection
Vet Immunol Immunopathol
109
2006
245
16169599
227
Pepin
AC
Tandon
R
Cattori
V
Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets
of long-term experimentally infected cats
Virus Res
127
2007
9
17434224
228
Pesavento
PA
MacLachlan
NJ
Dillard-Telm
L
Pathologic, immunohistochemical, and electron microscopic findings in naturally occurring
virulent systemic feline calicivirus infection in cats
Vet Pathol
41
2004
257
15133174
229
Pesteanu-Somogyi
L
Radzai
C
Pressler
B
Prevalence of feline infectious peritonitis in specific cat breeds
J Feline Med Surg
8
2006
1
15994104
230
Phadke
AP
de la Concha-Bermejillo
A
Wolf
AM
Pathogenesis of a Texas feline immunodeficiency virus isolate: an emerging subtype
of clade B
Vet Microbiol
115
2006
64
16574348
231
Phillips
K
Arai
M
Tanabe
T
FIV-infected cats respond to short-term rHuG-CSF treatment which results in anti-G-CSF
neutralizing antibody production that inactivates drug activity
Vet Immunol Immunopathol
108
2005
357
16098604
232
Poli
A
Abramo
F
Matteucci
D
Renal involvement in feline immunodeficiency virus infection: p24 antigen detection,
virus isolation and PCR analysis
Vet Immunol Immunopathol
46
1995
13
7618253
233
Poli
A
Abramo
F
Taccini
E
Renal involvement in feline immunodeficiency virus infection: a clinicopathological
study
Nephron
64
1993
282
8321363
234
Porter
CJ
Radford
AD
Gaskell
RM
Comparison of the ability of feline calicivirus (FCV) vaccines to neutralise a panel
of current UK FCV isolates
J Feline Med Surg
10
2008
32
17720588
235
Poulet
H
Jas
D
Lemeter
C
Efficacy of a bivalent inactivated non-adjuvanted feline calicivirus vaccine: relation
between in vitro cross-neutralization and heterologous protection in vivo
Vaccine
26
2008
3647
18541348
236
Pu
R
Coleman
J
Coisman
J
Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype
B FIV isolate
J Feline Med Surg
7
2005
65
15686976
237
Pu
R
Okada
S
Little
ER
Protection of neonatal kittens against feline immunodeficiency virus infection with
passive maternal antiviral antibodies
AIDS
9
1995
235
7755911
238
Quimby
JM
Elston
T
Hawley
J
Evaluation of the association of Bartonella species, feline herpesvirus 1, feline
calicivirus, feline leukemia virus and feline immunodeficiency virus with chronic
feline gingivostomatitis
J Feline Med Surg
10
2008
66
17766156
239
Radford
AD
Addie
D
Belak
S
Feline calicivirus infection ABCD guidelines on prevention and management
J Feline Med Surg
11
2009
556
19481035
240
Raith
K
Müntener
T
Vandevelde
M
Encephalomyelitis resembling human and ruminant rhombencephalitis caused by Listeria
monocytogenes in a feline leukemia virus-infected cat
J Vet Intern Med
24
2010
983
20412434
241
Rand
J
Parent
J
Percy
D
Clinical, cerebrospinal fluid, and histological data from twenty-seven cats with primary
inflammatory disease of the central nervous system
Can Vet J
35
1994
103
8069819
242
Ravi
M
Wobeser
GA
Taylor
SM
Naturally acquired feline immunodeficiency virus (FIV) infection in cats from western
Canada: prevalence, disease associations, and survival analysis
Can Vet J
51
2010
271
20514250
243
Rees
TM
Lubinski
JL
Oral supplementation with L-lysine did not prevent upper respiratory infection in
a shelter population of cats
J Feline Med Surg
10
2008
510
18547855
244
Reeves
N
Pollock
R
Thurber
E
Long-term follow-up study of cats vaccinated with a temperature-sensitive feline infectious
peritonitis vaccine
Cornell Vet
82
1992
117
1320554
245
Reeves
NA
Helps
CR
Gunn-Moore
DA
Natural Borna disease virus infection in cats in the United Kingdom
Vet Rec
143
1998
523
9839363
246
Reggeti
F
Bienzle
D
Feline immunodeficiency virus subtypes A, B and C and intersubtype recombinants in
Ontario, Canada
J Gen Virol
85
2004
1843
15218168
247
Reynolds
BS
Poulet
H
Pingret
J-L
A nosocomial outbreak of feline calicivirus associated virulent systemic disease in
France
J Feline Med Surg
11
2009
633
19201637
248
Rice
M
Wilks
CR
Jones
BR
Detection of astrovirus in the faeces of cats with diarrhoea
N Z Vet J
41
1993
96
16031703
249
Richards
JR
Elston
TH
Ford
RB
The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel
report
J Am Vet Med Assoc
229
2006
1405
17078805
250
Ritz
S
Egberink
H
Hartmann
K
Effect of feline interferon-omega on the survival time and quality of life of cats
with feline infectious peritonitis
J Vet Intern Med
21
2007
1193
18196725
251
Rogers
A
Hoover
E
Fetal feline immunodeficiency virus infection is prevalent and occult
J Infect Dis
186
2002
895
12232829
252
Rohrbach
BW
Legendre
AM
Baldwin
CA
Epidemiology of feline infectious peritonitis among cats examined at veterinary medical
teaching hospitals
J Am Vet Med Assoc
218
2001
1111
11318361
253
Romatowski
J
Lubkin
S
Use of an epidemiologic model to evaluate feline leukemia virus control measures
Feline Pract
25
1997
6
254
Rottier
PJ
Nakamura
K
Schellen
P
Acquisition of macrophage tropism during the pathogenesis of feline infectious peritonitis
is determined by mutations in the feline coronavirus spike protein
J Virol
79
2005
14122
16254347
255
Rupprecht
CE
Childs
J
Feline rabies
Feline Pract
24
1996
15
256
Sand
C
Englert
T
Egberink
H
Evaluation of a new in-clinic test system to detect feline immunodeficiency virus
and feline leukemia virus infection
Vet Clin Pathol
39
2009
210
19930142
257
Savarino
A
Pistello
M
D’Ostilio
D
Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency
virus replication in vitro and provide a rationale to redesign antiretroviral treatment
for feline AIDS
Retrovirology
4
2007
79
17971219
258
Savigny
MR
Macintire
DK
Use of oseltamivir in the treatment of canine parvoviral enteritis
J Vet Emerg Crit Care (San Antonio)
20
2010
132
20230441
259
Schoeman
J
Kahn
R
Meers
J
Seroprevalence of FIV and FeLV infection and determination of FIV subtypes in sick
domestic cats in South Africa (abstract)
J Vet Intern Med
19
2005
950
260
Schorr-Evans
E
Poland
A
Johnson
W
An epizootic of highly virulent feline calicivirus disease in a hospital setting in
New England
J Feline Med Surg
5
2003
217
12878149
261
Schulman
FY
Krafft
AE
Janczewski
T
Feline cutaneous fibropapillomas: clinicopathologic findings and association with
papillomavirus infection
Vet Pathol
38
2001
291
11355659
262
Schulze
C
Alex
M
Schirrmeier
H
Generalized fatal Cowpox virus infection in a cat with transmission to a human contact
case
Zoonoses Public Health
54
2007
31
17359444
263
Scipioni
A
Mauroy
A
Vinje
J
Animal noroviruses
Vet J
178
2008
32
18294883
264
Scott F: Update on FIP, Proceedings of the 12th Kal Kan Symposium, 1988, p 43.
265
Shalev
Z
Duffy
SP
Adema
KW
Identification of a feline leukemia virus variant that can use THTR1, FLVCR1, and
FLVCR2 for infection
J Virol
83
2009
6706
19369334
266
Shelton
GH
Grant
CK
Linenberger
ML
Severe neutropenia associated with griseofulvin therapy in cats with feline immunodeficiency
virus infection
J Vet Intern Med
4
1990
317
2074557
267
Siebeck
N
Hurley
DJ
Garcia
M
Effects of human recombinant alpha-2b interferon and feline recombinant omega interferon
on in vitro replication of feline herpesvirus-1
Am J Vet Res
67
2006
1406
16881854
268
Sigurdardottir
OG
Kolbjornsen
O
Lutz
H
Orchitis in a cat associated with coronavirus infection
J Comp Pathol
124
2001
219
11222021
269
Simons
FA
Vennema
H
Rofina
JE
A mRNA PCR for the diagnosis of feline infectious peritonitis
J Virol Methods
124
2005
111
15664058
270
Smith
AW
Iversen
PL
O’Hanley
PD
Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline
calicivirus infection
Am J Vet Res
69
2008
23
18167083
271
Sparkes
A
Gruffydd-Jones
T
Harbour
D
An appraisal of the value of laboratory tests in the diagnosis of feline infectious
peritonitis
J Am Anim Hosp Assoc
30
1994
345
272
Sparkes
AH
Feline leukaemia virus and vaccination
J Feline Med Surg
5
2003
97
12670435
273
Sparkes
AH
Gruffydd-Jones
TJ
Harbour
DA
Feline infectious peritonitis: a review of clinicopathological changes in 65 cases,
and a critical assessment of their diagnostic value
Vet Rec
129
1991
209
1949515
274
Sponseller
BA
Strait
E
Jergens
A
Influenza A pandemic (H1N1) 2009 virus infection in domestic cat
Emerg Infect Dis
16
2010
534
20202440
275
Squires
RA
An update on aspects of viral gastrointestinal diseases of dogs and cats
N Z Vet J
51
2003
252
16032339
276
Stiles
J
McDermott
M
Bigsby
D
Use of nested polymerase chain reaction to identify feline herpesvirus in ocular tissue
from clinically normal cats and cats with corneal sequestra or conjunctivitis
Am J Vet Res
58
1997
338
9099374
277
Stiles
J
Pogranichniy
R
Detection of virulent feline herpesvirus-1 in the corneas of clinically normal cats
J Feline Med Surg
10
2008
154
18155950
278
Sukura
A
Salminen
T
Lindberg
LA
A survey of FIV antibodies and FeLV antigens in free-roaming cats in the capital area
of Finland
Acta Vet Scand
33
1992
9
1317991
279
Sundberg
JP
Van Ranst
M
Montali
R
Feline papillomas and papillomaviruses
Vet Pathol
37
2000
1
10643975
280
Suntz
M
Failing
K
Hecht
W
High prevalence of non-productive FeLV infection in necropsied cats and significant
association with pathological findings
Vet Immunol Immunopathol
136
2010
71
20398945
281
Takano
T
Azuma
N
Hashida
Y
B-cell activation in cats with feline infectious peritonitis (FIP) by FIP-virus-induced
B-cell differentiation/survival factors
Arch Virol
154
2009
27
19043660
282
Takano
T
Hohdatsu
T
Hashida
Y
A “possible” involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes
of cats with feline infectious peritonitis
Vet Microbiol
119
2006
121
17046178
283
Tammer
R
Evensen
O
Lutz
H
Immunohistological demonstration of feline infectious peritonitis virus antigen in
paraffin-embedded tissues using feline ascites or murine monoclonal antibodies
Vet Immunol Immunopathol
49
1995
177
8588340
284
Thiry
E
Addie
D
Belak
S
Feline herpesvirus infection ABCD guidelines on prevention and management
J Feline Med Surg
11
2009
547
19481034
285
Thiry
E
Addie
D
Belak
S
H5N1 avian influenza in cats ABCD guidelines on prevention and management
J Feline Med Surg
11
2009
615
19481042
286
Thiry
E
Zicola
A
Addie
D
Highly pathogenic avian influenza H5N1 virus in cats and other carnivores
Vet Microbiol
122
2007
25
17250978
287
Tiensin
T
Chaitaweesub
P
Songserm
T
Highly pathogenic avian influenza H5N1, Thailand, 2004
Emerg Inf Dis
11
2005
1664
288
Timmann
D
Cizinauskas
S
Tomek
A
Retrospective analysis of seizures associated with feline infectious peritonitis in
cats
J Feline Med Surg
10
2008
9
17765591
289
Torres
AN
Mathiason
CK
Hoover
EA
Re-examination of feline leukemia virus: host relationships using real-time PCR
Virology
332
2005
272
15661159
290
Torres
AN
O’Halloran
KP
Larson
LJ
Feline leukemia virus immunity induced by whole inactivated virus vaccination
Vet Immunol Immunopathol
134
2010
122
20004483
291
Townsend
WM
Stiles
J
Guptill-Yoran
L
Development of a reverse transcriptase-polymerase chain reaction assay to detect feline
herpesvirus-1 latency-associated transcripts in the trigeminal ganglia and corneas
of cats that did not have clinical signs of ocular disease
Am J Vet Res
65
2004
314
15027679
292
Troyer
JL
Vandewoude
S
Pecon-Slattery
J
FIV cross-species transmission: an evolutionary prospective
Vet Immunol Immunopathol
123
2008
159
18299153
293
Truyen
U
Addie
D
Belak
S
Feline panleukopenia ABCD guidelines on prevention and management
J Feline Med Surg
11
2009
538
19481033
294
Uckun
FM
Chen
CL
Samuel
P
In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency
virus-infected cats
Antimicrob Agents Chemother
47
2003
1233
12654652
295
Uckun
FM
Waurzyniak
B
Tibbles
H
In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in
dogs and feline immunodeficiency virus-infected cats
Arzneimittelforschung
56
2006
176
16570826
296
Vahlenkamp
TW
Harder
TC
Giese
M
Protection of cats against lethal influenza H5N1 challenge infection
J Gen Virol
89
2008
968
18343838
297
VandeWoude
S
O’Brien
SJ
Langelier
K
Growth of lion and puma lentiviruses in domestic cat cells and comparisons with FIV
Virology
233
1997
185
9201228
298
Veir
JK
Lappin
MR
Dow
SW
Evaluation of a novel immunotherapy for treatment of chronic rhinitis in cats
J Feline Med Surg
8
2006
400
16857403
299
Veir
JK
Ruch-Gallie
R
Spindel
ME
Prevalence of selected infectious organisms and comparison of two anatomic sampling
sites in shelter cats with upper respiratory tract disease
J Feline Med Surg
10
2008
551
18539065
300
Vennema
H
Poland
A
Hawkins
K
A comparison of the genomes of FECVs and FIPVs and what they tell us about the relationships
between feline coronaviruses and their evolution
Feline Pract
23
1995
40
301
Wang
C
Johnson
C
Ahluwalia
S
Dual-emission FRET real-time PCR differentiates feline immunodeficiency virus and
separates infected from vaccinated cats
J Clin Microbiol
48
2010
1667
20335417
302
Wardley
RC
Povey
RC
The clinical disease and patterns of excretion associated with three different strains
of feline caliciviruses
Res Vet Sci
23
1977
7
905658
303
Weaver
EA
A detailed phylogenetic analysis of FIV in the United States
PLoS One
2010
5
Weiss
ATA
Klopfleisch
R
Gruber
AD
Prevalence of feline leukaemia provirus DNA in feline lymphomas
J Feline Med Surg
12
2010
929
21036089
304
White
JD
Malik
R
Norris
JM
Association between naturally occurring chronic kidney disease and feline immunodeficiency
virus infection status in cats
J Am Vet Med Assoc
236
2010
424
20151865
305
Wilkes
RP
Kania
SA
Evaluation of the effects of small interfering RNAs on in vitro replication of feline
herpesvirus-1
Am J Vet Res
71
2010
655
20513181
306
Willis
AM
Feline leukemia virus and feline immunodeficiency virus
Vet Clin North Am Small Anim Pract
30
2000
971
11033869
307
Wright
KN
Gompf
RE
DeNovo
RC
Jr
Peritoneal effusion in cats: 65 cases (1981-1997)
J Am Vet Med Assoc
214
1999
375
10023401
308
Yilmaz
H
Ilgaz
A
Harbour
DA
Prevalence of FIV and FeLV infections in cats in Istanbul
J Feline Med Surg
2
2000
69
11716594
Kennedy
Melissa
Little
Susan E.
Baral
Randolph M.
Bacterial Infections
Primary bacterial diseases are less common in cats compared with other domestic species
and humans. Important canine bacterial diseases, such as leptospirosis and Lyme disease
(borreliosis), are not clinically important in cats even though seroconversion after
exposure has been documented. Secondary bacterial infections, however, are common
complications of many conditions, such as viral diseases, trauma, and surgery. The
most common bacterial diseases are discussed elsewhere in this book along with the
relevant body system. This chapter addresses bartonellosis, mycobacterial infections,
and nocardiosis. A summary of less common bacterial diseases is found in Table 33-8
.
TABLE 33-8
Less Common Bacterial Diseases of Cats
Disease
Agent
Clinical Signs
Diagnosis
Treatment
Comments
Tetanus5,7,30
Clostridium tetani
Motile, gram-positive, anaerobic, spore-forming bacillus
Appear within 5 to 21 days; localized and generalized forms; limb stiffness, stiff
gait, dorsally curved tail, muscle rigidity, hyperthermia, cranial nerve signs, facial
and masticatory muscle spasms, reflex muscle spasms/tonic contraction, seizures, death
from respiratory compromise
History of a recent wound, clinical signs; serum antibody titers to tetanus toxin
Tetanus antitoxin, penicillin G or metronidazole; chlorpromazine, barbiturates, benzodiazepines;
muscle relaxants, such as methocarbamol; nursing care
Transmission by environmentally resistant spores introduced into wounds; disease caused
by neurotoxin formed during vegetative growth; localized forms have better prognosis,
mortality from complications in generalized disease is high
Tularemia4,28,70,73
Francisella tularensis
Gram-negative, non–spore- forming bacillus
Fever, depression, generalized lymphadenomegaly, hepatomegaly, splenomegaly, oral
ulcers, icterus, draining abscesses, panleukopenia
Serology for microscopic agglutinating antibody
No validated treatment; suggested antibiotics include aminoglycosides, tetracyclines,
fluoroquinolones
Zoonotic; type A and B strains isolated from cats in United States; transmission through
contact with wildlife reservoirs (rodents, rabbits), tick vectors or contaminated
environment
Plague24,61
Yersinia pestis
Gram-negative, non–spore- forming, facultative anaerobe coccobacillus
Bubonic form: fever, dehydration, lymphadenomegaly, cervical/submandibular abscesses,
hyperesthesia; septicemic form: septic shock, rapidly fatal; pneumonic form can develop
by hematogenous or lymphogenous spread; 50% die acutely
Clinical signs, epidemiologic information; contact public health laboratory for guidance
on submission of samples for culture (fluids, tissues, aspirates, blood), direct fluorescent
antibody testing, serology
Strict barrier nursing techniques required; eliminate fleas; recommended antimicrobials
include aminoglycosides, penicillins
Zoonotic; transmitted by ingestion of infected rodents or rabbits, bites from infected
fleas on prey
Bartonellosis
Bartonella spp. are receiving increasing attention both in veterinary and human medicine.
Historically, their role in feline disease has been unclear and without consensus.
As more is learned about these bacteria, their function as disease-causing agents
will become clarified. The current understanding of Bartonella in cats is discussed
here.
Bartonella spp. are very small gram-negative bacteria that can survive and replicate
intracellularly in their mammalian hosts, not unlike rickettsial organisms. Their
primary targets are vascular endothelial cells and red blood cells, and spread to
various tissues is facilitated through infection of macrophages.
11
There are many species of Bartonella, and many of them can infect humans. Various
species of mammalian hosts are adapted to the various Bartonella spp. and maintain
a bacteremia for long periods without any effects. The organisms are spread by a variety
of vectors, including sand flies, lice, and fleas; ticks may be a vector, but this
has not been definitively proven.
11
Several Bartonella species have been identified in cats. B. clarridgeiae causes asymptomatic
bacteremia of cats. Other species have been found in isolated cases, but the primary
species of concern in cats is B. henselae, the agent of cat scratch disease.
35
Epidemiology
Bartonella-infected cats have been found throughout the world, but prevalence appears
to be highest in warm, humid climates.
35
In the United States, prevalence studies have shown rates from 5% to 40%. In addition
to transmission by biting insect vectors, cats may become infected by a bite or scratch
from another infected animal.
10
Infection of domestic and nondomestic felids with B. henselae has been documented.
Interestingly, the genetic variation among B. henselae isolates is significant, which
may account for the bacteria's ability to persist in an infected animal as well as
the fact that infected cats may be reinfected with heterologous strains.
35
B. henselae is naturally transmitted among cats by cat fleas (Ctenocephalides felis
felis), specifically by flea excrement. Cat-to-cat transmission, even by transplacental
exposure, is rare to nonexistent.
35
The resultant bacteremia is often chronic in nature though it may be intermittent.
Pathogenesis and Clinical Signs
After infection, the bacteria enter red blood cells and endothelial cells where they
are protected from the immune response. In experiments, infection of bone marrow progenitor
cells has been documented and may be the mechanism for red blood cell infection.
10
The intraerythrocyte locale facilitates transmission throughout the host tissues,
as well as vector transmission. Transient fever has been associated with primary infection
as well as recurrence of bacteremia in chronically infected cats following a stressor,
such as surgery.
10
Lethargy, anorexia, and lymphadenomegaly have been reported following experimental
infection, and less commonly, transient mild neurologic manifestations, such as nystagmus
and tremors, have been noted.
35
In natural infection, however, clinical signs are uncommon. Bartonella infection has
been associated with gingivostomatitis, but causation has not been shown.
67
In fact, a lack of association of Bartonella infection and chronic gingivostomatitis
has also been documented.
23
No association with other disease syndromes, including kidney, pancreatic, neurologic,
nasal, or ocular diseases, has been proven. More severe disease has been seen in immunocompromised
humans infected with Bartonella, but no such enhancement of disease has been found
with concurrent FIV or FeLV infection in cats. However, an association between FeLV
and B. henselae co-infection has been observed, indicating that infection with the
former may predispose to infection with the latter.
14
Large epidemiologic studies are needed to determine what role, if any, B. henselae
plays in feline disease.
Diagnosis
Veterinarians may be asked to test pet cats because of a diagnosis of Bartonella-associated
disease in the cat owner. Diagnosis of active infection is difficult, and will likely
rely on multiple assays. Finding the organism in red blood cells on smears is notoriously
insensitive and is not considered a viable method for diagnosis.
35
Serology alone is also difficult, because both false-negative and false-positive results
occur. Antibody levels may remain elevated for prolonged periods, even if the organism
is cleared; in addition, the latter is difficult to document. Antigen preparations
vary among the different serologic assays, affecting results. Having said this, although
the positive predictive value of a positive test is low, the negative predictive value
of a seronegative result is much higher.
35
Definitive diagnosis of infection should be performed with culture and/or PCR on blood
samples. Generally, multiple samples must be tested because of the intermittent nature
of bacteremia. Culture is done by sterile blood collection in ethylenediaminetetraacetic
acid (EDTA)-containing tubes. Tubes should be kept chilled until reaching the diagnostic
laboratory. Because special conditions and enriched media are required, labs having
experience with this organism should be selected and consulted for optimal collection
and transport methods.
35
Nucleic acid detection by PCR is much more rapid, but is no more sensitive than culture,
and reveals nothing about organism viability. The same care as required for sample
collection for culture is required for PCR.
Treatment
The efficacy of treatment is difficult to assess because of the intermittent nature
of the bacteremia. Because of concern over antibiotic resistance, only treatment of
clinically ill cats is recommended.
34
Optimal treatment regimens have not been determined. Currently, recommendations are
that doxycycline or amoxicillin-clavulanate should be used initially; if no response
is seen in 7 days, and other diagnoses are ruled out, treatment with azithromycin
or fluoroquinolones may be needed.
13
In addition, prolonged treatment (at least 4 weeks) is recommended. Owners should
be made aware of the limitations of diagnostics as well as the caveats of positive
results.
Prevention
The emphasis for control of Bartonella infections should focus on year-round flea
control.
13
Cats that are seropositive for Bartonella should not be used as blood donors.
35
No vaccine is available.
Mycobacterial Infections
Mycobacterium is a genus of aerobic, non–spore-forming, nonmotile, gram-positive,
pleomorphic bacterial rods with wide variations in host affinity and pathogenic potential.
Traditionally, mycobacteria are classified by their growth in culture (slow, difficult
to cultivate, rapid), whether they produce tubercles or lepromatous or granulomatous
disease, and whether or not there is dissemination (Table 33-9
). More recently, DNA sequencing of various genomic regions has provided more insight
into taxonomy and discovered three new fastidious mycobacterial species. In cats,
this diverse class of bacteria produces various, seemingly unrelated syndromes that
this chapter will address as
1
Slow-growing organisms that do or do not produce tubercles
a
Tuberculous mycobacteria
b
Mycobacterium avium complex (MAC) and other slow-growing saprophytes
2
Leproid granuloma-producing organisms that cannot be cultured using standard methods
a
Feline leprosy
3
Rapidly growing mycobacteria that are easily cultivated
TABLE 33-9
Species of Mycobacterium Infecting Cats
Organism
Environmental Factors
Clinical Features
Drug Susceptibility or Reported Successful Therapy*
SLOW-GROWING TUBERCULOUS: TUBERCLES AND LYMPHADENITIS, OCCASIONAL DISSEMINATION
M. tuberculosis
Urban, close contact with affected person
Usually respiratory, pulmonary localization, can disseminate systemically
Isoniazid, rifampin, ethambutol, pyrazinamide
M. bovis
Rural cats, ingest raw beef or dairy products or infected wildlife
Usually alimentary disorders; may get respiratory, cutaneous, or lymphatic involvement,
sometimes systemic dissemination
Rifampin, clarithromycin, fluoroquinolones, ethambutol, isoniazid, surgical excision
of skin lesions
M. microti
Rural, suburban, hunter, bite wounds, prey exposure, ingestion of rodents
Nodular cutaneous lesions draining, ulceration, peripheral lymphadenomegaly, local
myositis, arthritis, osteomyelitis, sometimes pneumonia, peritoneal infection, or
systemic dissemination
Clarithromycin/azithromycin, fluoroquinolones + rifampin; rifampin, isoniazid, ethambutol
LEPROMATOUS: CUTANEOUS NODULAR DERMATOSIS
M. lepraemurium
Cooler wet climates, winter months, cats less than 3 years of age exposed to infected
rodent prey
Single to multiple cutaneous and subcutaneous dermal nodules on head and extremities,
ulcers, fistulas, abscesses regional spread only
Clarithromycin, clofazimine, doxycycline or minocycline, rifampin, surgical removal
Feline leprosy, Mycobacterium sp. strain Tarwin
Central coast New South Wales, Australia, New Zealand, older cats greater than 10
years of age, feline immunodeficiency virus predisposes
Multiple subcutaneous dermal nodules, no ulceration, sometimes dissemination
Clarithromycin, clofazimine, rifampin
“Candidatus M. visibile”
Western Canada and United States, environmental exposure?
Cutaneous and disseminated
Clofazimine
NONTUBERCULOUS: PYOGRANULOMATOUS
Saprophytic Slow Growing: Cutaneous Lesions, Lymphadenitis, Dissemination in Immunocompromised
Hosts
M. avium complex
Exposure to infected soil, water or dust; acidic soils contaminated with bird feces
or carcasses, most prevalent in Siamese and Abyssinian cats
Dermal and regional lymph node granulomas, alimentary infiltration, corneal granulomas,
systemic dissemination
Clarithromycin, clofazimine, doxycycline or minocycline, rifabutin, ethambutol; rifampin
preferred for better penetration if central nervous system involvement
M. genavense
Environmental exposure in immunocompromised host
Disseminated lymphadenitis
Clarithromycin, ethambutol, fluoroquinolones, clofazimine
M. terrae complex
Environmental exposure
Cutaneous lesions
Clarithromycin, fluoroquinolones, rifampin
M. simiae
Environmental exposure
Cutaneous and disseminated
Clarithromycin, fluoroquinolones, rifampin?
M. ulcerans
Environmental exposure
Cutaneous
Surgical removal, clarithromycin
Saprophytic Rapidly Growing Mycobacteria (RGM): Cutaneous and Subcutaneous Pyogranulomatous
Infections
Mycobacterial panniculitis:
M. smegmatis (Australia), M. fortuitum (United States)
Soil and water exposure; bite and puncture wounds; immunocompromised host
Cutaneous and subcutaneous granulomas, especially inguinal region, ulcers, drainage,
with regional spread only; secondary wound infections
Surgical removal, wide excision, variable susceptibility to fluoroquinolones, doxycycline,
aminoglycosides, clofazimine, clarithromycin, trimethoprim-sulfonamide
*
A minimum of two and often three drugs should always be used in combination.
Adapted from Table 50-2 in Greene CE, editor: Infectious diseases of the dog and cat,
ed 3, St Louis, 2006, Elsevier.
Mycobacterium tuberculosis Complex
Feline tuberculosis is caused by the Mycobacterium tuberculosis complex, primarily
M. microti and M. bovis. Tuberculous mycobacteria survive within mammalian hosts.
The only reservoir hosts for M. tuberculosis are humans, cattle are the predominant
host for M. bovis, and M. microti is prevalent in small rodents, such as voles, shrews
and field mice in the United Kingdom. Cats are naturally more resistant to M. tuberculosis
than to M. bovis or M. microti.
Epidemiology
Feline infections with M. tuberculosis are considered an anthropozoonosis; the direction
of transmission is from human to animal. Spread of infection back from cats to people
has not been reported. In general, the tubercle bacilli are not as transmissible as
other bacterial pathogens, requiring frequent exposure or exposure to a large dose
of pathogen to produce disease.
The primary mode of transmission of M. tuberculosis is by inhalation of aerosolized
droplets of about 3 to 5 µm diameter that are able to reach the alveoli. The prevalence
of human and animal M. tuberculosis infections has been decreasing in developed countries
because of effective infection control measures in people, although unanticipated
increases in prevalence have occurred in certain human populations because of many
factors, such as immunosuppression from HIV infection and illicit drug use. Multidrug-resistant
tuberculosis has thus emerged in these populations because of poor compliance with
drug therapy. This may increase the risk of infection in cats in contact with these
human populations.
M. bovis infects many species of animals as well as people, and is found worldwide,
although bovine tuberculosis has been eradicated in most industrialized countries.
The most common route of infection for M. bovis is via the gastrointestinal tract
through the consumption of contaminated milk or meat from cattle. Bovine tuberculosis
has become established in wildlife hosts in many countries (e.g., white-tailed deer
in Michigan,
45
badgers in the United Kingdom,
21
and brushtail possums in New Zealand
15
) so that cats may continue to become infected even in areas where infection of domestic
animals is uncommon. In this situation, cats are most likely to be infected by eating
secondarily infected small wild mammals.20, 22
Cats are more commonly infected with M. bovis than dogs, and can excrete the organism
in feces and thus disseminate and maintain infection on farms. In the United States,
cats are rarely responsible for transmission of infection to humans.
71
However, in some areas of the world, such as Buenos Aires, M. bovis infection of cats
may be a significant human health hazard.
75
M. microti infection is most commonly seen in rural cats in Great Britain. Infection
is most likely transmitted by hunting and ingesting prey species, such as mice and
voles.33, 41
Pathogenesis
Tubercle bacilli enter the body through either the respiratory or alimentary tract
or by skin penetration. In cats, M. bovis infection is more common than M. tuberculosis
infection so that tonsils, mandibular lymph nodes, and ileocecal lymph nodes are often
infected. The ileocecal nodes are the most common sites for localization and shedding
of M. bovis organisms.
Cats with mucocutaneous infections caused by M. tuberculosis or M. avium-complex organisms
develop a pyogranulomatous infiltrate with variable amounts of necrosis, presence
of multinucleated giant cells, and degrees of lymphoid infiltration.
47
M. tuberculosis organisms are frequently extracellular, whereas M. avium complex organisms
are usually intracellular.
Clinical Signs
Feline tuberculosis is frequently a subclinical disease, often acquired through contact
with M. tuberculosis or M. bovis-infected people.
69
When clinical signs are present, they are similar whether infection is by M. tuberculosis,
M. microti, or M. bovis and typically reflect the site of granuloma formation. Cats
may develop localized cutaneous infections with M. bovis and M. microti seen as dermal
nodules and nonhealing, draining ulcers at the site of a bite or scratch wound or
a penetrating injury. Regional lymphadenomegaly may develop.
33
Pulmonary infection causes dyspnea and cough.
33
Dysphagia, retching, hypersalivation, and tonsillar enlargement may result from ulcerated
and chronically draining oropharyngeal lesions. Localized intestinal lesions may cause
weight loss, anemia, vomiting, and diarrhea, as well as enlarged mesenteric lymph
nodes and abdominal effusion.
Disseminated disease resulting from M. bovis or M. microti may develop from cutaneous
lesions and cause respiratory dysfunction.
33
Other signs of disseminated disease include abdominal masses, organ enlargement, generalized
lymphadenomegaly, anorexia, weight loss, and fever. M. bovis may be associated with
tuberculous choroiditis and retinal detachment.
25
Sudden death can also occur.
Mycobacterium avium Complex
The M. avium complex (MAC) organisms are opportunistic mycobacteria that survive in
soil and water (i.e., are saprophytic). Other slow-growing saprophytic mycobacteria,
such as M. genavense, M. simiae, M. xenopi, M. terrae, and M. kansasii, have a similar
environmental niche and can cause similar clinical disease in cats and thus should
be considered in the same context. Clinical infection with these organisms results
in granulomas but not true tubercles. In cats, localized lymphadenitis can occur,
but disease can disseminate if the cat does not mount an appropriate immune response.
Disseminated MAC infection occurs, therefore, in immunocompromised animals, such as
cats receiving immunosuppressive therapy after renal transplantation
31
and cats with retroviral infections;
40
congenital immune deficiencies are also considered to be a possible predisposing factor.
6
Epidemiology
MAC and other slow-growing saprophytic mycobacteria are ubiquitous worldwide in soil
and water when conditions are acidic (pH 5.0 to 5.5) and soils are high in organic
matter, such as swamps, coastal plains, and brackish coastal waters.
48
MAC is found in large numbers in the feces of infected birds. Infection of cats occurs
by ingestion of infected meat or contact with infected soil or contaminated fomites.
Despite the widespread nature of MAC organisms in the environment, infections in cats
have been uncommon because of natural resistance. No evidence has been found for spread
of MAC organisms from animals to people.
Pathogenesis
Infection with MAC organisms begins with ingestion of contaminated food or contact
with the organism in the environment. MAC infections in cats are often disseminated
through many tissues and are due to organisms closely related to the M. avium subspecies
paratuberculosis that causes chronic granulomatous enteritis in ruminants (Johne's
disease). It is thought that animals with Johne's disease acquire the infection as
neonates, although it initially becomes quiescent. Stress or immunosuppression later
in life allows the organisms to replicate and produce disease. A similar scenario
may occur in predisposed cat breeds (Siamese, Abyssinian) in which disseminated infections
typically develop while cats are young, possibly because of defects in cell-mediated
immunity.6, 44
Clinical Signs
Localized infections often follow bite or scratch wounds so that clinical signs include
enlarged regional lymph nodes and subcutaneous swellings, especially around the head
and face. Other signs include weight loss, anorexia, and fever. Disseminated infection
can occur with clinical signs reflecting the areas involved.6, 8 Clinical findings
may include thickened intestinal loops, hepatomegaly, splenomegaly, and lymphadenomegaly;
in one series of 12 cats, 10 of 12 cats had enlarged mesenteric lymph nodes, and 6
of 12 had enlarged popliteal lymph nodes.
6
Pulmonary nodular interstitial infiltration is commonly recognized radiographically
but does not necessarily result in respiratory signs (FIGURE 33-25, FIGURE 33-26
). Disseminated infection is particularly noted in Abyssinians, where signs of illness
develop before 5 years of age.6, 66
FIGURE 33-25
Lateral radiograph of a 1-year-old neutered male Abyssinian. The diffuse pulmonary
interstitial pattern was caused by disseminated MAC infection.
Rights were not granted to include this figure in electronic media. Please refer to
the printed book.
(From Baral RM, Metcalfe SS, Krockenberger MB et al: Disseminated Mycobacterium avium
infection in young cats: overrepresentation of Abyssinian cats, J Feline Med Surg
8:23, 2006.)
© 2012 J Feline Med Surg
2012
Since January 2020 Elsevier has created a COVID-19 resource centre with free information
in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre
is hosted on Elsevier Connect, the company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related research that is
available on the COVID-19 resource centre - including this research content - immediately
available in PubMed Central and other publicly funded repositories, such as the WHO
COVID database with rights for unrestricted research re-use and analyses in any form
or by any means with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
FIGURE 33-26
A high-power photomicrograph of a lymph node from the cat shown in Figure 33-25. The
Ziehl-Neelsen stain shows intracellular acid-fast bacilli (staining pink with the
carbol fuchsin) in macrophages.
(Courtesy Dr. Randolph Baral.)
Diagnosis of M. tuberculosis Complex and MAC Infections
Clinical laboratory findings in mycobacterial infections are typically nonspecific.
Non-regenerative anemia may be seen, and has been reported to be macrocytic in some
cats with intestinal infections.
44
Other findings include neutrophilic leukocytosis, hyperglobulinemia, and hypercalcemia.1,
6, 59 Imaging studies may reveal masses in various organ systems. Tracheobronchial
lymphadenomegaly, interstitial pulmonary infiltrates, calcified pulmonary lesions,
and pleural or pericardial fluid may be seen with thoracic radiography. Hepatomegaly,
splenomegaly, solitary abdominal masses, and ascites may be seen on abdominal radiography
or ultrasonography.
Specific diagnostic methods include acid-fast staining, mycobacterial culture, biopsy
with histopathologic examination and direct detection of organisms. Intradermal tuberculin
testing is not reliable in cats, unlike other species, including dogs.
Acid-fast (Ziehl-Neelsen) staining of cytologic specimens obtained by tissue aspirates
or impressions smears from biopsy samples is a widely available and useful method
of diagnosis. Acid-fast organisms may also be demonstrated within lesions on histopathologic
examination of tissue biopsy samples or in direct smears of exudates or fluids. Intracellular
tubercle bacilli have a clubbed shape and beaded appearance. M. tuberculosis bacilli
may be found in extracellular locations.
47
MAC organisms are generally smaller and present in high numbers within infected cells.
When biopsy samples are obtained from lesions where mycobacterial infection is suspected,
the sample should be divided into three pieces. One piece is fixed in formalin for
histopathology and acid-fast staining, and one is sent for routine bacterial culture.
A third piece is placed in a sterile container and frozen. If the first sample is
acid-fast positive, the frozen sample can be submitted for mycobacterial culture.
PCR testing can be performed on formalin-fixed samples.
Finding acid-fast staining organisms confirms mycobacterial infection, but culture
is required to determine the species in order to evaluate zoonotic risk, sources of
infection, and treatment options. Unfortunately, mycobacterial organisms are very
slow-growing and may fail to culture. A specialized laboratory should be consulted
for advice on specimen preparation and transport media.
Specific detection methods for mycobacterial organisms in body fluids and tissue specimens
include enzyme-linked immunosorbent assay, radioimmunoassay and PCR. PCR appears to
be highly sensitive when organisms are abundant in the specimen, but false-negative
results are possible when organisms are few because the nucleic acid is difficult
to extract and purify. Therefore methods based on detection of nucleic acid should
not replace conventional mycobacterial isolation methods but may be complementary,
such as to identify organisms found in culture of clinical specimens.
At necropsy, generalized emaciation is a common finding. Multifocal granulomas appear
in many organs as grayish-white to yellow, circumscribed, nodular lesions. The primary
lesion sites in cats are ileocecal and mesenteric lymph nodes. Disseminated infection
may lead to lesions in the mesenteric lymph nodes, spleen, and skin. Uncommon sites
for lesions include bones, joints, genitals, and conjunctiva. Histologically, granulomas
consist of focal necrosis surrounded by plasma cells and macrophages in a connective
tissue capsule.
Precautions should always be taken whenever handling potentially tuberculous material
to prevent human infection. In many countries, specific laws govern the diagnosis
and reporting of suspected tuberculosis cases.
Therapy of M. tuberculosis Complex and MAC Infections
Treatment of tuberculous mycobacterial infections should be considered separate from
treatment of disseminated infections with slow-growing saprophytic mycobacteria. This
is because of the zoonotic potential of M. tuberculosis; M. bovis–infected cats do
not appear to be a major risk for their owners,18, 19 and reports of M. microti infections
in people appear to be associated with direct contact with rodents.
60
Additional considerations are the need for long-term (sometimes indefinite) drug administration
that is expensive and can make patient compliance uncertain; and whether immunosuppressed
people may be exposed. Also, increasing antimicrobial resistance to drugs used to
treat human tuberculosis must be considered, because the routine treatment of animal
infections might contribute to the development of resistance. Infections with saprophytic
mycobacteria, such as MAC and M. microti, are the appropriate mycobacterial infections
to consider treating.
When a decision to treat a cat has been made, treatment should be started based on
cytologic or histopathologic diagnosis, because results of mycobacterial culture and
species identification typically take several weeks if the organism grows in culture
at all. Treatment of mycobacterial disease poses several difficulties. To be effective,
antimicrobials must reach therapeutic concentrations within phagocytes in various
tissues but with minimal toxicity to the host. Importantly, there is a propensity
for mycobacteria species, in general, and MAC organisms, in particular, to spontaneously
and rapidly develop antibiotic-resistant mutants.
58
Multiple agents should therefore be used to reduce the chance of resistant clones
developing. Using several agents concurrently, however, increases the likelihood of
adverse drug reactions, because each agent has a potential toxicity profile. Furthermore,
some of these toxicity profiles overlap.
58
M. bovis and M. microti infections in cats have been successfully treated with a combination
of rifampin, plus enrofloxacin or marbofloxacin, plus clarithromycin or azithromycin.18,
33 It is appropriate to treat localized MAC infections (or other slow-growing saprophytes)
with surgical excision followed by combination antibiotic therapy with clarithromycin
and doxycycline.
46
Disseminated MAC infections (or other slow-growing saprophyte) are best treated with
clarithromycin in combination with at least one other agent, such as clofazimine or
rifampin.
6
There is widespread resistance of MAC strains to the traditional fluoroquinolones,
2
but newer agents, such as moxifloxacin, may have some role in treating these organisms.
More details about these drugs including dosages are included in Table 33-10
.
TABLE 33-10
Antimicrobial Drug Therapy for Slow-Growing Mycobacterial Infections
Drug
Dose (mg/kg)a
Route
Interval (Hour)
Toxicities
TUBERCULOUS MYCOBACTERIA: M. TUBERCULOSIS, M. BOVIS, M. MICROTI
Treatment (minimum of two, and preferably three, of different classes of the following
drugs in combination)
b
Isoniazid
10-20c
PO
24
Hepatotoxic, seizures, acute renal failure, peripheral neuritis
Rifampi(ci)n
10-20d
PO
24
Hepatotoxic; discolors mucosae, tears, and urine
Ethambutol
10-25
PO
24
Optic neuritis
Dihydrostreptomycin
15
IM
24
Ototoxic
Pyrazinamidee
15-40
PO
24
Hepatotoxic, GI signs, arthralgia
Clarithromycin
5-15
PO
12
GI signs, hepatotoxic, cutaneous erythema, allergic reactions
62.5 total
PO
12
Azithromycin
7-15
PO
24
GI signs?
Enrofloxacin
5
PO
24
Vomiting, retinal toxicity
Marbofloxacin
2
PO
24
Retinal toxicity?
SLOW-GROWING SAPROPHYTIC MYCOBACTERIA: M. AVIUM COMPLEX, M. TERRAE, M. SIMIAE, M.
ULCERANS
Clarithromycin
7.5-15
PO
12
Cutaneous erythema, hepatotoxicity
Clofaziminef
8-10
PO
24
Orange staining body fluids, hepatotoxic, GI signs, photosensitization
25 mg totalg
PO
24
Rifampi(ci)n
10-20
PO
24
Hepatotoxic, cutaneous erythema, discolors body fluids
75 mg total
PO
24
Doxycycline
5-10h
PO
12
Vomiting, esophagitis
GI, Gastrointestinal; IM, intramuscular; PO, by mouth.
a
Dose per administration at specified interval. After daily dosing for weeks to months,
switch to twice weekly administration for 6 to 9 months.
b
Treatment for 2 months minimum with three drugs in combination (e.g., rifampin with
a fluoroquinolone [e.g., marbofloxacin] and with either clarithromycin or azithromycin).
Maintenance therapy for 4 months thereafter consists of the same dosages of any two
of the three drugs.
c
Maximum 300 mg daily.
d
Maximum 600 mg daily.
e
Ineffective for M. bovis strains.
f
Only available from a compounding pharmacist in most countries.
g
Alternatively, 50 mg total can be given every 48 hours.
h
Can increase dosage up to 10 mg/kg for improved efficacy, but only if this level is
tolerated; give with food or administer water to avoid esophageal injury; if possible,
use monohydrate salt to minimize gastrointestinal irritation.
Adapted from Table 50-4 in Greene CE, editor: Infectious diseases of the dog and cat,
ed 3, St Louis, 2006, Elsevier.
Prevention of Mycobacterium tuberculosis Complex and MAC Infections and Public Health
Considerations
Cats (and dogs) should be evaluated as temporary sources for dissemination of infection
when M. tuberculosis is identified in people and when outbreaks of M. bovis in cattle
occur on farms. Prevention of infection in cats involves discouraging the hunting
of prey and avoiding the feeding of potentially infected meat and milk. MAC organisms
may be acquired from the environment by both cats and people.
Mycobacteria are more resistant to heat, pH changes, ultraviolet light, and routine
disinfection than are other pathogenic bacteria. Contaminated equipment should always
be manually cleaned with a neutral detergent before disinfection. Mycobacteria are
killed by 5% household bleach within 15 minutes and 2% glutaraldehyde for 10 minutes
at room temperature. Ethyl and isopropyl alcohols can be used as a terminal rinse.
Feline Leprosy
Feline leprosy was first described in the 1960s and consists of solitary or multiple,
well-circumscribed, nodular granulomas in the skin and/or subcutis, resulting from
mycobacterial infection. Unfortunately, the causative species are fastidious and typically
cannot be grown using routine mycobacteriologic techniques, even in specialist laboratories.
Recent studies incorporating PCR methodologies have led to the recognition that there
are numerous agents associated with feline leprosy, including M. lepraemurium as well
as at least three novel mycobacterial agents.4, 7, 27 In Australia and New Zealand,
feline leprosy has typically been considered to be composed of two syndromes: one
caused by M. lepraemurium (affecting younger, mostly immunocompetent cats) and one
caused by a novel mycobacterial species currently described as Mycobacterium sp. cat
(affecting older, immunocompromised cats).
52
However, a recent study has recognized another organism from a specific regional area,
described as Mycobacterium sp. strain Tarwin, with no obvious age or sex predisposition
in affected cats.
27
In a study of 26 cases in New Zealand and British Columbia, Canada, various species
were identified, such as M. lepraemurium, M. intracellulare, M. mucogenicum, M. septicum,
as well as one case of Mycobacterium sp. cat.
17
Three cats from the northwestern United States and western Canada have been diagnosed
with diffuse cutaneous and disseminated disease similar to diffuse lepromatous leprosy
in people caused by M. visibile.
7
Feline leprosy has been reported from many areas of the world, including New Zealand,
Australia, the United Kingdom, the Netherlands, the United States, Canada, and Italy.
Many cases originate in temperate coastal areas, suggesting that the route of infection
may be rodent or insect bites or contamination of cat fight wounds with soilborne
organisms.
56
Feline leprosy is characterized by single or multiple nodules of the skin and/or subcutis,
often on the head, face, limbs or trunk. The nodules are painless, well circumscribed,
moveable, and firm or soft on palpation. Overlying skin may be intact or may ulcerate
if lesions are large. In advanced disease, regional lymph nodes and local tissues
may become involved as well as the liver or spleen.
Diagnosis is similar to that for other mycobacterial infections; an index of suspicion
on the part of the clinician is essential. Other causes of cutaneous and subcutaneous
nodular lesions must be ruled out (see Chapter 22). Samples obtained for cytology
and histopathology by fine-needle aspiration or biopsy can be stained with Ziehl-Neelsen
to demonstrate acid-fast organisms surrounded by granulomatous to pyogranulomatous
inflammation. With Romanowski stains, mycobacterial rods are “negatively” stained
and are typically located within macrophages and giant cells. Culturing these organisms
is usually unsuccessful, but they are readily detected using PCR methodologies in
laboratories with mycobacterial expertise.
Feline leprosy is divided into two forms: lepromatous and tuberculoid, which correspond
to the host's immune response to infection.
65
The lepromatous form corresponds with a poor cell-mediated immune response. Histopathologic
findings are primarily pyogranulomatous, and lymphocytes and plasma cells are absent.
Large numbers of mycobacterial organisms are present. The tuberculoid form is associated
with a more effective cell-mediated immune response and is characterized by pyogranulomatous
dermatitis and panniculitis. Histopathologic findings are primarily epitheloid histiocytes
with moderate numbers of lymphocytes and plasma cells but moderate to few mycobacterial
organisms. The tuberculoid form accounts for about two-thirds of cases in Canada,
17
most cases in New Zealand and the Netherlands, but few cases in Australia.
52
Invasion of peripheral nerves, a feature of human leprosy, is not usually found in
feline patients.
Because the organisms responsible for feline leprosy cannot be grown in culture, therapy
cannot be guided by susceptibility testing, and no firm guidelines exist to direct
therapy. Aggressive surgical resection of lesions with wound reconstruction when required
is often recommended, especially when the disease is diagnosed early and lesions are
localized.50, 62, 72 Adjunctive antibiotic therapy is recommended to prevent local
recurrence and should be continued for at least 2 months.24, 52 The most commonly
recommended drugs are a combination of clarithromycin, rifampicin, and/or clofazimine.
52
Monotherapy is avoided to prevent development of resistance.
Human leprosy is acquired from the environment and is caused by M. leprae. M. lepraemurium
has no zoonotic potential.
Rapidly Growing Mycobacteria
Rapidly growing mycobacteria (RGM) were formerly called Runyon group IV or atypical
mycobacteria and are characterized by the ability to form colonies in solid media
culture within 1 week. These mycobacteria are ubiquitous in the environment, including
soil and water sources. The taxonomy of RGM has been redefined based on molecular
methods and now includes the Mycobacterium chelonae-abscessus, Mycobacterium fortuitum,
and Mycobacterium smegmatis groups among others. RGM are not known to be transmissible
among animals.
RGM cause opportunistic disease in both healthy and immunocompromised cats. Disseminated
disease typically occurs only in cats with underlying immunosuppression. The most
common presentation is localized infection in healthy cats, most typically chronic
panniculitis
72
; there have been occasional reports of pneumonia caused by RGM.16, 26 Many individual
case reports are in the veterinary literature as well as a case series of 29 affected
cats in Australia.
17
Other countries with reported cases include the United States,
49
Canada,17, 74 New Zealand,
17
France,
68
Finland,
1
the Netherlands,
43
and Switzerland.
3
In Australia, organisms from the M. smegmatis group account for most feline cases,53,
57 while in the United States, most cases are caused by members of the M. fortuitum
group.39, 42
Infection typically starts in the inguinal fat pad, possibly after a cat-fight wound
has become contaminated,
56
and it may spread to the abdominal wall, perineum, and tail base. Other penetrations
of the integument (such as through bite wounds, penetrating foreign bodies, injections,
surgical wounds) may also allow RGM infections to become established in subcutaneous
tissues, especially in fat. RGM organisms appear to prefer tissues rich in lipid so
that certain areas of the body are more likely to be affected, and overweight or obese
cats are at most risk. Initial lesions are circumscribed plaques or nodules at the
site of injury, although trauma to the skin is not always reported.
39
Many patients are initially treated for a cat fight abscess with surgical drainage
and antibiotics, although the lesions do not have a fetid odor or the typical bacterial
discharge. Wound breakdown and development of a nonhealing suppurating tract then
occurs. Later, the subcutaneous tissue becomes thickened, and the overlying skin becomes
adherent and alopecic, with watery exudate discharging from fistulas. Gradually, the
affected area may involve the entire ventral abdomen, adjacent flank areas, and limbs.
Lesions typically remain localized, and most cats have few signs of systemic illness.
In severe cases, depression, fever, inappetence, weight loss, and reluctance to move
may be noted. Hypercalcemia of granulomatous disease develops only occasionally.
Diagnosis of mycobacterial panniculitis is similar to other mycobacterial infections;
an index of suspicion on the part of the clinician is essential. Specimens for cytology
(acid-fast staining) and culture are best obtained by fine-needle aspiration of pockets
of purulent material through intact skin that has been disinfected with 70% ethanol
(to eliminate skin-dwelling mycobacterial species).
55
Material from draining tracts is usually unsuitable, because of the high numbers of
contaminating secondary bacteria. Tissue homogenates from surgically collected samples
can also be used for cytology and culture. The diagnostic laboratory should be consulted
in advance for advice on sample submission and supplies.
The medical and surgical management of mycobacterial panniculitis is well described.
55
However, recommendations continue to evolve as new drugs, such as fourth-generation
fluoroquinolones and tetracycline derivatives, become available.
29
The use of appropriate antimicrobial agents based on susceptibility data and aggressive
surgical resection, when warranted, improves outcome. However, some cases, especially
those caused by M. fortuitum in the United States remain frustrating to treat.
39
Initial treatment should be with one or two oral antimicrobials chosen empirically,
then adjusted based on susceptibility data. In Australia, doxycycline and/or a fluoroquinolone
(such as pradofloxacin or moxifloxacin) are appropriate choices for first-line therapy,
whereas in the United States, clarithromycin is the drug of choice for empiric therapy.
Treatment durations are typically 3 to 12 months, and agents should be administered
for at least 1 to 2 months after affected tissues look and feel completely normal.
Surgical resection of persistently nonhealing tissue may be necessary.
63
In human medicine, RGM infections may develop resistance to quinolones (but not doxycycline
or clarithromycin) during therapy.
12
For this reason, many veterinary dermatologists in Australia routinely use combination
therapy with doxycycline and a fluoroquinolone from the outset. Although some RGM
strains show in vitro susceptibility to amoxicillin-clavulanate, this drug combination
has no efficacy in vivo.
Once susceptibility data is obtained, drug therapy may be refined. The highest possible
doses are used because of the poor perfusion of affected tissues. Patients should
be reassessed every 3 to 4 weeks to determine response to treatment and whether surgical
resection is required. If surgery is required, it is most important to remove as much
abnormal subcutaneous tissue as possible. Some cases require removal of large portions
of infected tissue followed by reconstruction to close the wound without tension.
Latex or closed suction drains must be used in large areas of dead space. Vacuum-assisted
wound closure has been used in some challenging cases.
32
Nocardiosis
Nocardiosis is caused by several species of gram-positive aerobic actinomycetes that
are ubiquitous soil saprophytes. These facultative intracellular pathogens with a
propensity to erode blood vessels grow in branching filaments, often in tangles, and
fragment into rods and cocci. They are somewhat acid fast. The most commonly isolated
species are the Nocardia asteroides complex (including N. farcinica, N. nova), but
infections in cats have also been reported to be caused by N. brasiliensis, N. otitidiscaviarum,
N. elegans, N. tenerifensis, and N. africana.9, 36, 37, 38, 51, 54, 64 Infections
are opportunistic and are introduced primarily through scratches and bite wounds.
Males are overrepresented in the published cases. The most common clinical scenario
is infection of the skin and subcutis following penetrating wounds, with lesions typically
located in regions subjected to cat bite or scratch injuries, including limbs, body
wall, inguinal panniculus, and the nasal bridge (Figure 33-27
). Pneumonia and pyothorax, possibly following aspiration of plant material, such
as grass awns, and disseminated disease associated with immunodeficiency have also
been documented.
FIGURE 33-27
Lesion on the paw of a 13-year-old neutered male Devon Rex. Tangles of gram-positive
branching filaments were seen on cytologic examination, and pyogranulomatous inflammation
was seen on histopathologic examination. Nocardia nova infection was confirmed on
culture. Treatment with clarithromycin (62.5 mg/cat, PO, every 12 hours) for 1 month
resolved the lesion.
(Courtesy Dr. Randolph Baral.)
Chronic nonhealing wounds often start as an abscess but spread circumferentially as
well as by development of satellite lesions. The clinical appearance may be very similar
to those caused by rapidly growing mycobacteria. In a series of 17 cases from eastern
Australia, the majority of cats presented with spreading lesions of the skin and subcutis
associated with draining tracts.
54
Most of the cats were male (14 of 17) and random bred (14 of 17). About half (9 of
17) were 10 years old or older. The majority of infections were due to N. nova. Several
of the cats had conditions predisposing to immunosuppression, such as renal transplantation,
chronic corticosteroid administration, postsurgical status, and FIV infection. The
prognosis was considered to be guarded, and factors predisposing to treatment failure
included delayed treatment resulting from misdiagnosis and insufficient duration of
treatment.
Differential diagnoses include other infections associated with pyogranulomatous inflammation,
such as mycobacterial panniculitis, Rhodococcus spp., Corynebacterium spp., and sporotrichosis.
Clinical laboratory findings are nonspecific, such as nonregenerative anemia, neutrophilic
leukocytosis with a left shift, monocytosis, and hyperproteinemia. Hypercalcemia associated
with granulomatous disease has been reported,
59
but localized infections may show no clinical laboratory changes. Analysis of fluids
and aspirates of abscesses demonstrates a suppurative to pyogranulomatous inflammation.
The causative agent may be observed as a gram-positive, partially or weakly acid-fast,
branching filamentous organism, either individually or in groups. Sulfur granules
are not common. Diagnosis is confirmed by culture, usually within a few days, although
2 to 4 weeks of incubation may be necessary if samples have a high bacterial load
or the patient was receiving antibiotics. Species identification is important for
determining optimal antimicrobial treatment. Although traditionally species have been
identified by phenotypic features, DNA-based techniques provide more rapid and reliable
detection methods.
The primary drugs for treatment of nocardiosis are sulfonamides, such as trimethoprim-sulfamethoxazole
(15 to 30 mg/kg, PO, every 12 hours). Prolonged courses of treatment, such as 3 to
6 months, are required to prevent recurrence. Sulfonamides may not be well tolerated
for such long treatment durations because of drug reactions (anemia, leukopenia) and
gastrointestinal side effects. N. nova infections are often susceptible to ampicillin,
sulfonamides, clarithromycin, tetracyclines, amikacin, and imipenem but resistant
to fluoroquinolones and amoxicillin clavulanate.38, 54 One recommended treatment regime
for N. nova infections is amoxicillin (20 mg/kg, PO, every 12 hours) and/or erythromycin
(10 mg/kg, PO, every 8 hours) or clarithromycin (62.5 mg/cat, PO, every 12 hours).
Extensive débridement of skin lesions may be necessary in some cases.
References
1
Alander-Damsten
Y
Brander
E
Paulin
L
Panniculitis, due to Mycobacterium smegmatis, in two Finnish cats
J Feline Med Surg
5
2003
19
12547619
2
Alangaden
GJ
Lerner
SA
The clinical use of fluoroquinolones for the treatment of mycobacterial diseases
Clin Infect Dis
25
1997
1213
9402384
3
Albini
S
Mueller
S
Bornand
V
[Cutaneous atypical mycobacteriosis due to Mycobacterium massiliense in a cat]
Schweiz Arch Tierheilkd
149
2007
553
18225411
4
Baldwin
CJ
Panciera
RJ
Morton
RJ
Acute tularemia in three domestic cats
J Am Vet Med Assoc
199
1991
1602
1778744
5
Baral
R
Catt
M
Malik
R
Localised tetanus in a cat
J Feline Med Surg
4
2002
221
12468317
6
Baral
RM
Metcalfe
SS
Krockenberger
MB
Disseminated Mycobacterium avium infection in young cats: overrepresentation of Abyssinian
cats
J Feline Med Surg
8
2006
23
16226469
7
Baral
RM
Norris
JM
Malik
R
Localized and generalized tetanus in cats
August
J
Consultations in feline internal medicine
2006
Saunders
Philadelphia
57
8
Barry
M
Taylor
J
Woods
JP
Disseminated Mycobacterium avium infection in a cat
Can Vet J
43
2002
369
12001504
9
Beaman
BL
Sugar
AM
Nocardia in naturally acquired and experimental infections in animals
J Hyg (Lond)
91
1983
393
6363525
10
Breitschwerdt
EB
Feline bartonellosis and cat scratch disease
Vet Immunol Immunopathol
123
2008
167
18295347
11
Breitschwerdt
EB
Maggi
RG
Chomel
BB
Bartonellosis: an emerging infectious disease of zoonotic importance to animals and
human beings
J Vet Emerg Crit Care
20
2010
8
12
Brown-Elliott
BA
Wallace
RJ
Jr
Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly
growing mycobacteria
Clin Microbiol Rev
15
2002
716
12364376
13
Brunt
J
Guptill
L
Kordick
DL
American Association of Feline Practitioners 2006 Panel report on diagnosis, treatment,
and prevention of Bartonella spp. infections
J Feline Med Surg
8
2006
213
16846781
14
Buchmann
AU
Kershaw
O
Kempf
VAJ
Does a feline leukemia virus infection pave the way for Bartonella henselae infection
in cats?
J Clin Microbiol
48
2010
3295
20610682
15
Caley
P
Hickling
GJ
Cowan
PE
Effects of sustained control of brushtail possums on levels of Mycobacterium bovis
infection in cattle and brushtail possum populations from Hohotaka, New Zealand
N Z Vet J
47
1999
133
16032090
16
Couto
SS
Artacho
CA
Mycobacterium fortuitum pneumonia in a cat and the role of lipid in the pathogenesis
of atypical mycobacterial infections
Vet Pathol
44
2007
543
17606521
17
Davies
JL
Sibley
JA
Myers
S
Histological and genotypical characterization of feline cutaneous mycobacteriosis:
a retrospective study of formalin-fixed paraffin-embedded tissues
Vet Dermatol
17
2006
155
16674729
18
de Lisle
GW
Collins
DM
Loveday
AS
A report of tuberculosis in cats in New Zealand, and the examination of strains of
Mycobacterium bovis by DNA restriction endonuclease analysis
N Z Vet J
38
1990
10
16031566
19
Dean
R
Gunn-Moore
D
Shaw
S
Bovine tuberculosis in cats
Vet Rec
158
2006
419
16565345
20
Delahay
RJ
Cheeseman
CL
Clifton-Hadley
RS
Wildlife disease reservoirs: the epidemiology of Mycobacterium bovis infection in
the European badger (Meles meles) and other British mammals
Tuberculosis (Edinb)
81
2001
43
11463223
21
Delahay
RJ
De Leeuw
AN
Barlow
AM
The status of Mycobacterium bovis infection in UK wild mammals: a review
Vet J
164
2002
90
12359464
22
Delahay
RJ
Smith
GC
Barlow
AM
Bovine tuberculosis infection in wild mammals in the South-West region of England:
a survey of prevalence and a semi-quantitative assessment of the relative risks to
cattle
Vet J
173
2007
287
16434219
23
Dowers
KL
Hawley
JR
Brewer
MM
Association of Bartonella species, feline calicivirus, and feline herpesvirus 1 infection
with gingivostomatitis in cats
J Feline Med Surg
12
2010
314
19959386
24
Eidson
M
Tierney
LA
Rollag
OJ
Feline plague in New Mexico: risk factors and transmission to humans
Am J Public Health
78
1988
1333
3421391
25
Formston
C
Retinal detachment and bovine tuberculosis in cats
J Small Anim Pract
35
1994
5
26
Foster
SF
Martin
P
Davis
W
Chronic pneumonia caused by Mycobacterium thermoresistibile in a cat
J Small Anim Pract
40
1999
433
10516950
27
Fyfe
JA
McCowan
C
O’Brien
CR
Molecular characterization of a novel fastidious mycobacterium causing lepromatous
lesions of the skin, subcutis, cornea, and conjunctiva of cats living in Victoria,
Australia
J Clin Microbiol
46
2008
618
18057130
28
Gliatto
JM
Rae
JF
McDonough
PL
Feline tularemia on Nantucket Island, Massachusetts
J Vet Diagn Invest
6
1994
102
8011763
29
Govendir
M
Hansen
T
Kimble
B
Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin,
enrofloxacin and moxifloxacin
Vet Microbiol
147
2011
113
20619975
30
Greene
CE
Tetanus
Greene
CE
Infectious diseases of the dog and cat
ed 3
2006
Saunders Elsevier
St Louis
395
31
Griffin
A
Newton
A
Aronson
L
Disseminated Mycobacterium avium complex infection following renal transplantation
in a cat
J Am Vet Med Assoc
222
2003
1097
12710773
32
Guille
AE
Tseng
LW
Orsher
RJ
Use of vacuum-assisted closure for management of a large skin wound in a cat
J Am Vet Med Assoc
230
2007
1669
17542735
33
Gunn-Moore
DA
Jenkins
PA
Lucke
VM
Feline tuberculosis: a literature review and discussion of 19 cases caused by an unusual
mycobacterial variant
Vet Rec
138
1996
53
8629329
34
Guptill
L
Bartonellosis
Vet Microbiol
140
2010
347
20018462
35
Guptill
L
Feline bartonellosis
Vet Clin North Am Small Anim Pract
40
2010
1073
20933137
36
Harada
H
Endo
Y
Sekiguchi
M
Cutaneous nocardiosis in a cat
J Vet Med Sci
71
2009
785
19578288
37
Hattori
Y
Kano
R
Kunitani
Y
Nocardia africana isolated from a feline mycetoma
J Clin Microbiol
41
2003
908
12574314
38
Hirsh
DC
Jang
SS
Antimicrobial susceptibility of Nocardia nova isolated from five cats with nocardiosis
J Am Vet Med Assoc
215
1999
815
10496134
39
Horne
KS
Kunkle
GA
Clinical outcome of cutaneous rapidly growing mycobacterial infections in cats in
the southeastern United States: a review of 10 cases (1996-2006)
J Feline Med Surg
11
2009
627
19201237
40
Hughes
M
Ball
N
Love
D
Disseminated Mycobacterium genavense infection in a FIV-positive cat
J Feline Med Surg
1
1999
23
11919012
41
Huitema
H
Jaartsveld
FH
Mycobacterium microti infection in a cat and some pigs
Antonie Van Leeuwenhoek
33
1967
209
5298436
42
Jang
S
Hirsh
D
Rapidly growing members of the genus Mycobacterium affecting dogs and cats
J Am Anim Hosp Assoc
38
2002
217
12022405
43
Jassies-van der Lee
A
Houwers
DJ
Meertens
N
Localised pyogranulomatous dermatitis due to Mycobacterium abscessus in a cat: a case
report
Vet J
179
2009
304
18083608
44
Jordan
HL
Cohn
LA
Armstrong
PJ
Disseminated Mycobacterium avium complex infection in three Siamese cats
J Am Vet Med Assoc
204
1994
90
8125827
45
Kaneene
JB
Bruning-Fann
CS
Dunn
J
Epidemiologic investigation of Mycobacterium bovis in a population of cats
Am J Vet Res
63
2002
1507
12428659
46
Kaufman
A
Greene
C
Rakich
P
Treatment of localized Mycobacterium avium complex infection with clofazimine and
doxycycline in a cat
J Am Vet Med Assoc
207
1995
457
7591945
47
Kipar
A
Schiller
I
Baumgartner
W
Immunopathological studies on feline cutaneous and (muco)cutaneous mycobacteriosis
Vet Immunol Immunopathol
91
2003
169
12586480
48
Kirschner
R
Parker
B
Falkinham
J
Epidemiology of infection by nontuberculosis mycobacteria
Am Rev Respir Dis
145
1992
271
1736730
49
Kunkle
GA
KGulbas
NK
Fadok
V
Rapidly growing mycobacteria as a cause of cutaneous granulomas: report of five cases
J Am Anim Hosp Assoc
19
1983
513
50
Lewis
DT
Kunkle
GA
Feline leprosy
Greene
CE
Infectious diseases of the dog and cat
ed 2
1998
Saunders
Philadelphia
321
51
Luque
I
Astorga
R
Tarradas
C
Nocardia otitidiscaviarum infection in a cat
Vet Rec
151
2002
488
52
Malik
R
Hughes
M
James
G
Feline leprosy: two different clinical syndromes
J Feline Med Surg
4
2002
43
11869054
53
Malik
R
Hunt
GB
Goldsmid
SE
Diagnosis and treatment of pyogranulomatous panniculitis due to Mycobacterium smegmatis
in cats
J Small Anim Pract
35
1994
524
54
Malik
R
Krockenberger
MB
O’Brien
CR
Nocardia infections in cats: a retrospective multi-institutional study of 17 cases
Aust Vet J
84
2006
235
16879126
55
Malik
R
Martin
P
Wigney
D
Infections caused by rapidly growing mycobacteria
Greene
CE
Infectious diseases of the dog and cat
ed 3
2006
Elsevier
St Louis
482
56
Malik
R
Norris
J
White
J
Wound cat
J Fel Med Surg
8
2006
135
57
Malik
R
Wigney
DI
Dawson
D
Infection of the subcutis and skin of cats with rapidly growing mycobacteria: a review
of microbiological and clinical findings
J Feline Med Surg
2
2000
35
11716590
58
Masur
H
Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex
disease in patients infected with the human immunodeficiency virus. Public Health
Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex
N Engl J Med
329
1993
898
8395019
59
Mealey
K
Willard
M
Nagode
L
Hypercalcemia associated with granulomatous disease in a cat
J Am Vet Med Assoc
215
1999
959
10511860
60
Niemann
S
Richter
E
Dalugge-Tamm
H
Two cases of Mycobacterium microti derived tuberculosis in HIV-negative immunocompetent
patients
Emerg Infect Dis
6
2000
539
10998387
61
Orloski
K
Lathrop
S
Plague: a veterinary perspective
J Am Vet Med Assoc
222
2003
444
12597416
62
Pedersen
NC
Atypical mycobacteriosis
Pedersen
NC
Feline infectious diseases
1988
American Veterinary Publications
Goleta, Calif
197
63
Plaus
WJ
Hermann
G
The surgical management of superficial infections caused by atypical mycobacteria
Surgery
110
1991
99
1866699
64
Ramos-Vara
JA
Wu
CC
Lin
TL
Nocardia tenerifensis genome identification in a cutaneous granuloma of a cat
J Vet Diagn Invest
19
2007
577
17823408
65
Schiefer
HB
Middleton
DM
Experimental transmission of a feline mycobacterial skin disease (feline leprosy)
Vet Pathol
20
1983
460
6353741
66
Sieber-Ruckstuhl
NS
Sessions
JK
Sanchez
S
Long-term cure of disseminated Mycobacterium avium infection in a cat
Vet Rec
160
2007
131
17259458
67
Sykes
JE
Westropp
JL
Kasten
RW
Association between Bartonella species infection and disease in pet cats as determined
using serology and culture
J Feline Med Surg
12
2010
631
20570199
68
Thorel
MF
Boisvert
H
Abscess due to Mycobacterium chelonei in a cat
Bull Acad Vet France
47
1974
415
69
Une
Y
Mori
T
Tuberculosis as a zoonosis from a veterinary perspective
Comp Immun Microbiol Infect Dis
30
2007
415
70
Valentine
BA
DeBey
BM
Sonn
RJ
Localized cutaneous infection with Francisella tularensis resembling ulceroglandular
tularemia in a cat
J Vet Diagn Invest
16
2004
83
14974853
71
Wilkins
MJ
Bartlett
PC
Berry
DE
Absence of Mycobacterium bovis infection in dogs and cats residing on infected cattle
farms: Michigan, 2002
Epidemiol Infect
136
2008
1617
18325127
72
Wilkinson
GT
Mason
KV
Clinical aspects of mycobacterial infections of the skin
August
JR
Consultations in feline internal medicine
1991
Saunders
Philadelphia
129
73
Woods
J
Crystal
M
Morton
R
Tularemia in two cats
J Am Vet Med Assoc
212
1998
81
9426784
74
Youssef
S
Archambault
M
Parker
W
Pyogranulomatous panniculitis in a cat associated with infection by the Mycobacterium
fortuitum/peregrinum group
Can Vet J
43
2002
285
11963662
75
Zumarraga
MJ
Vivot
MM
Marticorena
D
Mycobacterium bovis in Argentina: isolates from cats typified by spoligotyping
Rev Argent Microbiol
41
2009
215
20085184
Veir
Julia
Lappin
Michael R.
Molecular Assays Used for the Diagnosis of Feline Infectious Diseases
Infectious agents of cats are associated with many clinical disease syndromes evaluated
by practicing veterinarians. A definitive diagnosis is best made by documenting current
infection, which can be achieved with a variety of techniques that vary by the body
system; these include fecal flotation, cytology, histopathology, immunohistochemistry,
culture, antigen tests, and molecular diagnostic assays. For some agents, antibody
test results are also used to help make a clinical diagnosis. However, presence of
antibodies may only document prior exposure, not current infection.
Sensitivity is the ability of an assay to detect a positive sample; specificity is
the ability of an assay to detect a negative sample. Sensitivity and specificity vary
with each assay. Positive predictive value (PPV) is the ability of a test result to
predict presence of disease; negative predictive value (NPV) is the ability of a test
result to predict absence of disease. Many of the infectious agents encountered in
feline practice infect a large percentage of the population, resulting in positive
organism detection techniques or serum antibody production. However, they only induce
disease in a small number of cats in the infected group. Classic examples include
coronaviruses, Toxoplasma gondii, and Bartonella spp. For these agents, even though
assays with good sensitivity and specificity are available, the predictive value of
a positive test is actually very low.
Molecular Assays
Types of molecular assays used in cats were recently reviewed.
33
Molecular assays rely upon detection of the nucleic acids deoxyribonucleic (DNA) and
ribonucleic (RNA) acid. Nucleic acids are part of the genetic makeup of the organism
and consist of four nucleotides in varying sequences. Many portions of DNA and RNA
are highly conserved among organisms, while others are specific to the organism on
a family, genus, species, or even strain level. The sequence specificity is used to
detect the organisms within clinical samples using some form of complementary sequence
and sometimes a signaling molecule. Signaling molecules are often some form of a fluorescent
molecule in order to improve sensitivity.
Detection of Pathogens Without Amplification
The simplest application of molecular tools for detection of infectious organisms
is to apply a complementary nucleic acid sequence, termed a probe, which has been
tagged with a fluorescent molecule. This probe is then applied directly to a clinical
sample and hybridizes to a target sequence in an organism if present. Probes with
different fluorescent tags can be applied to a single sample, allowing for detection
of several organisms. However, sensitivity is poor compared with other molecular techniques,
because the target DNA is not amplified. When probes are designed for use with tissues,
it is termed in situ hybridization. Use of this technique can allow for detection
of the organisms of interest in association with inflammatory lesions or specific
areas of tissue. Fluorescent molecules are the most common signaling mechanism used
with this technique, which is abbreviated FISH (fluorescent in situ hybridization).
Detection of Pathogens with Amplification: Polymerase Chain Reaction
The polymerase chain reaction (PCR) was first described in 1985.
28
This technique results in the cyclic amplification of a single strand of DNA to produce
an exponential number of identical copies that then can be easily detected, usually
on a gel (conventional or end-point PCR), to determine if it is the predicted size
for the reaction (Figure 33-28
). PCR is superior in sensitivity to probe hybridization techniques because of this
amplification step. The great sensitivity of these assays requires strict adherence
to good laboratory practice to avoid false-positive results from contamination within
the laboratory.
FIGURE 33-28
Traditional polymerase chain reaction. A, Short sequences of nucleotides called primers
are annealed to the target DNA after the separation of the double strands. A proprietary
enzyme is used to produce complementary strands of DNA during the synthesis step.
Denaturation is repeated, and replication of the newly formed DNA strands, as well
as the original target DNA, is repeated. B, The DNA produced in the reaction is then
visualized using gel electrophoresis. The size of the product is compared with a standard
to confirm that the predicted product has been obtained.
Rights were not granted to include this figure in electronic media. Please refer to
the printed book.
(From Veir JK, Lappin MR: Molecular diagnostic assays for infectious diseases in cats,
Vet Clin North Am Small Anim Pract 40:1189, 2010.)
© 2012 Vet Clin North Am Small Anim Pract
2012
Since January 2020 Elsevier has created a COVID-19 resource centre with free information
in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre
is hosted on Elsevier Connect, the company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related research that is
available on the COVID-19 resource centre - including this research content - immediately
available in PubMed Central and other publicly funded repositories, such as the WHO
COVID database with rights for unrestricted research re-use and analyses in any form
or by any means with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Detection of microbial nucleic acids in a feline sample does not prove the organism
is alive, capable of replication, or actually causing clinical signs in the host.
Correlation with clinical signs of a known syndrome associated with the organism and/or
a response to therapy must be used in conjunction with results of PCR. False-negative
reactions can occur with PCR on some tissues or fluids that may have PCR inhibitors
present. This problem varies by the syndrome as well as the assay and should be considered
in each case. Finally, in order to prevent false negatives, samples tested should
be obtained prior to treatment, which may decrease organism load below the level of
detection of the assay even though the organism is still present in the host.
The enzyme used in PCR can only duplicate strands of DNA, and so, to detect RNA, the
sample must first have a reverse transcription (RT) step to create a complementary
strand of DNA from the target RNA. Amplification of the complementary DNA by polymerase
chain reaction is then performed; this method is commonly known as RT-PCR.
PCR is used most commonly in veterinary medicine to detect infectious disease agents:
The primers used in PCR can be designed to amplify the nucleic acids only of members
of a certain genus, species, or even strain of organism. When a single organism is
targeted in an assay, it is termed a singleplex PCR. If multiple targets can be detected
in a single assay, it is termed a multiplex assay. It is clearly most attractive to
investigate the presence of multiple organisms in a single assay. However, each target
sequence competes with the others for the common building blocks in the PCR assay:
the enzyme, nucleotide, and various buffers and ions that allow the reaction to proceed.
Therefore multiplex reactions can be less sensitive than singleplex assays.
The use of broad-range or degenerate primers amplifying members of an entire genus
or even kingdom can be used, targeting highly conserved regions of the nucleic acids.
The most common application of this is for rapid detection and identification of eubacteria
or fungi in clinical samples.18, 29 Subsequent analysis of the PCR product may then
be used to identify the infecting organism much more rapidly than traditional microbiologic
techniques and may be more sensitive for detection of fastidious organisms. It must
be noted that antimicrobial sensitivity is not available using this technique; therefore
it is complementary to traditional culture techniques. However, the use of PCR for
detection of certain genes that encode for antimicrobial resistance genes is starting
to gain clinical use as well and may provide additional rapid information prior to
sensitivity results being available.
23
It is difficult to acquire quantification information using traditional end-point
PCR. Real-time PCR or quantitative PCR (qPCR) is the most recent application of PCR.
12
In this technique, production of DNA is monitored during each amplification cycle
so that the original starting quantity could be extrapolated by identification of
the logarithmic amplification phase of each individual reaction. This technique uses
fluorescent dyes or probes that produce a signal after formation of the product (Figure
33-29
). During each amplification cycle, a detector records the amount of fluorescence
in the sample. Pathogen detection and load are one of the many applications of this
technology. This assay has all the advantages of traditional end-point PCR (good sensitivity,
specificity) but also offers a more rapid result and the ability to quantify microbial
DNA or RNA load and so can be used to monitor therapy in some cases (see the following
sections of the chapter). Because qPCR is very sensitive, strict quality control must
be maintained. In addition, accuracy of quantification is reliant upon the availability
of a reproducible, high-quality, standard curve. Although minimum laboratory standards
have been proposed and are generally met for published protocols,
4
many diagnostic laboratories use proprietary reactions that are not subject to peer
review. Thus all laboratories providing PCR assays may not be equivalent, and so,
use of laboratories that have published results of their assays may be prudent.
FIGURE 33-29
Quantitative polymerase chain reaction. A, The standard PCR assay is enhanced by using
a fluorescent probe that fluoresces only after the removal of a quencher dye in close
proximity to the reporter dye. The quencher dye is removed by the enzyme that synthesizes
new strands of DNA as in traditional PCR. At each step, fluorescence is measured,
allowing for the extrapolation of the amount of product present during each replication
phase. B, The change in fluorescence is then plotted against time (number of cycles),
and a starting quantity can be calculated by the extrapolation of the signal produced
during the exponential replication phase.
Rights were not granted to include this figure in electronic media. Please refer to
the printed book.
(From Veir JK, Lappin MR: Molecular diagnostic assays for infectious diseases in cats,
Vet Clin North Am Small Anim Pract 40:1189, 2010.)
© 2012 Vet Clin North Am Small Anim Pract
2012
Since January 2020 Elsevier has created a COVID-19 resource centre with free information
in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre
is hosted on Elsevier Connect, the company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related research that is
available on the COVID-19 resource centre - including this research content - immediately
available in PubMed Central and other publicly funded repositories, such as the WHO
COVID database with rights for unrestricted research re-use and analyses in any form
or by any means with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Current Clinical Applications of Molecular Assays in Feline Medicine
In the following subsections, a brief review of the benefits and problems associated
with PCR assays currently used in feline medicine is presented.
Respiratory Agents
Feline calicivirus (FCV) is a common differential diagnosis for cats with clinical
evidence of rhinitis and stomatitis. Less commonly, FCV is associated with conjunctivitis,
polyarthritis, and lower airway disease in kittens. Virus isolation can be used to
document current infection but takes at least several days for results to return.
Because of widespread exposure and vaccination, the positive predictive value of serologic
tests is poor. Reverse transcriptase (RT)-PCR assays can be used to amplify the RNA
of FCV, and results can be returned quickly. However, these assays also amplify vaccine
strains of FCV.
27
FCV RNA can be amplified from samples collected from normal carrier cats as well as
clinically ill cats and so have poor positive predictive value.
24
For example, in one study in our laboratory, presence of FCV RNA failed to correlate
with the presence or absence of stomatitis in cats.
26
In addition, amplification of FCV RNA cannot be used to prove virulent systemic calicivirus
infection. The negative predictive value for FCV RT-PCR assays is currently unknown.
Feline caliciviruses, as RNA viruses, have genetic variability among the different
strains. Depending on the viral genetic region targeted by the assay, the degree of
genetic variation among strains at that site will vary. Most laboratories design their
assays to target conserved regions of the viral genome, but even this cannot guarantee
that all strains are detectable by any individual assay.
FHV-1 is a common differential diagnosis for cats with clinical evidence of rhinitis,
stomatitis, conjunctivitis, keratitis, and facial dermatitis. Because of widespread
exposure and vaccination, the positive predictive value of serologic tests is poor.
FHV-1 can be documented by direct fluorescent staining of conjunctival scrapings,
virus isolation, or PCR. FHV-1 DNA can be amplified from conjunctiva, nasal discharges,
and pharynx of healthy cats, and so, the positive predictive value of conventional
PCR assays is low.
34
Currently used PCR assays also detect vaccine strains of FHV-1, further lessening
the positive predictive value of the assays.
21
In one study in our laboratory, presence of FHV-1 DNA failed to correlate with the
presence or absence of stomatitis in cats.
26
Quantitative PCR may ultimately prove to correlate with the presence or absence of
disease, but it failed to correlate with the presence of conjunctivitis in one study.
20
The negative predictive value of FHV-1 PCR assays is also in question, because many
cats that are likely to have FHV-1 associated disease are negative. This may relate
to clearance of FHV-1 DNA from tissues by a hypersensitivity reaction. Tissue biopsies
have greater sensitivity than conjunctival swabs but do not necessarily have greater
predictive value. FHV-1 DNA can be amplified from aqueous humor of some cats, but
whether this indicates FHV-1 associated uveitis is unknown.
22
Mycoplasma spp., Chlamydophila felis, and Bordetella bronchiseptica are other common
respiratory pathogens in cats. As for FHV-1 and FCV, PCR-positive test results for
these organisms cannot be used to distinguish a carrier from a clinically ill cat.
However, in one recent study, Mycoplasma spp. DNA was amplified from conjunctival
swabs from more kittens with conjunctivitis than control cats in the same shelters,
suggesting the organism can be pathogenic in some cats.
36
In addition, PCR assays do not provide antimicrobial drug susceptibility testing,
and so, for cats with potential bordetellosis, culture and sensitivity is the optimal
diagnostic technique, especially if an outbreak is occurring. Toxoplasma gondii DNA
has been amplified from airway washings of some cats with lower respiratory tract
disease, and so, PCR is an option for evaluation of samples from diseased animals
from which the organism is not identified cytologically.
Gastrointestinal Agents
The diagnosis of Giardia spp. infection is generally made with the combination of
fecal flotation techniques and wet mount examination. Fecal antigen tests are also
accurate, and there are several assays available for point-of-care use, including
one labeled for veterinary use. Fecal PCR assays are often falsely negative because
of PCR inhibitors in stool, and so, PCR should not be used as a screening procedure
for this agent. However, Giardia spp. PCR can be used to determine whether the infective
species is a zoonotic assemblage, which is the primary indication for this technique.
However, it now appears that assemblage determination should be performed on more
than one gene for most accurate results.
30
Although Cryptosporidium spp. infection is common, it is unusual to find C. felis
oocysts after fecal flotation in cats. Acid-fast staining of a thin fecal smear is
cumbersome and insensitive. Antigen assays titrated for use with human feces are inaccurate
when used with cat feces. Thus PCR may be aid in the diagnosis of cryptosporidiosis
in dogs and cats and has been shown to be more sensitive than immunofluorescence assay
(IFA) in cats.
31
Cryptosporidium spp. PCR assays are indicated in IFA-negative cats with unexplained
small bowel diarrhea and when the genotype of Cryptosporidium is to be determined.
However, C. felis infection in cats is common, and so, positive tests results do not
always prove that the agent is the cause of the clinical disease. No drug is known
to eliminate Cryptosporidium spp. infections, and small animal strains are not considered
significant zoonotic agents; so, PCR is never indicated in healthy animals.
PCR assays are also available for detection of DNA of Tritrichomonas foetus, Salmonella
spp., Campylobacter spp., Clostridium spp., parvoviruses, and T. gondii, and a RT-PCR
assay is available for coronaviruses. Trophozoites of T. foetus can often be detected
on wet mount examination of fresh feces, which can be completed as an in-clinic test.
PCR for T. foetus DNA is indicated if wet mount examination is negative and results
return more quickly than culture. However, DNA of T. foetus can be detected in healthy
carrier cats, and so, positive results do not always prove illness from the organism.
8
Cases with suspected salmonellosis or campylobacteriosis should be cultured rather
than assessed by PCR to determine the anti-microbial susceptibility patterns. In dogs,
the PPV of Clostridium spp. PCR assays on feces is low and, if used, should be combined
with enterotoxin assays. Information in cats is currently lacking. There is no current
evidence that parvovirus PCR on feces is superior to currently available antigen assays.
It was recently shown that cats vaccinated with modified live panleukopenia–containing
vaccines shed parvovirus DNA in feces within several hours.
7
Thus parvovirus PCR testing should not be used to diagnose panleukopenia virus outbreaks
in recently vaccinated cats. Toxoplasma gondii is only shed for about 7 to 10 days,
and millions of oocysts are generally shed during this time, making the organism very
easy to identify. Thus PCR assays are usually not needed to diagnosis this infection.
Because virus isolation is not practical clinically, RT-PCR is used most frequently
to detect coronavirus RNA in feces. However, positive test results do not differentiate
FIP-inducing strains from enteric coronaviruses. Additionally, in one study, presence
of coronavirus RNA did not correlate to the presence of diarrhea in shelter cats.
7
Bloodborne Agents
Mycoplasma haemofelis (Mhf), “Candidatus Mycoplasma haemominutum” (Mhm), and “Candidatus
M. turicensis” (Mtc) all can be found in cats. In experimentally infected cats, Mhf
is apparently more pathogenic than Mhm. It appears that Mtc has intermediate pathogenicity.
Diagnosis is based on demonstration of the organism on the surface of erythrocytes
on examination of a thin blood film or PCR assay. Organism numbers fluctuate, and
so, blood film examination can be falsely negative up to 50% of the time. The organism
may be difficult to find cytologically, particularly in the chronic phase. Thus PCR
assays are the tests of choice because of sensitivity.
13
Primers are available that can amplify all three hemoplasmas. Real-time PCR assays
can be used to monitor copy numbers during and after treatment but do not have greater
sensitivity, specificity, or predictive value than conventional PCR assays.
32
PCR assays should be considered in the evaluation of cats with unexplained fever or
anemia that are cytologically negative. In addition, the American College of Veterinary
Internal Medicine (ACVIM) recommends screening cats for use as blood donors by PCR
assays for hemoplasmas.
35
Many cats (approximately 15%) are carriers of the relatively nonpathogenic Candidatus
M. haemominutum, and so, positive test results may not always correlate with the presence
of disease (poor PPV).
Cats can be infected by E. canis-like organism
2
and Anaplasma phagocytophilum.
15
Little is known about the other agents in these genera regarding cats. Because the
organisms are in different genera, serologic cross reactivity is variable. Thus although
the clinical syndromes can be similar, there is no one serologic test to document
infection, and there is currently no standardized serology for cats. In addition,
some cats with E. canis infection do not seroconvert, and so, PCR assay is superior
to serology in cats. PCR assays can be designed to amplify each organism. Alternatively,
primers are available to amplify all of the organisms in a single reaction, and then
sequencing can be used to determine the infective species. However, positive test
results do not always correlate with the presence of disease. Anaplasma phagocytophilum
DNA has been amplified from the blood of healthy cats for more than 10 weeks after
experimental infection by exposure to Ixodes ticks (MR Lappin, unpublished data, 2011).
Cats can be infected by Rickettsia felis and have been shown to have antibodies against
R. rickettsii. Fever, headache, myalgia, and macular rash in humans have been attributed
to R. felis infection in several countries around the world. In recent study in our
laboratory, we assayed 92 pairs of cat blood and flea extracts from Alabama, Maryland,
and Texas, using PCR assays that amplify a region of the citrate synthase gene (gltA)
and the outer membrane protein B gene (ompB). Of the 92 pairs, 62 of 92 (67.4%) flea
extracts and none of the cat blood samples were positive for R. felis DNA.
11
In another study, we showed R. felis and R. rickettsii antibody prevalence rates in
cats with fever to be 5.6% and 6.6%, respectively, but neither organism was amplified
from blood.
1
These results prove that cats are sometimes exposed, but further data are needed to
determine the significance of disease associations. Whether Rickettsia spp. PCR assays
are indicated for use in cats at this time is unknown.
Blood culture, PCR assay on blood, and serologic testing can be used to assess individual
cats for Bartonella spp. infection.
3
Cats that are culture negative or PCR negative and antibody negative, and cats that
are culture negative or PCR negative and antibody positive, are probably not a source
of flea, cat, or human infection. However, bacteremia can be intermittent, and false-negative
culture or PCR results can occur, limiting the predictive value of a single battery
of tests.
17
Although serologic testing can be used to determine whether an individual cat has
been exposed, both seropositive and seronegative cats can be bacteremic, limiting
the diagnostic utility of serologic testing. Thus testing healthy cats for Bartonella
species infection is not currently recommended.3, 14 Testing should be reserved for
cats with suspected clinical bartonellosis. Because Bartonella spp. infection is so
common in healthy cats, even culture-positive or PCR-positive results do not prove
clinical bartonellosis. For example, although we detected Bartonella spp. DNA in more
cats with fever than in pair-matched cats without fever, the healthy cats were still
commonly positive.
16
Combined serology with PCR in evaluation of cats with suspected bartonellosis is likely
to give the best predictive value.
Cytauxzoon felis is usually easily identified on cytologic examination of blood smears
or splenic aspirates during evaluation of clinically ill cats. Serologic testing is
not commercially available at this time. PCR can be used to amplify organism DNA from
blood from cats that are cytologically negative.
9
Antibodies against feline immunodeficiency virus (FIV) are detected in serum in clinical
practice most frequently by enzyme-linked immunosorbent assay (ELISA). Comparisons
among different tests have shown the results of most assays are comparable.
10
Results of virus isolation or RT-PCR on blood are positive in some antibody-negative
cats. False-positive reactions can occur using ELISA; hence, positive ELISA results
in healthy or low-risk cats should be confirmed using Western blot immunoassay. Kittens
can have detectable, colostrum-derived antibodies for several months. If antibodies
persist at 6 months of age, the kitten is likely infected. Virus isolation or RT-PCR
on blood can also be performed to confirm infection. However, FIV is not present in
the blood at high levels, and so, false-negative results are common. In addition,
there are variable results among laboratories.
6
Most cats with feline leukemia virus infection are viremic, and so, molecular diagnostic
assays are not usually needed in clinical practice. However, use of newer sensitive
real-time PCR assays has been used to accurately characterize the stages of infection.
19
However, these assays are not commonly available commercially.
RNA of both FIPV and FECV can be amplified from the blood of cats, and so, positive
test results do not always correlate with the development of FIP. Amplification of
the mRNA of the M gene by RT-PCR had mixed results in two studies performed to date.
In the one study, 13 of 26 apparently normal cats were positive for FECV mRNA in blood,
suggesting that the positive predictive value of this assay for the diagnosis of FIP
was low.
5
Ocular Agents
Toxoplasma gondii, Bartonella spp., FHV-1 and coronavirus are the organisms for which
DNA or RNA has been amplified most frequently from the aqueous humor of cats with
endogenous uveitis.22, 25 Although little is known about the predictive value of these
assays when used with aqueous humor, the combination of molecular assays with local
antibody production indices may aid in the diagnosis of some cases.
References
1
Bayliss
DB
Morris
AK
Horta
MC
Prevalence of Rickettsia species antibodies and Rickettsia species DNA in the blood
of cats with and without fever
J Feline Med Surg
11
2009
266
18786845
2
Breitschwerdt
EB
Abrams-Ogg
ACG
Lappin
MR
Molecular evidence supporting Ehrlichia canis-like infection in cats
J Vet Intern Med
16
2002
642
12465759
3
Brunt
J
Guptill
L
Kordick
DL
American Association of Feline Practitioners 2006 Panel report on diagnosis, treatment,
and prevention of Bartonella spp. infections
J Feline Med Surg
8
2006
213
16846781
4
Bustin
SA
Benes
V
Garson
JA
The MIQE guidelines: minimum information for publication of quantitative real-time
PCR experiments
Clin Chem
55
2009
611
19246619
5
Can-Sahna
K
Soydal Ataseven
V
Pinar
D
The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR
J Feline Med Surg
9
2007
369
17478116
6
Crawford
P
Slater
M
Levy
J
Accuracy of polymerase chain reaction assays for diagnosis of feline immunodeficiency
virus infection in cats
J Am Vet Med Assoc
226
2005
1503
15882000
7
Gingrich
E
Scorza
A
Leutenegger
C
Common enteric pathogens in cats before and after placement in an animal shelter [poster]
J Vet Intern Med
24
2010
766
8
Gookin
JL
Stebbins
ME
Hunt
E
Prevalence of and risk factors for feline Tritrichomonas foetus and Giardia infection
J Clin Microbiol
42
2004
2707
15184456
9
Haber
MD
Tucker
MD
Marr
HS
The detection of Cytauxzoon felis in apparently healthy free-roaming cats in the USA
Vet parasitol
146
2007
316
17391852
10
Hartmann
K
Griessmayr
P
Schulz
B
Quality of different in-clinic test systems for feline immunodeficiency virus and
feline leukaemia virus infection
J Feline Med Surg
9
2007
439
17604205
11
Hawley
JR
Shaw
SE
Lappin
MR
Prevalence of Rickettsia felis DNA in the blood of cats and their fleas in the United
States
J Feline Med Surg
9
2007
258
17276123
12
Higuchi
R
Dollinger
G
Walsh
PS
Simultaneous amplification and detection of specific DNA sequences
Biotechnology (N Y)
10
1992
413
1368485
13
Jensen
W
Lappin
M
Kamkar
S
Use of a polymerase chain reaction assay to detect and differentiate two strains of
Haemobartonella felis in naturally infected cats
Am J Vet Res
62
2001
604
11327472
14
Kaplan
JE
Benson
C
Holmes
KK
Guidelines for prevention and treatment of opportunistic infections in HIV-infected
adults and adolescents
MMWR Recomm Rep
58
2009
1
15
Lappin
M
Breitschwerdt
E
Jensen
W
Molecular and serologic evidence of Anaplasma phagocytophilum infection in cats in
North America
J Am Vet Med Assoc
225
2004
893
15485049
16
Lappin
MR
Breitschwerdt
EB
Brewer
M
Prevalence of Bartonella species antibodies and Bartonella species DNA in the blood
of cats with and without fever
J Feline Med Surg
11
2009
141
18760647
17
Lappin
MR
Hawley
J
Presence of Bartonella species and Rickettsia species DNA in the blood, oral cavity,
skin and claw beds of cats in the United States
Vet Dermatol
20
2009
509
20178489
18
Lau
A
Chen
S
Sorrell
T
Development and clinical application of a panfungal PCR assay to detect and identify
fungal DNA in tissue specimens
J Clin Microbiol
45
2007
380
17122000
19
Levy
J
Crawford
C
Hartmann
K
2008 American Association of Feline Practitioners’ feline retrovirus management guidelines
J Feline Med Surg
10
2008
300
18455463
20
Low
HC
Powell
CC
Veir
JK
Prevalence of feline herpesvirus 1, Chlamydophila felis, and Mycoplasma spp DNA in
conjunctival cells collected from cats with and without conjunctivitis
Am J Vet Res
68
2007
643
17542698
21
Maggs
D
Clarke
H
Relative sensitivity of polymerase chain reaction assays used for detection of feline
herpesvirus type 1 DNA in clinical samples and commercial vaccines
Am J Vet Res
66
2005
1550
16261828
22
Maggs
D
Lappin
M
Nasisse
M
Detection of feline herpesvirus-specific antibodies and DNA in aqueous humor from
cats with or without uveitis
Am J Vet Res
60
1999
932
10451199
23
Mapes
S
Rhodes
DM
Wilson
WD
Comparison of five real-time PCR assays for detecting virulence genes in isolates
of Escherichia coli from septicaemic neonatal foals
Vet Rec
161
2007
716
18037693
24
Pedersen
N
Sato
R
Foley
J
Common virus infections in cats, before and after being placed in shelters, with emphasis
on feline enteric coronavirus
J Feline Med Surg
6
2004
83
15123152
25
Powell
CC
McInnis
CL
Fontenelle
JP
Bartonella species, feline herpesvirus-1, and Toxoplasma gondii PCR assay results
from blood and aqueous humor samples from 104 cats with naturally occurring endogenous
uveitis
J Feline Med Surg
12
2010
923
20817587
26
Quimby
JM
Elston
T
Hawley
J
Evaluation of the association of Bartonella species, feline herpesvirus 1, feline
calicivirus, feline leukemia virus and feline immunodeficiency virus with chronic
feline gingivostomatitis
J Feline Med Surg
10
2008
66
17766156
27
Ruch-Gallie RA, Veir JK, Hawley JR et al: Results of molecular diagnostic assays targeting
feline herpesvirus-1 and feline calicivirus in adult cats administered modified live
vaccines, J Feline Med Surg, in press. Epub March 23, 2011.
28
Saiki
RK
Scharf
S
Faloona
F
Enzymatic amplification of beta-globin genomic sequences and restriction site analysis
for diagnosis of sickle cell anemia
Science
230
1985
1350
2999980
29
Schabereiter-Gurtner
C
Nehr
M
Apfalter
P
Evaluation of a protocol for molecular broad-range diagnosis of culture-negative bacterial
infections in clinical routine diagnosis
J Appl Microbiol
104
2008
1228
18028360
30
Scorza A, Lappin M, Ballweber L: Genotyping of Giardia duodenalis isolates of mammals
(dogs, cats, bobcats and cattle) by the β-giardin, glutamate dehydrogenase and triose
phosphate isomerase genes [poster], Third International Giardia and Cryptosporidium
Conference, Orvieto, Italy, 2009.
31
Scorza
AV
Brewer
MM
Lappin
MR
Polymerase chain reaction for the detection of Cryptosporidium spp. in cat feces
J Parasitol
89
2003
423
12760674
32
Tasker
S
Helps
CR
Day
MJ
Use of a Taqman PCR to determine the response of Mycoplasma haemofelis infection to
antibiotic treatment
J Microbiol Methods
56
2004
63
14706751
33
Veir
JK
Lappin
MR
Molecular diagnostic assays for infectious diseases in cats
Vet Clin North Am Small Anim Pract
40
2010
1189
20933144
34
Veir
JK
Ruch-Gallie
R
Spindel
ME
Prevalence of selected infectious organisms and comparison of two anatomic sampling
sites in shelter cats with upper respiratory tract disease
J Feline Med Surg
10
2008
551
18539065
35
Wardrop
K
Reine
N
Birkenheuer
A
Canine and feline blood donor screening for infectious diseases
J Vet Intern Med
19
2005
135
15715062
36
Zirofsky
D
Powell
CC
Reckers
W
Feline herpesvirus-1 and Mycoplasma spp. infections in cats with acute conjunctivitis
in an animal shelter (abstract)
J Vet Intern Med
24
2010
705